phenylephrine profile

Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6041
CHEMBL ID	1215
CHEBI ID	8093
SCHEMBL ID	4711
MeSH ID	M0016556

Synonym
BIDD:GT0157
(r)-(-)-phenylephrine
3-[(1r)-1-hydroxy-2-methylaminoethyl]phenol
gtpl485
benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (r)-
KBIO1_000597
DIVK1C_000597
fenilefrina
phenylephrinum
benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-
r(-)-phenylephrine
CHEBI:8093 ,
(-)-m-hydroxy-alpha-(methylaminomethyl)benzyl alcohol
l-(3-hydroxyphenyl)-n-methylethanolamine
benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (r)-
mesatonum
phenylephrinum [inn-latin]
metasynephrine
l-1-(m-hydroxyphenyl)-2-methylaminoethanol
m-methylaminoethanolphenol
m-synephrine
m-sympathol
mesatone
fenilefrina [inn-spanish]
ai3-02402
l-m-hydroxy-alpha-((methylamino)methyl)benzyl alcohol
metaoxedrinum
einecs 200-424-8
metaoxedrine
l-alpha-hydroxy-beta-methylamino-3-hydroxy-l-ethylbenzene
isophrin
phenylephrine, l-
metaoxedrin
phenylephrine [inn:ban]
ah-chew
hsdb 3383
cyclomydril
SPECTRUM_001101
IDI1_000597
SPECTRUM5_001411
NCGC00015825-01
lopac-p-6126
BSPBIO_002420
PDSP2_001092
LOPAC0_000920
PDSP1_001108
neosynephrine
visadron
metasympatol
(r)-2-hydroxy-2-(3-hydroxyphenyl)-n-methylethylamine
3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol
m-oxedrine
isophrim
m-sympatol
mesaton
mezaton
C07441
59-42-7
phenylephrine
DB00388
KBIO3_001640
KBIO2_001581
KBIO2_004149
KBIOSS_001581
KBIO2_006717
KBIOGR_001313
SPECTRUM3_000770
NINDS_000597
SPECTRUM2_001280
SPECTRUM4_000967
SPBIO_001280
NCGC00024257-03
duo-medihaler
NCGC00024257-05
NCGC00015825-02
NCGC00024257-06
meta-synephrine
(r)-phenylephrine
phenylephrine, (r)-
(-)-phenylephrine
CHEMBL1215
ab-101 (phenylephrine)
j8.601k ,
r(-)-mezaton
phenylephrine minims
D08365
phenylephrine (inn)
phenylephrine minims (tn)
P0395
l-phenylephrine
bdbm50067212
A832309
3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol;l-phenylephrine
AKOS006282042
unii-1ws297w6mv
hemorid
ccris 8464
ec 200-424-8
1ws297w6mv ,
neo-synephrine nasal drops
phenoptic
ocugestrin
neo-synephrine nasal jelly
spersaphrine
dilatair
neofrin
alconefrin nasal drops 50
nostril spray pump
doktors
ocu-phrin sterile eye drops
duration
relief eye drops for red eyes
alconefrin nasal spray 25
neo-synephrine nasal spray
alconefrin nasal drops 25
ak-dilate
i-phrine
alconefrin nasal drops 12
ak-nefrin
nostril spray pump mild
minims phenylephrine
CCG-205002
NCGC00024257-07
phenylephrine [hsdb]
phenylephrine [mart.]
phenylephrine [inn]
phenylephrine [ep monograph]
(-)-3 hydroxy-.alpha.-((methylamino)methyl)benzenemethanol
phenylephrine [mi]
phenylephrine [vandf]
(-)-1-(3-hydroxyphenyl)-2-methylaminoethanol
phenylephrine [who-dd]
phenylephrine [ep impurity]
(r)-3-(1-hydroxy-2-(methylamino)ethyl)phenol
AM100999
r-phenylephrine
SCHEMBL4711
Q-201560
r-(-)-phenylephrine
AT-057/40243664
component of relief (salt/mix)
l-.alpha.-hydroxy-.beta.-methylamino-3-hydroxy-l-ethylbenzene
(-)-m-hydroxy-.alpha.-(methylaminomethyl)benzyl alcohol
component of histalet forte (salt/mix)
3-[1-hydroxy-2-(methylamino)ethyl]phenol, (r)-
component of zincfrin (salt/mix)
neophryn (salt/mix)
component of comhist (salt/mix)
l-m-hydroxy-.alpha.-((methylamino)methyl)benzyl alcohol
(r)-3-hydroxy-.alpha.-[(methylamino)methyl]benzenemethanol
component of cyclomydril (salt/mix)
nostril (salt/mix)
ak-dilate (salt/mix)
component of vasosulf (salt/mix)
mydfrin (salt/mix)
component of ru-tuss tablets (salt/mix)
component of demazin (salt/mix)
adrianol (salt/mix)
component of dristan cold (salt/mix)
biomydrin (salt/mix)
(-)-m-oxedrine
component of prefrin-a (salt/mix)
component of hycomine compound (salt/mix)
component of dristan nasal mist (salt/mix)
component of cerose dm (salt/mix)
prefrin (salt/mix)
alcon efrin (salt/mix)
component of ru-tuss liquid (salt/mix)
component of entex (salt/mix)
component of decongestant (salt/mix)
ak-nefrin (salt/mix)
benzenemethanol, 3-hydroxy-a-[(methylamino)methyl]-, (.alpha.r)-
AB00053522_11
AB00053522_12
DTXSID9023465 ,
HY-B0769
CS-6187
3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol, aldrichcpr
mfcd00044749
phenylephrine; (1r)-1-(3-hydroxyphenyl)-2-(methylamino)ethanol
SBI-0050895.P004
1228015-39-1
neo-synephrine pediatric nasal drops
AS-13635
Q421910
SDCCGSBI-0050895.P005
NCGC00024257-19
phenylene
l-phenylephrinephenylephrine
(r)-(-)-phenylephrine; l-phenylephrine
(alphar)-3-hydroxy-alpha-[(methylamino)methyl]benzenemethanol
EN300-160202
Z1198723489
phenylephrinum (inn-latin)
(-)-3 hydroxy-alpha-((methylamino)methyl)benzenemethanol
phenylephrine (ep impurity)
phenylephrine (ep monograph)
r01aa04
r01ab01
r01ba03
s01ga05
s01fb01
phenylephrine (mart.)
dtxcid903465
3-((1r)-1-hydroxy-2-(methylamino)ethyl)phenol
fenilefrina (inn-spanish)
c01ca06

Research Excerpts

Toxicity

Phenylephrine is widely used to obtain a sympathomimetic mydriaticum. However eye drops may be followed by a certain number of adverse effect. LS180 cells were used as a model of the human intestinal epithelium to examine phenylephrine metabolism.

Excerpt	Reference	Relevance
" Clinicians are encouraged to report possible adverse drug reactions to the National Registry of Drug-Induced Ocular Side Effects, which has been moved to the Department of Ophthalmology, University of Oregon Health Sciences Center, Portland, OR 97201."	( Interim report: National Registry of Possible Drug-Induced Ocular Side Effects. Fraunfelder, FT, 1979)	0.26
"To see whether the Na/H antiporter plays a role in digitalis cardiotoxicity, we investigated the influence of modulators of Na/H exchange on the toxic effects of ouabain in isolated, paced (0."	( Opposite modulation of ouabain cardiotoxicity by hexamethyleneamiloride and phenylephrine. Anagnostopoulos, T; Terzic, A; Vogel, SM, 1991)	0.28
" The toxic effect of epinephrine was eliminated by the addition of propranolol or selective beta 2 blockade, but not by alpha or beta 1 blockade."	( Toxic effects of catecholamines on skin. Burk, RW; Klitzman, B; Serafin, D, 1990)	0.28
" Our data suggest that epinephrine or phenylephrine added to bupivacaine may be more toxic to cardiorespiratory systems than plain bupivacaine or epinephrine alone or phenylephrine alone when injected intravenously in rats."	( Epinephrine and phenylephrine increase cardiorespiratory toxicity of intravenously administered bupivacaine in rats. Holaday, DA; Kambam, JR; Kinney, WW; Matsuda, F; Wright, W, 1990)	0.28
" Cards were completed hourly to evaluate symptoms of allergic rhinitis and adverse experiences caused by therapy."	( Randomized, double-blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinitis using an acute model. Donnelly, A; Gellhaus, M; Weiler, JM; Weiler, K, 1990)	0.28
"Phenylephrine is widely used to obtain a sympathomimetic mydriaticum, however eye drops may be followed by a certain number of adverse effects notably cardio-vascular as our observation shows, but also allergic effects, irian pigment liberation in the anterior chamber and iatrogenic corneal oedema."	( [Adverse effects of neosynephrine]. Brasdefer, D; Cantineau, D; Courteville, H; Leroy, MP, 1989)	0.28
"To investigate the relationship between alterations of cytosolic Ca2+ concentration and development of cytotoxicity, isolated rat hepatocytes were loaded with the fluorescent indicator Quin-2 AM and then incubated with non-toxic or toxic levels of menadione (2-methyl-1,4-naphthoquinone) or tert-butyl hydroperoxide (t-BH)."	( Correlation between cytosolic Ca2+ concentration and cytotoxicity in hepatocytes exposed to oxidative stress. Bellomo, G; McConkey, D; Nicotera, P; Orrenius, S; Svensson, SA, 1988)	0.27
" A search of the English literature from 1966 to 1984 revealed 12 prospective clinical studies out of 37 articles that specifically addressed the potential adverse pressor effect of SMDs."	( Are oral decongestants safe in hypertension? An evaluation of the evidence and a framework for assessing clinical trials. Deck, CC; Radack, K, 1986)	0.27
" The ocular drugs causing serious adverse ocular or systemic side effects in children include glaucoma medications, corticosteroids, phenylephrine, and the anticholinergic cycloplegics."	( How safe are ocular drugs in pediatrics? Palmer, EA, 1986)	0.27
"A drug registry was established at Southern California College of Optometry (SCCO) to study use rates and incidence of adverse side effects of the nine pharmaceutical agents in the California optometry law."	( Use of diagnostic pharmaceutical agents and incidence of adverse effects. Applebaum, M; Jaanus, SD, 1983)	0.27
"We examined the effect of a toxic concentration of allyl alcohol (0."	( Allyl alcohol cytotoxicity in isolated rat hepatocytes: mechanism of cell death does not involve an early rise in cytosolic free calcium. Cai, Y; Hornbrook, KR; Rikans, LE, 1994)	0.29
" The aim of our study was to determine whether induced hypertension in stroke is safe and to examine its effects on neurological deficits in patients presenting with acute cerebral ischemia."	( Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety. Buonanno, F; Cramer, SC; Efird, JT; Koroshetz, WJ; Rordorf, G; Schwamm, LH, 1997)	0.3
"Based on this limited series of patients, we believe that it may be safe to use HA in patients treated with GDC for SAH."	( Safety of hemodynamic augmentation in patients treated with Guglielmi detachable coils after acute aneurysmal subarachnoid hemorrhage. Aiyagari, V; Cross , DT; Dacey , RG; Deibert, E; Diringer, MN, 2001)	0.31
" Alpha1-adrenergic agonists are shown to potentiate the toxicity of nephrotoxicants that exert their toxic effects via glutathione conjugation or Ca2+ deregulation."	( Alpha1-adrenergic receptors and their significance to chemical-induced nephrotoxicity--a brief review. Cardozo-Pelaez, F; Harbison, RD; Luzardo, GE; Muro-Cacho, C; Stedeford, T; Vultaggio, B, )	0.13
" Both regimens were safe with regard to their cardiovascular effects."	( Randomized clinical trial of the efficacy and safety of tropicamide and phenylephrine in preoperative mydriasis for phacoemulsification. Chi, SC; Lam, DS; Lam, PT; Poon, BT; Wu, WK, 2003)	0.32
" Although these medications may be handled and administered daily, clinicians must be vigilant in their efforts to ensure safe handling practices."	( Patient safety first alert--epinephrine and phenylephrine in surgical settings. Beyea, SC; Hicks, RW, 2003)	0.32
" This study was to examine the efficacy and adverse effects of the alpha-1 adrenergic agonist phenylephrine, which causes contraction of the internal anal sphincter and raises the resting pressure in these patients."	( The efficacy and adverse effects of topical phenylephrine for anal incontinence after low anterior resection in patients with rectal cancer. Kang, SB; Kim, DW; Kim, HL; Namgung, HW; Park, JS, 2007)	0.34
"In the patients with anal incontinence after low anterior resection for rectal cancer, phenylephrine gel did not seem to be helpful in relieving symptoms with some adverse effects."	( The efficacy and adverse effects of topical phenylephrine for anal incontinence after low anterior resection in patients with rectal cancer. Kang, SB; Kim, DW; Kim, HL; Namgung, HW; Park, JS, 2007)	0.34
"Intracameral injection of Mydrin-P appears to be effective and safe for dilating the pupil in cases with poor mydriasis after preoperative instillation of mydriatics."	( Intraoperative mydriasis by intracameral injection of mydriatic eye drops: in vivo efficacy and in vitro safety studies. Amano, S; Kagaya, F; Miyai, T; Miyata, K; Mori, Y; Nagai, N; Osakabe, Y, 2011)	0.37
" There were no withdrawals, serious adverse events and it was well tolerated overall."	( The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. Abrams, P; Cardozo, L; Ellis-Jones, J; Heath, P; Robinson, D; Wyllie, M, 2011)	0.37
" Crocin improved toxic effects of DZN via reducing lipid peroxidation and restoring altered contractile and relaxant responses in rat aorta."	( Protective effect of crocin on diazinon induced vascular toxicity in subchronic exposure in rat aorta ex-vivo. Abnous, K; Hosseinzadeh, H; Imenshahidi, M; Razavi, BM, 2014)	0.4
" A total of 154 eyes of 77 patients were randomly divided into 2 groups: group 1 consisted of 78 eyes, group 2 consisted of 76 eyes, and the patients were monitored for pupillary dilation, blood pressure, heart rate, and possible adverse effects at 0, 20, 40, 60, and 90 minutes."	( Evaluation of the efficacy and safety of the ophthalmic insert Mydriasert in patients undergoing retinal angiography. Cagini, C; Caricato, A; Cesari, C; Fiore, T; Pascale, A; Tosi, G, )	0.13
"No severe adverse effects were observed in either group."	( Evaluation of the efficacy and safety of the ophthalmic insert Mydriasert in patients undergoing retinal angiography. Cagini, C; Caricato, A; Cesari, C; Fiore, T; Pascale, A; Tosi, G, )	0.13
" No serious side effect could be ascribed to the use of phenylephrine 5% eye drops in this study."	( [Serious adverse side effects after pupillary dilation in preterm infants]. Denion, E; Fedrizzi, S; Guillois, B; Lux, AL; Mouriaux, F; Peyro-Saint-Paul, L, 2015)	0.42
"To perform a meta-analysis of available evidence regarding cardiovascular adverse effects of topical phenylephrine."	( Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis. Finger, RP; Guymer, RH; Harper, CA; McGuinness, MB; Stavert, B, 2015)	0.42
"5%, is safe to use in clinical routine."	( Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis. Finger, RP; Guymer, RH; Harper, CA; McGuinness, MB; Stavert, B, 2015)	0.42
"Administration of norepinephrine, dopamine, or phenylephrine by peripheral intravenous access was feasible and safe in this single-center medical intensive care unit."	( Safety of peripheral intravenous administration of vasoactive medication. Belchikov, YG; Cardenas-Garcia, J; Koenig, SJ; Mayo, PH; Narasimhan, M; Schaub, KF, 2015)	0.42
" Such formulations could increase phenylephrine-related cardiovascular adverse events particularly in susceptible individuals."	( Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. Anderson, BJ; Atkinson, HC; Potts, AL, 2015)	0.42
"MEDLINE and EMBASE databases were searched for papers discussing or describing any adverse effect, hypersensitivity or safety concerns related to phenylephrine alone or in combination with other drugs."	( Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. Anderson, BJ; Atkinson, HC; Potts, AL, 2015)	0.42
" Eight subjects reported nine mild adverse events; one (somnolence) was deemed to be treatment related."	( Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Gelotte, CK; Zimmerman, BA, 2015)	0.42
"Mydrane is an effective and safe alternative to standard eye drops for initiating and maintaining intraoperative mydriasis and analgesia."	( Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery. Alió, J; Behndig, A; Cochener, B; Colin, J; Findl, O; Hartani, D; Labetoulle, M; Lazreg, S; Lobo, C; Malecaze, F; Tassignon, MJ, 2016)	0.43
"Mortality and morbidity by toxic metals is an important issue of occupational health."	( Lead toxicity promotes autonomic dysfunction with increased chemoreceptor sensitivity. Carvalho, M; Geraldes, V; Goncalves-Rosa, N; Laranjo, S; Rocha, I; Tavares, C, 2016)	0.43
"Infusion of phenylephrine through PIV is safe when used in moderate doses for a short time and can be considered in lieu of placing a central line solely for this purpose."	( Safety of Phenylephrine Infusion Through Peripheral Intravenous Catheter in the Neurological Intensive Care Unit. Datar, S; Gutierrez, E; Schertz, A; Vachharajani, V, 2018)	0.48
" In conclusion, AKAP-Lbc emerges as a coordinator of signals that protect cardiomyocytes against the toxic effects of DOX."	( AKAP-Lbc mediates protection against doxorubicin-induced cardiomyocyte toxicity. Arambasic, M; Caso, S; Cotecchia, S; Diviani, D; Maric, D, 2017)	0.46
" We hypothesize that BDPE is a safe short-term vasopressor choice for hypotensive ED patients."	( Safety of bolus-dose phenylephrine for hypotensive emergency department patients. Braude, D; Daconti, L; Langsjoen, J; Rankin, S; Swenson, K; Villarreal, T, 2018)	0.48
" We defined an adverse event (AE) as sBP>180, dBP>110, or HR<50 within 30min of receiving BDPE."	( Safety of bolus-dose phenylephrine for hypotensive emergency department patients. Braude, D; Daconti, L; Langsjoen, J; Rankin, S; Swenson, K; Villarreal, T, 2018)	0.48
" LS180 cells were used as a model of the human intestinal epithelium to examine phenylephrine metabolism and its inhibition by generally recognized as safe (GRAS) and dietary compounds."	( Effects of generally recognized as safe (GRAS) and dietary compounds on phenylephrine metabolism in LS180 human intestinal cells. Gerk, PM; Zhang, Z, 2018)	0.48
"5% drop is effective and safe as mydriatic combination for retinopathy of prematurity screening."	( Efficiency and safety of phenylephrine and tropicamide used in premature retinopathy: a prospective observational study. Alpay, A; Aydemir, C; Canturk Ugurbas, S, 2019)	0.51
"Protocol-driven peripheral administration of lower concentration phenylephrine in an ICU setting is safe and feasible."	( Safety and Feasibility of Phenylephrine Administration Through a Peripheral Intravenous Catheter in a Neurocritical Care Unit. Ansari, S; Ballieu, P; Besharatian, Y, 2021)	0.62
" Safety analysis was carried out throughout the study and included the assessment of adverse events, laboratory data, vital signs, ECG assessment."	( [Results of an open, randomized, actively controlled study of the efficacy and safety of the new drug Freinozole nasal spray (Phenylephrine + Cetyrizine) in patients with acute respiratory infection]. Fridman, IL; Grinyov, IA; Karpishchenko, SA; Merkulov, ME; Pisarev, VV; Ushakova, SE, 2019)	0.51
"3% was safe for use in children and maintained mydriasis during cataract surgery."	( Safety and efficacy data supporting U.S. FDA approval of intracameral phenylephrine and ketorolac 1.0%/0.3% for pediatric cataract surgery: clinical safety and pupil and pain management. Plager, DA; Trivedi, RH; Wilson, ME, 2020)	0.56
" This study demonstrates that midline catheters are a safe alternative to CVCs, for the safe and efficacious administration of vasopressors for prolonged periods of time."	( Safety and efficacy of vasopressor administration through midline catheters. Davison, D; Haridasa, N; Hawkins, K; Prasanna, N; Sparks, A; Yamane, D, 2021)	0.62
"To evaluate systemic adverse events after screening for retinopathy of prematurity (ROP) performed with mydriatic."	( Systemic adverse events after screening of retinopathy of prematurity with mydriatic. Imamura, T; Kakinoki, M; Maruo, Y; Obata, S; Ohji, M; Yanagi, T, 2021)	0.62
" The numbers of infants with abdominal and/or systemic adverse events were compared between pre- and post-examination periods."	( Systemic adverse events after screening of retinopathy of prematurity with mydriatic. Imamura, T; Kakinoki, M; Maruo, Y; Obata, S; Ohji, M; Yanagi, T, 2021)	0.62
"Screening for ROP with mydriatic may have adverse effects on systemic conditions."	( Systemic adverse events after screening of retinopathy of prematurity with mydriatic. Imamura, T; Kakinoki, M; Maruo, Y; Obata, S; Ohji, M; Yanagi, T, 2021)	0.62
" Otherwise, adverse events did not differ after either administration technique."	( Efficacy and safety of mydriatic microdrops for retinopathy of prematurity screening: an external pilot crossover randomized controlled trial. Diamanti, E; Georgiou, E; Haidich, AB; Lithoxopoulou, M; Mataftsi, A; Seliniotaki, AK; Talimtzi, P; Ziakas, N, 2022)	0.72
" Systemic absorption of the instilled mydriatic regimens has been associated with various adverse events in this fragile population."	( Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial. Boutou, E; Diamanti, E; Dokoumetzidis, A; Gika, H; Haidich, AB; Lithoxopoulou, M; Mataftsi, A; Nikolaidou, M; Raikos, N; Seliniotaki, AK; Virgiliou, C; Ziakas, N, 2022)	0.72
" Heart rate, oxygen saturation, blood pressure measurements, and 48-h adverse events will also be recorded."	( Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial. Boutou, E; Diamanti, E; Dokoumetzidis, A; Gika, H; Haidich, AB; Lithoxopoulou, M; Mataftsi, A; Nikolaidou, M; Raikos, N; Seliniotaki, AK; Virgiliou, C; Ziakas, N, 2022)	0.72
" There are various case reports, however, of ocular and systemic complications associated with intracameral phenylephrine such as generation of free radicals, toxic anterior segment syndrome, inconsistent pupillary dilation during surgery, and ventricular fibrillation."	( The safety of intracameral phenylephrine - A systematic review. Casson, R; Chan, WO; Gowda, A; Jie, WWJ, )	0.13
"To determine the safety and efficacy of hourly, high dose phenylephrine (>1000 μg) for acute ischemic priapism (AIP) through monitoring adverse hemodynamic events amongst risk profiles."	( Safety and Efficacy of Phenylephrine Administration for the Treatment of Ischemic Priapism: An Opportunity for Quality Improvement in Periprocedural Safety Assessment. Deebel, NA; Dutta, R; Matz, E; Scarberry, K; Terlecki, RP, 2022)	0.72
" The safety profile of phenylephrine for patients at risk for adverse hemodynamic events was examined."	( Safety and Efficacy of Phenylephrine Administration for the Treatment of Ischemic Priapism: An Opportunity for Quality Improvement in Periprocedural Safety Assessment. Deebel, NA; Dutta, R; Matz, E; Scarberry, K; Terlecki, RP, 2022)	0.72
"This study demonstrates that PDP phenylephrine and epinephrine are safe and efficacious in treating the acute hypotensive period."	( The safety and efficacy of push dose vasopressors in critically ill adults. Fuller, BM; Gibson, G; Pope, H; Singer, S, 2022)	0.72
"Intraoperative hypotension (IOH) is a highly prevalent adverse event associated with the induction and maintenance of general anesthesia."	( The Safety and Efficacy of Peripherally Administered Norepinephrine during the Perioperative Period. Simons, C, 2022)	0.72

Pharmacokinetics

Phenylephrine HCl 10 mg has been used as a nasal decongestant for over 50 years. We aimed to investigate pharmacokinetic interactions between acetaminophen and phenylephrine.

Excerpt	Reference	Relevance
" The pharmacokinetic parameters, apparent absorption, and elimination rate constants, of phenylephrine and the prodrug were determined from aqueous humor concentration-time and mydriasis-time profiles."	( Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes. Chien, DS; Schoenwald, RD, 1990)	0.28
" Pharmacokinetic parameters were obtained by computer-assisted, nonlinear, least-squares-fitting regression analysis."	( Pharmacokinetics and pharmacodynamics of trimazosin in man. Elliott, HL; Meredith, PA; Reid, JL, 1983)	0.27
" Pharmacokinetic analysis revealed identical absorption and elimination constants."	( Pharmacokinetics and neural blockade after subarachnoid lidocaine in the rhesus monkey. III. Effects of phenylephrine. Bridenbaugh, PO; Denson, DD; Thompson, GA; Turner, PA, 1984)	0.27
" From the time course of the mydriatic effects, the pharmacokinetic coefficients were calculated using a computer."	( Pharmacokinetics of topical phenylephrine hydrochloride in the normal human eye. Araie, M; Komuro, Y; Matsumoto, S; Tsuru, T, 1982)	0.26
" It is possible that each enantiomer can reflect significant enantioselective differences with regard to both pharmacokinetic and pharmacodynamic effects."	( Pharmacokinetics of oral decongestants. Dowse, R; Kanfer, I; Vuma, V, )	0.13
" The concentration-depth profiles for solutes in underlying tissues with variable blood flows were described by a compartment-in-series pharmacokinetic model in which each tissue's blood flows to and from a central compartment were incorporated."	( Effects of vasoconstriction on dermal pharmacokinetics and local tissue distribution of compounds. Roberts, MS; Singh, P, 1994)	0.29
"Recirculatory pharmacokinetic models for indocyanine green (ICG), inulin, and antipyrine facilitate description of intravascular mixing and tissue distribution following intravenous administration."	( Drug-induced hemodynamic perturbations alter the disposition of markers of blood volume, extracellular fluid, and total body water. Avram, MJ; Krejcie, TC; Wang, Z, 2001)	0.31
" Based on its pharmacokinetic profile and a relative uroselectivity 29-fold greater than the nonselective drugs, fiduxosin is expected to exhibit greater selectivity for urethral compared with vascular alpha(1)-adrenoceptors in human and should be a novel, long-acting, uroselective alpha(1)-adrenoceptor antagonist."	( Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. Brune, ME; Hancock, AA; Hui, YH; Katwala, SP; Kerwin, JF; Marsh, KC; Meyer, MD; Milicic, I; Stolarik, D; Witte, DG, 2002)	0.31
" The assay was applied to the analysis of samples from a pharmacokinetic study."	( Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of phenylephrine in human plasma and its application to a pharmacokinetic study. Klíma, J; Macek, J; Ptácek, P, 2007)	0.34
"To develop a pharmacodynamic model of portal hypertension from chronic hepatitis."	( A pharmacodynamic model of portal hypertension in isolated perfused rat liver. Cai, DY; Li, PT; Li, T; Song, M; Xu, XY; Yin, H; Zhang, T; Zhang, TT; Zhao, X; Zhou, H, 2012)	0.38
" In the isolated perfused rat livers with chronic hepatitis, both median effective concentrations were defined as the pharmacodynamic model of portal hypertension."	( A pharmacodynamic model of portal hypertension in isolated perfused rat liver. Cai, DY; Li, PT; Li, T; Song, M; Xu, XY; Yin, H; Zhang, T; Zhang, TT; Zhao, X; Zhou, H, 2012)	0.38
"A pharmacodynamic model of portal hypertension in isolated perfused rat livers with chronic hepatitis was defined as the median effective concentrations of phenylephrine and acetylcholine."	( A pharmacodynamic model of portal hypertension in isolated perfused rat liver. Cai, DY; Li, PT; Li, T; Song, M; Xu, XY; Yin, H; Zhang, T; Zhang, TT; Zhao, X; Zhou, H, 2012)	0.38
" We aimed to investigate pharmacokinetic interactions between acetaminophen and phenylephrine."	( Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. Anderson, BJ; Atkinson, HC; Potts, AL; Salem, II; Stanescu, I, 2015)	0.42
"Phenylephrine HCl 10 mg has been used as a nasal decongestant for over 50 years, yet only limited pharmacokinetic and metabolic data are available."	( Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Gelotte, CK; Zimmerman, BA, 2015)	0.42
" Pharmacokinetic blood samples were collected over 7 h, whereas pulse, blood pressure, and ECGs were measured over 12 h."	( Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Gelotte, CK; Zimmerman, BA, 2015)	0.42

Compound-Compound Interactions

Phenylephrine (PE) and norepinephrine (NE) may be used to maintain adequate blood pressure and tissue perfusion in patients with septic shock. The effect of NE combined with PE (NE-PE) on mortality remains unclear.

Excerpt	Reference	Relevance
"The effect of phenylephrine (PHE) boluses on left ventricular (LV) function was examined in patients without cardiovascular disease who developed arterial hypotension during high thoracic epidural anesthesia (TEA) combined with general anesthesia (GA) (group 1) or lumbar epidural anesthesia (LEA) combined with GA (group 2)."	( Effect of phenylephrine bolus administration on left ventricular function during high thoracic and lumbar epidural anesthesia combined with general anesthesia. Georgieff, M; Goertz, AW; Heinrich, H; Lindner, KH; Rockemann, MG; Seeling, W, 1993)	0.29
" In Groups 6-11, hemorrhage was or was not combined with head trauma, and large volumes of saline were given IV to achieve target MAPs of 70, 80, or 90 mm Hg."	( Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage. Artru, AA; Geva, D; Merkind, V; Roytblat, L; Shapira, Y; Shapiro, O; Talmor, D, 1999)	0.3
"The results of this study indicate that maintaining mean arterial blood pressure at 70, 80, or 90 mm Hg with either phenylephrine or large volumes of saline worsened the neurodeficit score and/or survival and did not affect cerebral edema formation in our rat model of head trauma combined with hemorrhage."	( Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage. Artru, AA; Geva, D; Merkind, V; Roytblat, L; Shapira, Y; Shapiro, O; Talmor, D, 1999)	0.3
"1%, preoperatory, if the general anesthesia must be combined with local anesthesia, anesthetics in association with adrenalin should not be used; immediately postoperatory local use of atropine should be applied with cautiousness."	( [Neosynephrine mydriasis combined with general anesthesia with halothane in ocular surgery]. Giuri, S, 2002)	0.31
" An examiner masked to drug combination and time used digital analysis to calculate pupil diameter for each photograph."	( Comparison of two drug combinations for dilating dark irides. Anderson, HA; Bertrand, KC; Fern, KD; Hu, YS; Manny, RE, 2010)	0.36
"Increased bioavailability of phenylephrine is reported when combined with paracetamol in over-the-counter formulations for the symptomatic treatment of the common cold and influenza."	( Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. Anderson, BJ; Atkinson, HC; Potts, AL, 2015)	0.42
"MEDLINE and EMBASE databases were searched for papers discussing or describing any adverse effect, hypersensitivity or safety concerns related to phenylephrine alone or in combination with other drugs."	( Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. Anderson, BJ; Atkinson, HC; Potts, AL, 2015)	0.42
"This study evaluated the effects of voluntary ethanol consumption combined with testosterone treatment on cardiovascular function in rats."	( Effect of Voluntary Ethanol Consumption Combined with Testosterone Treatment on Cardiovascular Function in Rats: Influence of Exercise Training. Crestani, CC; Engi, SA; Planeta, CS, 2016)	0.43
" The combination with topical phenylephrine did not have any additional effect on mydriasis compare with the cyclopentolate alone."	( Effect of topical cyclopentolate alone or combined with phenylephrine in healthy horses. Bessonnat, A; Vanore, M, 2021)	0.62
"Repeated administration of cyclopentolate alone or combined with phenylephrine induce a significant mydriasis for at least 48 h after the last administration in normal horses' eyes, and do not affect STT-1, IOP, digestive function, and HR."	( Effect of topical cyclopentolate alone or combined with phenylephrine in healthy horses. Bessonnat, A; Vanore, M, 2021)	0.62
"To investigate the therapeutic effect of phenylephrine combined with goal-directed fluid therapy (GDFT) in elderly patients undergoing total hip arthroplasty."	( Application of Phenylephrine Combined with Goal-Directed Fluid Therapy in Elderly Patients Undergoing Hip Arthroplasty: A Randomized Controlled Trial. Huang, S; Peng, W; Wang, A; Zhang, L, 2022)	0.72
" Patients in the control group were given GDFT alone, and patients in the experimental group were given phenylephrine combined with GDFT."	( Application of Phenylephrine Combined with Goal-Directed Fluid Therapy in Elderly Patients Undergoing Hip Arthroplasty: A Randomized Controlled Trial. Huang, S; Peng, W; Wang, A; Zhang, L, 2022)	0.72
"Phenylephrine combined with GDFT can be used in elderly patients undergoing hip arthroplasty to reduce fluid input and improve intraoperative hemodynamic stability, to reduce the occurrence of postoperative related complications."	( Application of Phenylephrine Combined with Goal-Directed Fluid Therapy in Elderly Patients Undergoing Hip Arthroplasty: A Randomized Controlled Trial. Huang, S; Peng, W; Wang, A; Zhang, L, 2022)	0.72
"Phenylephrine (PE) and norepinephrine (NE) may be used to maintain adequate blood pressure and tissue perfusion in patients with septic shock, but the effect of NE combined with PE (NE-PE) on mortality remains unclear."	( Norepinephrine combined with phenylephrine versus norepinephrine in patients with septic shock: a retrospective cohort study. Gu, WJ; He, D; Hong, L; Hu, H; Lu, X; Lyu, J; Yin, H; Zhang, L, 2023)	0.91
"NE combined with PE was inferior to NE alone in patients with septic shock, and it was associated with a higher hospital mortality rate."	( Norepinephrine combined with phenylephrine versus norepinephrine in patients with septic shock: a retrospective cohort study. Gu, WJ; He, D; Hong, L; Hu, H; Lu, X; Lyu, J; Yin, H; Zhang, L, 2023)	0.91
"The present work examined the effect of oral administration of rutin and its combination with metformin, an antidiabetic drug on blood glucose, total cholesterol and triglycerides level and vascular function in streptozotocin (STZ) -induced diabetic rats."	( Influence of rutin and its combination with metformin on vascular functions in type 1 diabetes. Chakravarthi, S; Chellian, J; David, SR; Lai, PPN; Rajabalaya, R, 2023)	0.91

Bioavailability

Phenylephrine has low and variable oral bioavailability in humans. Mercury increases the vasoconstrictor response to phenylephrine by reducing NO bioavailability and increasing the involvement of ROS and constrictor prostanoids.

Excerpt	Reference	Relevance
" In part, this appears to be related to the cardioinhibitory and negative chronotropic action of verapamil, but it is also likely to depend on increases in bioavailability of prazosin and higher plasma levels when the drug is given with verapamil."	( Clinical pharmacological studies on the interaction between alpha-adrenoceptors and calcium antagonists. Elliott, HL; Meredith, PA; Pasanisi, F; Reid, JL, 1985)	0.27
" A mean bioavailability of 70 and 58 per cent (Thomasin) or of 78 and 108 per cent (Thomasin retard) was calculated by comparison of the corresponding AUC- and CUE-values of the total etilefrine."	( [Bioavailability of etilefrine from Thomasin and Thomasin sustained-release tablets]. Haustein, KO; Hüller, G, 1985)	0.27
"The relative bioavailability of a prodrug of etilefrine, its stearic acid ester, was determined by means of plasma levels and renal excretion."	( Pharmacokinetic comparison of etilefrine to its prodrug, the stearic acid ester of etilefrine. Hitzenberger, G; Rominger, KL, 1980)	0.26
" In six volunteers bioavailability was reduced to 35% for a fast release tablet and to 17% for a sustained release preparation."	( Dihydroergotamine increases the bioavailability of orally administered etilefrine. Dengler, HJ; Hengstmann, JH; Hengstmann, R; Schwonzen, S, 1982)	0.26
" The bioavailability of oral trimazosin was 61 +/- 28%."	( Pharmacokinetics and pharmacodynamics of trimazosin in man. Elliott, HL; Meredith, PA; Reid, JL, 1983)	0.27
"28 hour-1 for the apparent absorption rate constant."	( Pharmacokinetics of topical phenylephrine hydrochloride in the normal human eye. Araie, M; Komuro, Y; Matsumoto, S; Tsuru, T, 1982)	0.26
" Both PPA and PDE are readily and completely absorbed, whereas PE, with a bioavailability of only approximately 38%, is subject to gut wall metabolism and is thought to be absorbed erratically."	( Pharmacokinetics of oral decongestants. Dowse, R; Kanfer, I; Vuma, V, )	0.13
"The in vitro dissolution and the relative ocular bioavailability of high- and low-melting phenylephrine oxazolidines (HMP and LMP) from a nonaqueous suspension (silicone fluid) were compared."	( Formulation, in vitro dissolution, and ocular bioavailability of high- and low-melting phenylephrine oxazolidines. Guillory, JK; Qiu, Y; Schoenwald, RD, 1993)	0.29
" Our findings suggest that, within the corpus cavernosum, neuronal release or synthesis of nitric oxide depends, at least in part, on intracellular bioavailability of calcium."	( Effect of alteration in the extracellular potassium and calcium on field-stimulated relaxation of the rabbit corpus cavernosum. Broderick, G; Levin, RM; Saito, M; Wein, AJ, 1996)	0.29
" This may represent a therapeutic strategy for vascular diseases characterized by decreased bioavailability of NO."	( Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Barber, DA; Crotty, TB; Gloviczki, P; Katusic, ZS; Kullo, IJ; Mozes, G; O'Brien, T; Schwartz, RS, 1997)	0.3
"8 hr and a bioavailability of 30 to 50% in dogs."	( Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. Brune, ME; Crowell, D; Hancock, AA; Ireland, LM; Katwala, S; Kerwin, JF; Marsh, KC; Meyer, MD; Milicic, I; Witte, DG, 1998)	0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"Previous studies from our group have shown a deficit in nitric oxide (NO) bioavailability and an excess production of the superoxide anion (O(2)(-)) in the stroke prone spontaneously hypertensive rat (SHRSP) compared to the normotensive Wistar Kyoto (WKY) strain."	( Gene transfer of endothelial nitric oxide synthase but not Cu/Zn superoxide dismutase restores nitric oxide availability in the SHRSP. Alexander, MY; Beattie, EC; Brosnan, MJ; Dominiczak, AF; Fennell, JP; Hamilton, CA; Heistad, DD; Jardine, E, 2000)	0.31
" These results indicate that short-term overexpression of a recombinant eNOS, but not Cu/ZnSOD gene, in carotid arteries of the SHRSP is an effective means of locally increasing NO bioavailability to improve endothelial function."	( Gene transfer of endothelial nitric oxide synthase but not Cu/Zn superoxide dismutase restores nitric oxide availability in the SHRSP. Alexander, MY; Beattie, EC; Brosnan, MJ; Dominiczak, AF; Fennell, JP; Hamilton, CA; Heistad, DD; Jardine, E, 2000)	0.31
" The increased responsiveness of diabetic vessels to exogenous peroxynitrite seems to be related to depressed basal NO bioavailability and may be considered as a compensatory way against activated contractile mechanisms of diabetic vascular smooth muscle."	( Effects of peroxynitrite on the reactivity of diabetic rat aorta. Cakici, I; Karasu , C; Zobali, F, 2001)	0.31
" (d) Our data therefore indicate superior endothelial function in the obese relative to the lean Zucker rat, reflected by a greater regulation of vasoconstrictor reactivity by basal NO, while the regulation of NO bioavailability by superoxide anion is similar."	( Investigation of basal endothelial function in the obese Zucker rat in vitro. Anggård, EE; Carrier, MJ; Laight, DW, 2000)	0.31
"These data show that the bioavailability of nitric oxide is reduced in aortae from diabetic rabbits due to excess production of superoxide, an effect augmented by homocysteine."	( Homocysteine enhances impairment of endothelium-dependent relaxation and guanosine cyclic monophosphate formation in aortae from diabetic rabbits. Angelini, GD; Jeremy, JY; Mikhailidis, DP; Shukla, N; Thompson, CS, 2002)	0.31
"The bioavailability of nitric oxide (NO) within the vascular wall is limited by superoxide anions (O2."	( Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Brandes, RP; Busse, R; Geiger, H; Jung, O; Marklund, SL; Pedrazzini, T, 2003)	0.32
" This study set out to test the hypothesis that in vivo gene transfer of GTPCH I to endothelial cells could increase bioavailability of BH4, enhance biosynthesis of nitric oxide and thereby enhance endothelium-dependent relaxations mediated by nitric oxide."	( In vivo expression and function of recombinant GTPCH I in the rabbit carotid artery. Hynes, SO; Katusic, ZS; Kovesdi, I; O'Brien, T; Richardson, DM; Smith, LA, 2004)	0.32
" These findings may represent an important contribution to reduced NO bioavailability in the microvasculature in diabetes."	( Vasorelaxation by red blood cells and impairment in diabetes: reduced nitric oxide and oxygen delivery by glycated hemoglobin. Frenneaux, MP; James, PE; Lang, D; Milsom, AB; Tufnell-Barret, T, 2004)	0.32
"Type 2 diabetes is preceded by years of insulin resistance and is characterized by reduced bioavailability of the antiatherosclerotic signaling molecule nitric oxide (NO) and premature atherosclerosis."	( Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Crossey, PA; Duncan, E; Kearney, MT; Li, JM; Noronha, BT; Shah, AM; Wheatcroft, SB, 2004)	0.32
"Decreased endothelial NO synthase (eNOS)-derived NO bioavailability and impaired vasomotor control are crucial factors in cardiovascular disease pathogenesis."	( A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Eidelman, DH; Govindaraju, K; Gros, R; Husain, M; Kabir, MG; Letarte, M; Toporsian, M; Vera, S, 2005)	0.33
" Our results show that tempol, in the dose used in this study, did not change the effects of L-NAME on blood pressure which suggests that tempol reduces bioavailability of nitric oxide on aortic isolated ring."	( The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. da Cunha, V; Preti, SC; Stefanon, I; Vassallo, DV, 2005)	0.33
" The present results suggest that chronic treatment with the flavonoids (baicalein, flavone, and quercetin) preserves vascular endothelial functions in hypertensive animals through several possible actions, including increasing endothelial nitric oxide production and bioavailability and reduction in blood pressure."	( Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. Machha, A; Mustafa, MR, 2005)	0.33
" In this regard, we investigated the role of tetrahydrobiopterin (BH4) bioavailability in regulating endothelial nitric oxide synthase (eNOS) activity, dimerisation and SO production in streptozotocin-induced diabetic mice."	( Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Alp, NJ; Cai, S; Channon, KM; Khoo, J; Mussa, S, 2005)	0.33
" We re-evaluated autoinhibition in single-unit recordings from deeply seated 5-hydroxytryptamine neurons in slices in which endogenous 5-hydroxytryptamine bioavailability was restored by supplementing its precursor L-tryptophan."	( Differential autoinhibition of 5-hydroxytryptamine neurons by 5-hydroxytryptamine in the dorsal raphe nucleus. Ballini, C; Corradetti, R; Della Corte, L; Mlinar, B; Nencioni, S; Tatini, F, 2005)	0.33
" The indirect evaluation of NO bioavailability analyzed by the area under the curve demonstrated a reduction on NO on the Ovx-Inf group that could contributes to increased response to phenylephrine."	( Myocardial infarction increases reactivity to phenylephrine in isolated aortic rings of ovariectomized rats. Bianchi, PR; Giuberti, K; Gumz, BP; Stefanon, I, 2006)	0.33
" Thus, enhanced PE contraction, blunted endothelium-dependent relaxation, and adaptations in nitric oxide bioavailability pathways provide the first evidence of chronic, in vivo BSO-induced, oxidative stress-mediated direct effects on the vasomotor function of arteries."	( Glutathione depletion in vivo enhances contraction and attenuates endothelium-dependent relaxation of isolated rat aorta. Denniss, SG; Ford, RJ; Graham, DA; Quadrilatero, J; Rush, JW, 2006)	0.33
" These results suggest that chronic oral administration of raloxifene to aging ovariectomized female rats augmented the bioavailability of endothelial nitric oxide in isolated aortic rings without altering eNOS protein levels."	( Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats. Au, CL; Fung, KP; Huang, Y; Laher, I; Tsang, SY; Vanhoutte, PM; Wong, CM; Yao, X, 2006)	0.33
" Basal and carbachol-stimulated nitric oxide (NO) bioavailability were studied in carotid artery rings in ovariectomized animals treated with estrogen or placebo for 2 weeks in vivo, or after 1 h of incubation in vitro."	( Estrogen treatment enhances nitric oxide bioavailability in normotensive but not hypertensive rats. Brosnan, MJ; Carswell, HV; Dominiczak, AF; Graham, D; Groves, S; Hamilton, CA, 2006)	0.33
"Basal NO bioavailability was increased in WKY treated with estrogen for 2 weeks compared to placebo."	( Estrogen treatment enhances nitric oxide bioavailability in normotensive but not hypertensive rats. Brosnan, MJ; Carswell, HV; Dominiczak, AF; Graham, D; Groves, S; Hamilton, CA, 2006)	0.33
" In the present report, we studied early mechanisms of reduction in the bioavailability of the antiatheroscerotic molecule nitric oxide (NO) in very mild insulin resistance."	( Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Duncan, ER; Ezzat, VA; Kearney, MT; Li, JM; Shah, AM; Walker, SJ; Wheatcroft, SB, 2007)	0.34
" This study investigated intracellular calcium concentrations [Ca2+]i and changes in phenylephrine-induced contractions as index of baseline nitric oxide (NO) bioavailability before plaque development."	( Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Bult, H; De Keulenaer, GW; Fransen, P; Guns, PJ; Herman, AG; Van Assche, T; Van Hove, CE, 2008)	0.35
" This response is endothelium mediated and involves the reduction of NO bioavailability and the action of reactive oxygen species."	( Low nanomolar concentration of mercury chloride increases vascular reactivity to phenylephrine and local angiotensin production in rats. Oliveira, EM; Padilha, AS; Peçanha, FM; Stefanon, I; Vassallo, DV; Wiggers, GA, 2008)	0.35
" The basal cytosolic NO concentration ([NO]c) is lower in 2K-1C than in 2K cells, and the bioavailability of the NO released from TERPY is larger in 2K than in 2K-1C VSMCs."	( Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats. Bendhack, LM; da Silva, RS; Laurindo, FR; Lima, RG; Lunardi, CN; Rodrigues, GJ; Santos, CX, 2008)	0.35
" We hypothesized that propofol increases nitric oxide (NO)-mediated vasodilation by enhancing its bioavailability in the aged adult vasculature, leading to greater vasodilation than in the young adult."	( The effects of propofol on vascular function in mesenteric arteries of the aging rat. Davidge, ST; Gragasin, FS, 2009)	0.35
" The data suggest that quercetin acts as a protective agent in mouse corpus cavernosum, increasing the bioavailability of exogenous nitric oxide by protecting it from superoxide anion (O(2)(-))."	( Protective effect of quercetin, a polyphenolic compound, on mouse corpus cavernosum. Ertuğ, PU; Oğülener, N; Olguner, AA; Singirik, E, 2010)	0.36
"Salt-induced vascular dysfunction in which underlying mechanisms involve reactive oxygen species (ROS)-mediated reduction of nitric oxide (NO) bioavailability has been well documented."	( Uncoupling protein 2 ablation exacerbates high-salt intake-induced vascular dysfunction. Hao, X; Liu, D; Luo, Z; Ma, L; Ma, S; Yang, D; Zhu, Z, 2010)	0.36
" Blood pressure (BP), mesenteric arterial reactivity, superoxide production, and NO bioavailability in the intact vessels were measured in each group."	( Uncoupling protein 2 ablation exacerbates high-salt intake-induced vascular dysfunction. Hao, X; Liu, D; Luo, Z; Ma, L; Ma, S; Yang, D; Zhu, Z, 2010)	0.36
"These findings suggest that UCP2 plays an important role in preventing salt-sensitive hypertension, which may be achieved by suppressing superoxide production and reserving NO bioavailability in blood vessels."	( Uncoupling protein 2 ablation exacerbates high-salt intake-induced vascular dysfunction. Hao, X; Liu, D; Luo, Z; Ma, L; Ma, S; Yang, D; Zhu, Z, 2010)	0.36
" Moreover, the increased reactivity to PHE promoted by Gd was endothelium-dependent, reducing NO bioavailability and involving an increased stimulation of angiotensin-converting enzyme and angiotensin II AT1 receptors."	( Gadolinium increases the vascular reactivity of rat aortic rings. Angeli, JK; Casali, EA; Fürstenau, CR; Ramos, DB; Sarkis, JJ; Souza, DO; Stefanon, I; Vassallo, DV, 2011)	0.37
" DHEA treatment corrected the increased PHE contraction and the impaired ACh-induced relaxation observed in OVX by an increment in NO bioavailability and decrease in ROS production."	( Dehydroepiandrosterone protects against oxidative stress-induced endothelial dysfunction in ovariectomized rats. Akamine, EH; Camporez, JP; Carvalho, CR; Davel, AP; Franci, CR; Rossoni, LV, 2011)	0.37
" Complementary studies in human umbilical vein EC in which IGF-1R was reduced using siRNA confirmed that reducing IGF-1R has favorable effects on NO bioavailability and EC insulin sensitivity."	( The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Abbas, A; Beech, DJ; Channon, KM; Cubbon, RM; Gage, M; Galloway, S; Grant, PJ; Imrie, H; Kahn, M; Kearney, MT; Rajwani, A; Smith, J; Sukumar, P; Viswambharan, H; Wheatcroft, SB; Xuan, S; Yuldeshava, N, 2011)	0.37
"These data demonstrate that IGF-1R is a critical negative regulator of insulin sensitivity and NO bioavailability in the endothelium."	( The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Abbas, A; Beech, DJ; Channon, KM; Cubbon, RM; Gage, M; Galloway, S; Grant, PJ; Imrie, H; Kahn, M; Kearney, MT; Rajwani, A; Smith, J; Sukumar, P; Viswambharan, H; Wheatcroft, SB; Xuan, S; Yuldeshava, N, 2011)	0.37
"Seven day exposure to a low concentration of lead acetate increases nitric oxide bioavailability suggesting a putative role of K+ channels affecting vascular reactivity."	( Activation of K+ channels and Na+/K+ ATPase prevents aortic endothelial dysfunction in 7-day lead-treated rats. Alonso, MJ; Azevedo, BF; Fiorim, J; Padilha, AS; Ribeiro, RF; Salaices, M; Simões, MR; Stefanon, I; Vassallo, DV, 2012)	0.38
" However, whether endogenous basal β(2)-AR activity controls vascular redox status and NO bioavailability is unclear."	( Increased vascular contractility and oxidative stress in β₂-adrenoceptor knockout mice: the role of NADPH oxidase. Brum, PC; Carvalho, MH; Ceravolo, GS; Davel, AP; Rossoni, LV; Wenceslau, CF, 2012)	0.38
"The present results demonstrate for the first time that enhanced NADPH-derived superoxide anion production is associated with reduced NO bioavailability in aortas of β(2)KO mice."	( Increased vascular contractility and oxidative stress in β₂-adrenoceptor knockout mice: the role of NADPH oxidase. Brum, PC; Carvalho, MH; Ceravolo, GS; Davel, AP; Rossoni, LV; Wenceslau, CF, 2012)	0.38
" Together, these data reveal for the first time that, in human skeletal muscle feed arteries, NO blockade can restore the heat-attenuated α(1)-adrenergic receptor-mediated vasocontraction and implicate endothelium-derived NO bioavailability as a major contributor to heat-induced sympatholysis."	( Heat and α1-adrenergic responsiveness in human skeletal muscle feed arteries: the role of nitric oxide. Andtbacka, RH; Ives, SJ; Kwon, SH; Noyes, RD; Richardson, RS; Ruan, T; Shiu, YT; Symons, JD; Zhang, QJ, 2012)	0.38
"Mercury is an environmental pollutant that reduces nitric oxide (NO) bioavailability and increases oxidative stress, having a close link with cardiovascular diseases, as carotid atherosclerosis, myocardial infarction, coronary heart disease and hypertension."	( Low mercury concentration produces vasoconstriction, decreases nitric oxide bioavailability and increases oxidative stress in rat conductance artery. Angeli, JK; Faria, Tde O; Lemos, NB; Padilha, AS; Ribeiro Junior, RF; Stefanon, I; Vassallo, DV, 2012)	0.38
" This metal elicits endothelial dysfunction causing decreased NO bioavailability via increased oxidative stress and contractile prostanoid production."	( Apocynin prevents vascular effects caused by chronic exposure to low concentrations of mercury. Alonso, MJ; Briones, AM; Escobar, AG; Peçanha, FM; Puntel, RL; Rizzetti, DA; Salaices, M; Santos, FW; Torres, JG; Vassallo, DV; Wiggers, GA, 2013)	0.39
"Mercury increases the vasoconstrictor response to phenylephrine by reducing NO bioavailability and increasing the involvement of ROS and constrictor prostanoids."	( Apocynin prevents vascular effects caused by chronic exposure to low concentrations of mercury. Alonso, MJ; Briones, AM; Escobar, AG; Peçanha, FM; Puntel, RL; Rizzetti, DA; Salaices, M; Santos, FW; Torres, JG; Vassallo, DV; Wiggers, GA, 2013)	0.39
" Cadmium exposure increased vasoconstrictor activity by reducing NO bioavailability owing to the increased production of ROS by NADPH oxidase."	( Cadmium exposure induces vascular injury due to endothelial oxidative stress: the role of local angiotensin II and COX-2. Angeli, JK; Cruz Pereira, CA; de Oliveira Faria, T; Padilha, AS; Stefanon, I; Vassallo, DV, 2013)	0.39
"The primary objective of this study was to compare the bioavailability of paracetamol, phenylephrine hydrochloride and guaifenesin in a new oral syrup with an established oral reference product."	( Bioavailability of paracetamol, phenylephrine hydrochloride and guaifenesin in a fixed-combination syrup versus an oral reference product. Janin, A; Monnet, J, 2014)	0.4
" It was thus concluded that NO bioavailability was reduced in the presence of ROS."	( Nitric oxide availability as a marker of oxidative stress. Bryan, NS; Pierini, D, 2015)	0.42
"The relative bioavailability of phenylephrine was increased when co-administered with acetaminophen."	( Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. Anderson, BJ; Atkinson, HC; Potts, AL; Salem, II; Stanescu, I, 2015)	0.42
"This study aimed to evaluate the effects of Wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), on aortic hyporeactivity to Phenylephrine (Phe) and nitric oxide bioavailability associated with pregnancy in hypertensive rats."	( The PI3K-Akt-eNOS pathway is involved in aortic hyporeactivity to Phenylephrine associated with late pregnancy in spontaneously hypertensive rats. Antoniali, C; Cavalari, P; Potje, SR; Sumida, DH; Troiano, JA; Zancheta, D, 2015)	0.42
" The aim of this current study was (i) to investigate the effects of a novel triphenylphosphonium derivatised dithiolethione (AP39), in the presence and absence of reduced nitric oxide bioavailability and (ii) to determine the effects of AP39 on myocardial membrane channels; CaV3, RyR2 and Cl(-)."	( Effects of AP39, a novel triphenylphosphonium derivatised anethole dithiolethione hydrogen sulfide donor, on rat haemodynamic parameters and chloride and calcium Cav3 and RyR2 channels. Cacanyiova, S; Grman, M; Kristek, F; Lacinova, L; Malekova, L; Misak, A; Ondrias, K; Pavlovicova, M; Perry, A; Tomasek, M; Tomaskova, Z; Tomasova, L; Whiteman, M; Wood, ME, 2015)	0.42
"Increased bioavailability of phenylephrine is reported when combined with paracetamol in over-the-counter formulations for the symptomatic treatment of the common cold and influenza."	( Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. Anderson, BJ; Atkinson, HC; Potts, AL, 2015)	0.42
"We determined whether decreased reactive oxygen species (ROS) production in the aorta of pregnant spontaneously hypertensive rats (SHR) resulted in increased nitric oxide (NO) bioavailability and hyporeactivity to phenylephrine (PE)."	( Decreased reactive oxygen species production and NOX1, NOX2, NOX4 expressions contribute to hyporeactivity to phenylephrine in aortas of pregnant SHR. Antoniali, C; Cavalari, P; Graton, ME; Nakamune, AC; Pereira, AA; Potje, SR; Sumida, DH; Tirapelli, CR; Troiano, JA; Vale, GT, 2016)	0.43
"Taken together, these results suggest that ROS production was decreased in the aortas of pregnant SHR and could contribute to higher NO bioavailability and hyporeactivity to PE in the aortas of pregnant SHR."	( Decreased reactive oxygen species production and NOX1, NOX2, NOX4 expressions contribute to hyporeactivity to phenylephrine in aortas of pregnant SHR. Antoniali, C; Cavalari, P; Graton, ME; Nakamune, AC; Pereira, AA; Potje, SR; Sumida, DH; Tirapelli, CR; Troiano, JA; Vale, GT, 2016)	0.43
" Thus, since acetylcholine-induced NO-mediated relaxation was impaired in diabetes because of reduced eNOS protein expression, pharmacological intervention improving NO bioavailability could be useful in the management of diabetic endothelial dysfunction."	( Reduced nitric oxide-mediated relaxation and endothelial nitric oxide synthase expression in the tail arteries of streptozotocin-induced diabetic rats. Leung, SW; Mokhtar, SS; Rasool, AH; Suppian, R; Vanhoutte, PM; Yusof, MI, 2016)	0.43
" The present data suggest that the oxidative stress and reduced bioavailability of nitric oxide may contribute to attenuation of vasodilator responses to ACh and Ang II, and hyperreactivity to Ang II in the mesentery of preeclamptic rat, which may contribute to the increased peripheral vascular resistance and BP, as well as intrauterine growth restriction in L-NAME-induced PE."	( Differential responses of mesenteric arterial bed to vasoactive substances in L-NAME-induced preeclampsia: Role of oxidative stress and endothelial dysfunction. Amaral, TAS; Carvalho, LCRM; Costa, CA; Moura, RS; Ognibene, DT; Resende, AC; Rocha, APM, 2018)	0.48
" Bioavailability was also similar to the ophthalmic formulation."	( The phenylephrine concentration-response relationship for blood pressure after nasal delivery in children. Anderson, BJ; Armstead, VE; Bilyeu, DP; Christensen, LK; Friesen, RH; Johnson, KE, 2017)	0.46
" The premise that acetaminophen increases phenylephrine bioavailability by competition for presystemic sulfation was corroborated by increased phenylephrine sulfate in urine."	( An open-label, randomized, four-treatment crossover study evaluating the effects of salt form, acetaminophen, and food on the pharmacokinetics of phenylephrine. Gelotte, CK, 2018)	0.48
" Obtained findings suggested that CLE was able to enhance nitric oxide bioavailability that might dampen the vasoconstriction effect of phenylephrine."	( Effects of citrus leaf extract on aortic vascular reactivity in hypertensive rats fed repeatedly heated vegetable oil. Jaarin, K; Kamisah, Y; Mohamed, S; Siti, HN, 2019)	0.51
"Phenylephrine (PE) has low and variable oral bioavailability in humans, due in part to presystemic metabolism by sulfation."	( Effects of generally recognized as safe (GRAS) and dietary compounds on phenylephrine metabolism in LS180 human intestinal cells. Gerk, PM; Zhang, Z, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Incubation of endothelium-intact aortic rings with 100 μM apocynin and 100 μM L-NAME suggested the role of NADPH oxidase in generation of reactive oxygen species (ROS) and decrease in bioavailability of nitric oxide (NO) from eNOS on exposure to cobalt."	( Cobalt-Induced Hypercontraction is Mediated by Generationof Reactive Oxygen Species and Influx of Calcium in Isolated RatAorta. Basir, SF; Khan, LA; Wani, SA, 2020)	0.56
" In this way, RSNOs are an emerging class of NO donors with a potential to restore NO bioavailability within cardiovascular disorders."	( S-Nitrosothiols as potential therapeutics to induce a mobilizable vascular store of nitric oxide to counteract endothelial dysfunction. Gaucher, C; Giummelly, P; Lartaud, I; Parent, M; Perrin-Sarrado, C; Salgues, V; Zhou, Y, 2020)	0.56
"Common cold symptoms may be mitigated by products in caplet, nasal spray, and oral solution formulations, although variations exist in the bioavailability of the active ingredients contained within these products."	( A single-dose, open-label, randomized, scintigraphic study to investigate the gastrointestinal behavior of 2 triple-combination cold products (acetaminophen, phenylephrine, and dextromethorphan) in healthy male volunteers. Armogida, M; Doll, WJ; Mallefet, P; Page, RC; Sandefer, EP, 2022)	0.72

Dosage Studied

Phenylephrine injected intracamerally does not have a linear mydriatic dose-response relationship in humans. The optimized phenylephrine nanosuspension was then freeze dried and incorporated into a multi-layered buccal patch.

Excerpt	Relevance	Reference
" Cumulative dose-response curves of calcium showed no increase in maximum responses although responses to low concentrations of calcium were augmented by sotalol and practolol."	( The influence of beta-adrenergic antagonists on the adrenergic responses of the rat vas deferens. Swamy, VC; Tomei, LD, 1976)	0.26
" The two drugs caused comparable shifts of the isoproterenol dose-response curve during anesthesia."	( Interaction of anesthesia, beta-receptor blockade, and blood loss in dogs with induced myocardial infarction. Bennett, MJ; Clarke, TN; Foëx, P; Prys-Roberts, C; Roberts, JG; Ryder, WA, 1976)	0.26
"Isoprenaline dose-response curves plotting increases in heart rate before and after labetalol are suggestive of competitive antagonism at beta-adrenoceptor sites."	( Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Prichard, BN; Richards, DA; Tuckman, J, 1976)	0.26
" Propranolol shifted the dose-response curves downward and to the right for all agonists; phentolamine, shifter the curves upward and to the left."	( Effects of adrenergic amines on electrophysiological properties and automaticity of neonatal and adult canine Purkinje fibers: evidence for alpha- and beta-adrenergic actions. Danilo, P; Hordof, AJ; Ilvento, JP; Rosen, MR, 1977)	0.26
"In aortic strips, the dose-response curves for phenylephrine were obtained before and after addition of droperidol."	( Droperidol, its alpha-adrenergic blocking action on the aortic strip and inhibitory action on norepinephrine uptake of the adrenergic terminal of the left atrial strip of rabbit. Kasama, A; Kaya, K; Satoh, M; Yamanaka, I; Yanagisawa, M, 1978)	0.26
" Cocaine or phentolamine shifted the dose-response curve to the left."	( Effects of ethylephrine on the rat atrial pacemaker. Aramendía, P; De Mikulic, LE; Márquez, MT, 1977)	0.26
" The dose-response curve for the chronotropic action of phenylephrine was parallel to that of isoprenaline, whilst the dose-response curve for the inotropic action of phenylephrine was less steep than that of isoprenaline."	( Characterization of adrenoceptors mediating positive inotropic responses in the ventricular myocardium of the dog. Endoh, M; Shimizu, T; Yanagisawa, T, 1978)	0.26
" Values of KA and A50 were calculated from dose-response curves obtained for three alpha-adrenergic agonists (phenylephrine, methoxamine and norepinephrine) in the presence and absence of partial irreversible blockade by phenoxybenzamine."	( Determination of the stimulus-response relation for three alpha-adrenergic agonists on rabbit aorta. Gero, A; Raffa, RB; Tallarida, RJ, 1979)	0.26
" In the dosage used (100 mg/day) ciclazindol was observed to be a peripheral Na-reuptake blocker with no significant effect on the postsynaptic alpha-receptors."	( Antidepressant activity and pharmacological interactions of ciclazindol. Bailey, J; Coppen, A; Ghose, K; Rama Rao, VA, 1978)	0.26
" Phentolamine, on the other hand, shifted the phenylephrine dose-response curve for contractility to the right without affecting the other parameters."	( Biochemical and mechanical effects of phenylephrine on the heart. McNeill, JH; Verma, SC, 1976)	0.26
" Furthermore the dose-response relationships for increases of cAMP and of developed tension elicited by phenylephrine were determined."	( Relationship between the level of cAMP and the contractile force under stimulation of alpha- and beta-adrenoceptors by phenylephrine in the isolated rabbit papillary muscle. Brodde, OE; Endoh, M; Schümann, HJ, 1976)	0.26
" The maximum phenylephrine inotropic response was not significantly changed after 15 min of exposure to theophylline; however, there was a slight shift to the left of the phenylephrine dose-response curve."	( The effect of theophylline on amine-induced cardiac cyclic AMP and cardiac contractile force. Martinez, TT; McNeil, JH, 1977)	0.26
"13 The vasoconstrictor actions of phenylephrine, noradrenaline and adrenaline were all antagonized by the systemic administration of phentolamine, all three dose-response curves being shifted to the right."	( The role of beta-adrenoceptors in the responses of the hepatic arterial vascular bed of the dog to phenylephrine, isoprenaline, noradrenaline and adrenaline. Richardson, PD; Withrington, PG, 1977)	0.26
" Subsequent to obtaining the first dose-response curve for norepinephrine, aortic strips were less sensitive to norepinephrine."	( Specific alpha-adrenergic receptor desensitization in vascular smooth muscle. Barron, KW; Carrier, O; Wedell, EK, 1978)	0.26
" The dose-response curve for dopamine was not affected by the antagonists pimozide (10(-6) M), yohimbine (10(-5) M) pindolol (3 x 10(-8) M) and phentolamine (10(-6) M) when these agents were given separately."	( No evidence for involvement of dopaminergic receptors in the positive inotropic action of dopamine on the isolated rabbit papillary muscle. Brodde, OE; Motomura, S; Schümann, HJ, 1978)	0.26
" Dose-response lines for all the compounds except clonidine were parallel."	( Comparison of pre-junctional alpha-adrenoceptors at the neuromuscular junction with vascular post-junctional alpha-receptors in cat skeletal muscle. Malta, E; McPherson, GA; Raper, C, 1979)	0.26
"Cumulative log dose-response curves of soterenol, isoproterenol, phenylephrine and norepinephrine on isolated pregnant rat uterus at different days of gestation, were investigated."	( Adrenoceptors involved in the contractile activity of islated pregnant rat uterus. Borda, E; Gimeno, AL; Gimeno, MF; Sauvage, J; Sterin-Borda, L, 1979)	0.26
" The characteristic parameters of drug-receptor interaction -- the maximal response and ED50 -- were calculated based on the conventional dose-response plot and its linear transformations."	( Phenylephrine interaction with specific red cell receptors. Banzaru, T; Fischer, I; Mihalas, GI; Plauchithiu, MG; Rocsin, M; Ursuta, R, 1979)	0.26
" The alpha-sympatholytic drug yohimbine (1 mg/kg) displaced both dose-response curves to the right, but the effect was greatest for guanfacine."	( Possible subdivision of postsynaptic alpha-adrenoceptors mediating pressor responses in the pithed rat. Kwa, HY; Timmermans, PB; van Zwieten, PA, 1979)	0.26
"In human adipose tissue in vitro, dose-response curves of lipolytic agents in releasing free fatty acids and glycerol into an albumine-containing medium were followed."	( Adrenergic lipolysis in human adipose tissue in vitro. Kuhn, E; Wenke, M; Wenkeová, J, 1975)	0.25
" Dose-response curves for acetylcholine with and without dopamine, isoprenaline, phenylephrine and noradrenaline were obtained."	( The depressor effect of dopamine on the electrical and mechanical activities of cat small intestine. Okawa, H; Wantanabe, M, 1975)	0.25
" The above agents, used individually for a total dosage of three drops in each eye did not provide adequate dilation for a thorough funduscopic examination."	( Systemic response to mydriatic eyedrops in neonates: mydriatics in neonates. Caputo, AR; Schnitzer, RE, )	0.13
" The lower dosage gave a submaximal increase in LES pressure."	( Modulation of lower esophageal sphincter relaxation in the opossum. Cohen, S; Fournet, J; Snape, WJ, 1979)	0.26
" However, the dose-response curve to EPI was shifted horizontally to the right 4 days after mating suggesting a tissue desensitization."	( The absence of sensitivity changes of the rabbit oviduct to phenylephrine and isoproterenol during early gestation. Heilman, RD; Reo, RR, 1977)	0.26
" Oviductal segments removed 2 h after endotoxin (26 h after hCG) showed electrical activity confined to the ampullary-isthmic-junction (AIJ), where ova were located; the dose-response curve for PE was shifted to the right and the maximum contraction was depressed."	( Accelerated ovum transport in rabbits induced by endotoxin II. Changes in oviductal smooth muscle activity. Harper, MJ; Hodgson, BJ; Valenzuela, G, 1978)	0.26
" Paired ion chromatography also was tried successfully for the quantitative determinations of isoproterenol, levodopa, methyldopa, and phenylephrine in some dosage forms."	( Applications of paired ion high-pressure liquid chromatography to catecholamines and phenylephrine. Das Gupta, D; Ghanekar, AG, 1978)	0.26
" When a similar dosage regimen was employed with pregnant rats beginning on day 16 of gestation, levodopa plus carbidopa delayed the average delivery time 12 hr."	( Investigation of a dopaminergic mechanism for regulating oxytocin release. Lewis, PR; Miller, JW; Seybold, VS, 1978)	0.26
"A method for the quantitative determination of potassium guaiacolsulfonate and phenylephrine hydrochloride in commercial dosage forms was developed."	( Applications of paired ion high-pressure liquid chromatography: quantitative determination of potassium guaiacolsulfonate and other ingredients in cough syrups. Gupta, VD, 1979)	0.26
"In human adipose tissue in vitro, dose-response curves were followed for different adrenomimetics releasing free fatty acids and glycerol into an albumin-containing medium."	( Some adrenomimetic drugs affecting lipolysis in human adipose tissue in vitro. Kuhn, E; Wenke, M; Wenkeová, J, 1976)	0.26
" Dose-response curves and ED50 values for levarterenol or phenylephrine in control and 6-hydroxydopamine-denervated tissues, both in the presence and absence of corticosterone, are shown."	( Role of neuronal and extraneuronal uptake in responses of rabbit iris dilator muscle to levarterenol and phenylephrine. Ahlquist, RP; Carrier, GO; Matheny, JL, 1977)	0.26
"47-fold shift to the left in the dose-response curve to norepinephrine and carbachol, respectively, after pretreatment with reserpine."	( Potassium release from the rat submaxillary gland in vitro. III. Effects of pretreatment with reserpine. Martinez, JR, 1977)	0.26
"5 Hz, the dose-response curve for phenylephrine via alpha-adrenoceptors was shifted to the left (delta pD2-0."	( Influence of temperature and frequency on the positive inotropic action of phenylephrine in the isolated rabbit papillary muscle. Endoh, M; Hillen, B; Schümann, HJ, 1977)	0.26
" The main object of this study was to determine if est rogene could cause the alpha-receptors to be more sensitive to the alpha -receptor stimulating drugs, so that by using an equal dosage of alpha-r eceptor stimulating drugs in a preliminary estrogenic treatment, a stronger tonic effect would be achieved in the urethra musculature than by using the alpha-receptor stimulating drugs alone."	( Estrogenic sensitivity of alpha-receptors in the urethra musculature. Fuchs, P; Schreiter, F; Stockamp, K, 1976)	0.26
" It was concluded that the model was suitable for comparative dose-response studies of PGA2, PGE1 and PGE2 and their analogs."	( A dose-response comparison of PGA2, PGE1 and PGE2 using the phenylephrine-stimulated perfused oviduct of the rabbit. Heilman, RD; Strainer, SM, 1976)	0.26
" Systemic administration of alpha-methyldopa to rats for 15 days shifted the log dose-response curves for all three catecholamines, but not vasopressin or potassium chloride, to the right of all three blood vessel types; the maximal contractile responses to these amines were, however, not affected by chronic treatment with alpha-methyldopa."	( Pharmacological effects of alpha-methyldopa, alpha-methylnorepinephrine, and octopamine on rat arteriolar, arterial, and terminal vascular smooth. Altura, BM, 1975)	0.25
" Dose-response curves to norepinephrine were shifted to the left along the log dose axis (enhanced potency) and the maximum degree of contraction that could be elicited was increased."	( Influence of temperature and cocaine on responses of the isolated mouse vas deferens to adrenergic amines. Bohuski, K; Buckner, CK; Ryan, CF, 1975)	0.25
" The dose-response curve for phenylephrine was markedly shifted to the right by raising the temperature (pD2=0."	( Influence of temperature on the positive inotropic effects mediated by alpha-and-beta-adrenoceptors in the isolated rabbit papillary muscle. Endoh, M; Schümann, HJ; Wagner, J, 1975)	0.25
" Intravenous use, however, was ineffective in the dosage with which total systemic alpha adrenergic blockade was obtained."	( Effect of phenoxybenzamine on experimental cerebral arterial spasm in cats. Handa, H; Handa, J; Koyama, T; Matsuda, M; Yoneda, S, 1975)	0.25
" The effects of phenylephrine and isoprenaline on the isometric contraction of guinea-pig ventricle were compared over the whole range of their respective dose-response curves."	( Studies on the positive inotropic effect of phenylephrine: a comparison with isoprenaline. Ledda, F; Marchetti, P; Mugelli, A, 1975)	0.25
" Intravenous administration of PBZ in the dosage with which the pressor response to phenylephrine was completely blocked, or three times that dosage, failed to show any preventive effect on the vasospasm."	( [Effect of phenoxybenzamine on the experimental cerebral vasospasm in cats (author's transl)]. Handa, H; Handa, J; Koyama, T; Matsuda, M; Yoneda, S, 1975)	0.25
" Intraventricular injection of phenylephrine produced a dose-dependent hypothermia, whereas no dose-response relationship was obtained by isoproterenol."	( [Role of brain biogenic amines in the central thermoregulatory mechanism of the rat (author's transl)]. Fukushima, N, 1975)	0.25
" Although all variables were affected, the dose-response relationships for methacholine were most pronounced for specific airway conductance and airway resistance, in contrast to maximal mid-expiratory flow, forced expiratory volume in 1 sec, and forced vital capacity."	( Response of asthmatics to methacholine and suggestion. Kinsman, RA; Kopetzky, MT; Luparello, TJ; Souhrada, J; Spector, S, 1976)	0.26
" In aging, the overall effect of standard phenylephrine dosage has been found to decrease."	( [Hemodynamic effects of stimulation of alpha 1-adrenoreceptors in healthy elderly and aged persons]. Korkuschko, OW; Mistrjukow, WM; Moros, GS; Sarkisow, KG; Schatilo, WB; Tarasenko, OB, )	0.13
" However, the chronic D2O treatment appeared to have little effect on the phenylephrine and potassium chloride induced dose-response curves of SHR and WKY rats, producing a decreased maximal contraction of the potassium chloride dose-response curve of SHR only."	( The effect of chronic and acute administration of deuterium oxide (D2O) on vascular smooth muscle contraction in spontaneously hypertensive and Wistar-Kyoto rats. Liepins, A; McWilliam, TM; Rankin, AJ, 1992)	0.28
"032), but there was no difference in the results from the phenylephrine dose-response curves between the groups."	( Responsiveness of superficial hand veins to alpha-adrenoceptor agonists in insulin-dependent diabetic patients. Blaschke, TF; Blöchl-Daum, B; Eichler, HG; Ford, GA; Hoffman, BB; Kraemer, FB, 1992)	0.28
" The doses of phenylephrine required to increase systolic BP by 20 mm Hg (PS20) were calculated using a quadratic fit to the individual dose-response curves."	( Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man. Guy, S; Harron, DW; Shanks, RG; Tham, TC, 1992)	0.28
" Carvedilol shifts the dose-response curve to isoprenaline to the right, as well as to alpha-stimulants such as phenylephrine."	( Clinical pharmacology of carvedilol. Graham, BR; Prichard, BN; Tomlinson, B; Walden, RJ, 1992)	0.28
" CEC treatment had little effect on the pressor dose-response curve of either phenylephrine or BHT 920."	( Effect of chlorethylclonidine on arterial blood pressure and heart rate in the conscious rat. Piascik, MT; Pruitt, TA; Sparks, MS, 1992)	0.28
" Moreover, these agonists caused a shift of the dose-response curve for phenylephrine to the right in a parallel fashion in non-preconstricted preparations."	( Vascular alpha-1 antagonistic and agonistic effects of beta adrenoceptor agonists in rabbit common carotid arteries. Chiba, S; Fujiwara, T, 1992)	0.28
"5 mm Hg, but had no effect on the dose-response curves of dose of PE or Ang II vs."	( Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. Kalliatakis, B; Patton, J; Radford, HM; Rosendorff, C, 1992)	0.28
" Solutions of epinephrine and phenylephrine were infused into the vasculature of pithed tadpoles, and the resulting changes in vascular resistance (Rv) were used to construct log dose-response relationships."	( Adrenergic receptors and the regulation of vascular resistance in bullfrog tadpoles (Rana catesbeiana). Kimmel, PB, 1992)	0.28
" Dose-response experiments to 5-HT were conducted before and during an infusion of half-maximal effective doses of norepinephrine (NE), phenylephrine (PE) or endothelin-1 (ET-1)."	( Vasoconstrictor and vasodilator effects of serotonin in the isolated rabbit kidney. Croce, K; Li, T; Winquist, RJ, 1992)	0.28
"0 micrograms) were injected into the functionally isolated hindlimb, and dose-response curves were generated."	( Reduced vascular responsiveness after a single bout of dynamic exercise in the conscious rabbit. DiCarlo, SE; Howard, MG, 1992)	0.28
"3-3 mg/kg); the former effect was not dose dependent (bell-shaped dose-response curve), whereas the latter effect was dose-dependent."	( Cardiovascular effects of cocaine in conscious rats: relative significance of central sympathetic stimulation and peripheral neuronal monoamine uptake and release mechanisms. Goldberg, SR; Schindler, CW; Tella, SR, 1992)	0.28
" Dose-response curves for bradykinin were constructed using the dorsal hand vein compliance technique in veins preconstricted with phenylephrine in 27 volunteers (16 male, 11 female) aged 18 to 81 years."	( Bradykinin-induced venodilation is not impaired with aging in humans. Blaschke, TF; Dachman, WD; Ford, GA; Hoffman, BB, 1992)	0.28
" The Ca2+ response to human hepatocyte growth factor was dose dependent; 10(-10) mol/L hHGF gave the highest Ca2+ response, similar to the dose-response curve of DNA synthesis."	( Intracellular calcium as a second messenger for human hepatocyte growth factor in hepatocytes. Daikuhara, Y; Fusamoto, H; Hayashi, N; Ito, T; Kamada, T; Kaneko, A; Sasaki, Y; Tanaka, Y; Tsubouchi, H, 1992)	0.28
" Insufficient dosage may explain the lack of haemodynamic effect, while possible reasons for the higher SvO2 and lower VO2 are either reduced whole body VO2 or peripheral shunting."	( Amrinone before termination of cardiopulmonary bypass: haemodynamic variables and oxygen utilization in the postbypass period. Bilodeau, J; DeJesus, JM; O'Connor, JP; Ralley, FE; Ramsay, JG; Robbins, GR; Wynands, JE, 1992)	0.28
" Dose-response analysis indicated that L-NNA was 87 and 230 times more potent than L-NMA and L-NAA, respectively."	( Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. Chaudhuri, G; Cuevas, JM; Ignarro, LJ; Vargas, HM, 1991)	0.28
" While there was no shift of the horizontal positioning of the dose-response curve to alpha 1-adrenergic stimulation in the presence of lithium, the alpha 1-adrenoceptor mediated inotropic effect was increased in a concentration dependent manner (0."	( Lithium increases the alpha 1-adrenoceptor mediated inotropic effect in rat heart. Husøy, EA; Osnes, JB; Schiander, IG; Skomedal, T; Tveiten, A, 1991)	0.28
" Therapeutic doses of nifedipine are associated with measurable shifts in the dose-response curves to these two alpha-adrenergic agonists in the hand vein."	( Responsiveness of peripheral veins to vasodilators and the effect of nifedipine on alpha-adrenergic responsiveness in hypertension. Blaschke, TF; Ford, GA; Hoffman, BB; Katzir, D, 1991)	0.28
" Neither adrenergic dose-response studies, adrenergic antagonist studies nor experiments in which alpha- and beta-agonists were added together provided any evidence for a positive alpha/beta synergism on either MEL release or cAMP accumulation by bovine pinealocytes."	( Bovine pinealocytes in monolayer culture: studies on the adrenergic regulation of melatonin secretion. Olcese, J; Rüppel, R, 1991)	0.28
"Determination of the alpha-adrenergic blocking potency of drugs in humans is usually done by measuring the shift in the blood pressure versus logarithm of intravenous phenylephrine dose-response relationship."	( Determination of alpha-adrenergic blocking potency. Brodie, CL; Jamieson, MJ; Kwan, CM; Shepherd, AM, 1991)	0.28
" Subsequently a dose-response curve of pressor responses to phenylephrine was constructed in pithed rats."	( Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with irindalone in the spontaneously hypertensive rat. Gradin, K; Hedner, T; Persson, B, 1991)	0.28
" In control aortic rings the dose-response curves for either clonidine or naphazoline were biphasic, consisting of high- and low-affinity components."	( Interaction of imidazolines with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes. Piascik, MT; Pruitt, TA; Sparks, MS, 1991)	0.28
" (as a bolus or by increments) produced significant alpha 1-adrenoceptor antagonism (with rightward shifts of more than two-fold in the phenylephrine pressor dose-response curves) but no significant effects on supine or erect blood pressure and heart rate."	( Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects. Elliott, HL; Howie, CA; Reid, JL; Schafers, RF, 1991)	0.28
"1) of the pressor dose-response curve for diastolic blood pressure."	( Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects. Elliott, HL; Meredith, PA; Miller, SH; Reid, JL; Schafers, RF, 1991)	0.28
" A higher dosage of clonidine (0."	( Effects of alpha-noradrenergic substances on the optokinetic and vestibulo-ocular responses in the rabbit: a study with systemic and intrafloccular injections. Collewijn, H; Pompeiano, O; Tan, HS; van Neerven, J, 1991)	0.28
"The electrical and contractile activity of isolated intracellularly stimulated ventricular myocytes has been recorded and dose-response curves to [Ca2+]o, and to beta adrenergic, alpha adrenergic, and muscarinic agonists and antagonists were examined."	( Neurohumoral regulation of excitation-contraction coupling in ventricular myocytes from cardiomyopathic hamsters. Beresewicz, A; Horackova, M; Rowden, G; Wilkinson, M, 1991)	0.28
" Doxazosin produced rightward shifts of the PE pressor dose-response curves but had no effect on responses to AII."	( Vascular pressor responses in treated and untreated essential hypertension. Donnelly, R; Elliott, HL; Howie, CA; Reid, JL; Sumner, DJ, 1990)	0.28
" Sixty percent D2O also depressed a calcium contraction dose-response curve by approximately 25%."	( Deuterium oxide reduces agonist and depolarization-induced contraction of rat aortic rings. Liepins, A; McWilliam, TM; Rankin, AJ, 1990)	0.28
"The efficacy of a controlled-release topical dosage form of glyceryl trinitrate (Nitroglycerin Transdermal Therapeutic System, Nitroderm TTS, NTG-TTS; CAS 55-63-0) was studied in the experimental model of congestive heart failure in beagles."	( Efficacy of the glyceryl trinitrate transdermal therapeutic system in a dog model of heart failure. Inukai, T; Katahira, J; Nakao, K; Tanaka, M, 1991)	0.28
" Dose-response curves were constructed for phenylephrine (an alpha 1-adrenergic agonist), ST-91 (an alpha 2-adrenergic agonist), angiotensin II, and arginine vasopressin (AVP)."	( Does magnesium sulfate alter the maternal cardiovascular response to vasopressor agents in gravid ewes? Chatterjee, P; Chestnut, DH; Sipes, SL; Thompson, CS; Vincent, RD; Weiner, CP, 1991)	0.28
" bolus reduced the entire NPY dose-response curve (0."	( D-myo-inositol-1,2,6-trisphosphate is a selective antagonist of neuropeptide Y-induced pressor responses in the pithed rat. Dahlöf, C; Edvinsson, L; Hedner, T; Sun, XY, 1991)	0.28
" In all rings, cooling caused an increase in the slope of the dose-response curve and a significant increase in the concentration of agonist required to evoke contractions, as assessed by that concentration of NE required to evoke a contraction equal to 10% of maximal (EC10)."	( Cooling augments alpha 2-adrenoceptor-mediated contractions in rat tail artery. Bowman, CJ; Harker, CT; Ousley, PJ; Porter, JM, 1991)	0.28
" Cumulative dose-response curves constructed for the effect of these amines during diestrous, and at days 3-7, 10-15, 17-21 of gestation, showed that EC50 values increased gradually as term approached, which could imply a lower capacity of the uterus to respond to adrenergic drugs."	( Changes in the response to adrenergic drugs on mouse uterine contractions during pregnancy. Cruz, MA; Rudolph, MI; Sepúlveda, WH, 1990)	0.28
"12 g) and docosahexaenoic acid (480 mg) were administered orally twice daily for 1 wk, and dose-response curves were repeated."	( Enhanced alpha-adrenergic vasoconstriction by n-3 fatty acids in conscious dogs. Brooks, HL; Kenny, D; Warltier, DC, 1990)	0.28
" Prazosin produced a dose-response decrease in EAD amplitude and reduced the prevalence of VT."	( Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. Ben-David, J; Zipes, DP, 1990)	0.28
" The phenylephrine dose-response curves for mean arterial blood pressure and total peripheral vascular resistance were shifted to the right but the maximal responses were not decreased."	( Alpha 1-adrenoceptor subtypes and the regulation of peripheral hemodynamics in the conscious rat. Barron, KW; Kusiak, JW; Piascik, MT, 1990)	0.28
" However, LY 53857 differs from ketanserin in that it shifts the pressor dose-response curve to 5-HT in a parallel way at low doses but in a noncompetitive way at higher doses."	( Comparison between ketanserin and LY 53857 on vascular and cardiac 5-HT2 and alpha 1-adrenergic receptors in the pithed rat. Chaouche-Teyara, K; Cherqui, C; Dabiré, H; Fournier, B; Schmitt, H, )	0.13
" In abdominal aortic rings from both groups of animals, cumulative dose-response curves to PE and AVP were completed in 21 and 3% O2 conditions."	( Attentuation of systemic vasoreactivity in chronically hypoxic rats. Doyle, MP; Walker, BR, 1991)	0.28
" Dose-response curves to phenylephrine, histamine and 5-hydroxytryptamine were obtained."	( The isolated, perfused bovine ear. A model for pharmacological study of cutaneous vasculature and anaphylaxis. Eghianruwa, KI; Eyre, P, 1991)	0.28
" The vasoconstrictor behavior of the dilated segment was then assessed by dose-response testing; long-axis, ultrasonic imaging combined with computerized edge-detection image processing was used to measure changes in segmental internal vessel diameters that were induced by phenylephrine."	( Determinants of smooth muscle injury during balloon angioplasty. Fischell, TA; Grant, G; Johnson, DE, 1990)	0.28
" To assess an age-related alteration in the responsiveness to an alpha 1-adrenergic agonist and to estimate changes in the apparent affinity of the alpha 1-adrenoceptor for the antagonist prazosin, we infused phenylephrine into 12 healthy elderly subjects and 12 healthy young subjects before and after an oral dose of prazosin, and we compared the shift in the dose-response curves for the two groups."	( The effect of age on the sensitivity of the alpha 1-adrenoceptor to phenylephrine and prazosin. Gerber, JG; Klein, C; Nies, AS; Payne, NA, 1990)	0.28
" Dose-response curves for PE were shifted both to the right and downward by increasing concentrations of amiloride, which indicates both competitive and noncompetitive types of inhibition."	( Influence of amiloride derivatives on alpha-1 adrenergic receptor-induced contractions of the rabbit aorta. Cragoe, EJ; Deth, RC; Lesburg, C; Li, S, 1990)	0.28
" Dose-response curves to noradrenaline were unaffected by prazosin (1 microM)."	( Alpha 2-adrenoceptor antisecretory responses in the rat jejunum. Dettmar, PW; Downing, OA; Roach, AG; Urquhart, CJ; Williams, RJ; Wilson, KA, 1990)	0.28
" No change in slope of the phenylephrine dose-response curve was noted; however, consistent with the dose ratio, verapamil shifted the curve to the right with a decrease in the y intercept determined by linear regression (60."	( Forearm vascular alpha 1-adrenergic blockade by verapamil. Abernethy, DR; Winterbottom, LM, 1990)	0.28
" Halothane did not influence the cardiovascular response to PHE: there was no dose-response shift for any cardiovascular variable."	( Halothane anaesthesia does not modify the cardiovascular response to phenylephrine in man. Azmy, SS; Grum, DF, 1990)	0.28
" An unexpected finding was that R-PIA, 2-CA and CHA all induced contractions at concentrations lower than were required for relaxation, giving a biphasic dose-response curve."	( The coexistence of adenosine A1 and A2 receptors in guinea-pig aorta. Shaw, JS; Stoggall, SM, 1990)	0.28
" In separate groups of rats, the log dose-response curve for bolus intravenous injection of AII was shifted to the right by SQ-29,548 while that for PE was unaffected."	( Thromboxane mediation of the pressor response to infused angiotensin II. Welch, WJ; Wilcox, CS, 1990)	0.28
" To examine the effect of pressure on the dose-response relationships of ANG II or PE, local perfusion pressure was adjusted to remain constant at various pressure levels that were independent of MAP during drug infusions."	( Combined effects of autoregulation and vasoconstrictors on hindquarters vascular resistance. Meininger, GA; Trzeciakowski, JP, 1990)	0.28
" Furthermore, the slope of the dose-response curves for systolic (2."	( Decreased sensitivity to alpha-adrenergic stimulation in hypothyroid patients. Kennedy, B; Nicod, P; Polikar, R; Smith, J; Ziegler, M, 1990)	0.28
" Dose-response curves to KCl and phenylephrine (PE) were constructed; the response to PE was significantly higher in DM than control arteries."	( Contribution of the arterial tissue to vascular pathology in diabetes mellitus. Carrara, MC, 1990)	0.28
"7 X 10(-4) M) doses or EA solvent (control) for 30 min, and dose-response curves were performed for GTN (10(-9) to 10(-5) M)."	( Ethacrynic acid: acute hemodynamic effects and influence on the in vivo and in vitro response to nitroglycerin in the dog. Abdollah, H; Armstrong, PW; Moffat, JA; Rollwage, D, )	0.13
" Cumulative dose-response curves of the alpha 1-agonists l-phenylephrine or cirazoline applied luminally in rat tail arteries and in side branches of canine femoral arteries were identical to those obtained by adventitial application in the intact arteries, and were not modified by removal of the endothelium (eliminating acetylcholine-induced dilations)."	( Endothelium-mediated dilations contribute to the polarity of the arterial wall in vasomotion induced by alpha 2-adrenergic agonists. Busse, R; Holtz, J; Kuon, E; Matsuda, H, )	0.13
" In concentrations greater than 10(-5) M, ouabain caused a parallel shift to the left of the phenylephrine dose-response curve, indicating potentiation."	( Effect of ouabain on the responses to vasoconstrictor agents in isolated perfused rat tail arteries. Armsworth, SJ; Marwood, JF; Stokes, GS, )	0.13
" The dose-response curve of blood pressure against rate of phenylephrine infusion was shifted to the right in keeping with alpha 1-adrenergic antagonism; the degree of shift was small compared with that after prazosin."	( Ketanserin and alpha 1-adrenergic antagonism in humans. Ball, SG; Robertson, JI; Zabludowski, JR, 1985)	0.27
" Bucindolol caused a parallel shift to the right of the dose-response curves for both serotonin (5-HT) and phenylephrine (PE), indicating competitive antagonism."	( Bucindolol has serotonin and alpha-adrenoceptor blocking properties. Marwood, JF; Stokes, GS, 1985)	0.27
" Dose-response curves were constructed both for the autonomic agonists and the histamine-releasing agents."	( Characterization of purified dog mastocytoma cells. Autonomic membrane receptors and pharmacologic modulation of histamine release. Barnes, PJ; Gold, WM; Phillips, MJ, 1985)	0.27
" After 4 days oral treatment, both verapamil and nisoldipine significantly attenuated the responses to angiotensin II with three- to fivefold rightward shifts of the mean pressor dose-response curves."	( Effect of calcium channel blockers on adrenergic and nonadrenergic vascular responses in man. Elliott, HL; Meredith, PA; Pasanisi, F; Reid, JL; Sumner, DJ, )	0.13
" Dose-response curves for MIX potentiation of cAMP-stimulated glycogenolysis and for MIX inhibition of the effects of insulin on cAMP-stimulated glycogenolysis suggested that at higher concentrations (250 microM) MIX may act at a site other than phosphodiesterase inhibition."	( Methylisobutylxanthine blocks insulin antagonism of cAMP-stimulated glycogenolysis at a site distinct from phosphodiesterase. Evidence favoring an insulin-insensitive calcium release mechanism. Gabbay, RA; Lardy, HA, 1986)	0.27
"In pithed rats two recently-introduced beta-blockers, nipradilol and arotinolol, as well as labetalol shifted the pressor dose-response curve for phenylephrine to the right."	( Alpha-blockade and vasodilatation induced by nipradilol, arotinolol and labetalol in pithed rats. Chin, WP; Imai, S; Nakagawa, Y; Nakahara, H, 1985)	0.27
" Higher concentrations of these antagonists shifted the Ca2+ dose-response curve to the right."	( Adrenergic-cholinergic interactions in left atria. II. Comparison of the antagonism of inotropic responses to alpha- and beta-adrenoceptor stimulation and BAY K 8644 by carbachol, D-600, and nifedipine. MacLeod, KM, 1987)	0.27
"05) the phenylephrine dose-response curve to the right on days 1 and 8 compared with placebo."	( Effect of acute and chronic indoramin administration on baroreflex function and tremor in humans. Deering, AH; Harron, DW; Riddell, JG; Shanks, RG, 1988)	0.27
" Whereas the blood pressure reduction to acute administration of ketanserin was directly related to its ability to shift the dose-response curve of phenylephrine (alpha 1-adrenergic blockade), the same relationship was not apparent following chronic treatment with ketanserin."	( Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat. Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1988)	0.27
" In addition, verapamil shifted the dose-response curves for both 5-HT and PE to the right in parallel, indicative of competitive antagonism."	( Studies on the site of the interaction between alpha 1-adrenoceptors and 5-HT2 receptors in rat tail arteries. Marwood, JF, 1988)	0.27
" Dose-response experiments revealed that insulin stimulated D-glucose transport and 2-deoxyglucose uptake between 10(-11) and 10(-7) M with a maximal four- to sixfold stimulation."	( Stimulation of glucose transport by insulin and norepinephrine in isolated rat brown adipocytes. Bukowiecki, LJ; Marette, A, 1989)	0.28
"Secretory dose-response curves were obtained with both acetylcholine and phenylephrine treatment in rat parotid and submandibular glands."	( Vasoactive intestinal peptide interacts with alpha-adrenergic-, cholinergic-, and substance-P-mediated responses in rat parotid and submandibular glands. Bobyock, E; Chernick, WS, 1989)	0.28
" Dose-response curves were plotted from data obtained following exposure to histamine (10(-7)-10(-3)) and GTN (10(-9)-10(-7)) and compared to responses from age-matched untreated controls, diabetic and diabetic rats treated with insulin (2 U/day)."	( Histamine relaxation of aortic rings from diabetic rats. Chang, KS; Tanz, RD; Weller, TS, 1989)	0.28
" Dose-response curves for phenylephrine and norepinephrine were constructed by plotting the change in mean arterial pressure following a bolus dose of the agent against the dose of the pressor agent used."	( Ethanol exhibits alpha receptor blocking-like properties in anesthetized rats. Abdel-Rahman, AA; Russ, RD; Wooles, WR, 1989)	0.28
" Dose-response data were obtained from extracellular records of the firing of DRN neurons recorded in midbrain slices perfused with artificial cerebral spinal fluid containing varying concentrations of the drugs investigated."	( Electrophysiological and biochemical characterization of the development of alpha 1-adrenergic and 5-HT1 receptors associated with dorsal raphe neurons. Gallager, DW; Smith, DA, 1989)	0.28
" This indicates that small doses of prazosin (1-2 mg) cause significant in vivo shifts in the dose-response relationship of alpha adrenergic agonists."	( Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy. Blaschke, TF; Eichler, HG; Ford, GA; Hoffman, BB; Swislocki, A, 1989)	0.28
"5 hr washout, shifted to the right in a dose-dependent manner the dose-response curves for phenylephrine and norepinephrine."	( Interaction of a chemically reactive prazosin analog with alpha-1 adrenoceptors of rat tissues. Kusiak, JW; Piascik, MT; Pitha, J, 1989)	0.28
" Dose-response curves were generated for the relatively selective alpha 1-receptor agonist phenylephrine, the alpha 2-receptor agonist BHT-920, and the alpha 1- and alpha 2-receptor agonist norepinephrine."	( Differences in alpha-adrenergic responsiveness between human internal mammary arteries and saphenous veins. Grossman, W; Johnson, RG; Morgan, KG; Thurer, RL; Weinstein, JS; Weintraub, RM, 1989)	0.28
" Alpha-adrenergic responsiveness was estimated with DPD15 (the dosage of neosynephrine required for an increase of diastolic pressure of 15mmHg); beta-adrenergic responsiveness with CD25 (the dosage of isoproterenol required for an increase of heart rate of 25 beats/minute)."	( Hyperkinetic hemodynamic pattern in some borderline hypertension: differential responses to alpha and beta agonists. Fan, J; Yang, Q; Yi, G, 1989)	0.28
" The drugs induced dose-dependent contractions in all subjects, and dose-response curves were constructed."	( Comparative effects of the alpha-adrenoceptor agonists noradrenaline, phenylephrine and clonidine in the human saphenous vein in vivo and in vitro. Andersson, KE; Norgren, L; Sjöberg, T; Steen, S, 1989)	0.28
"5 mg/kg and greater) shifted the phenylephrine dose-response curve to the right."	( Effect of an alkylating analog of prazosin on alpha-1 adrenoceptor subtypes and arterial blood pressure. Butler, BT; Holtman, JR; Kusiak, JW; Piascik, MT; Pitha, J, 1989)	0.28
" Dose-response curves (DRCs) were obtained in the absence and cumulative presence of propranolol (PROP; beta-antagonist), corynanthine (CORY; alpha 1-antagonist) and idazoxan (IDX; alpha 2-antagonist) to estimate effective dosages (ED) required for 15 and 75% peak reductions in renal blood flow."	( Unmasking sensitive alpha 2-adrenoceptor-mediated renal vasoconstriction in conscious rats. Colindres, RE; Strandhoy, JW; Wolff, DW, 1989)	0.28
" IBI at 10(-6) M shifted the dose-response curve of phenylephrine to the right with reduction in maxima."	( Paradoxical effects of isothiocyanate analog of tolazoline on rat aorta and human platelets. Feller, DR; Hamada, A; Miller, DD; Patil, PN; Shams, G; Venkataraman, BV, 1989)	0.28
" Removal of the endothelium or the presence of Hb caused significant shifts of the dose-response curves to the left and further increases in maxima."	( Effects of endothelial cell removal on constrictor and dilator responses of aortae of pregnant rats. Boura, AL; Jansakul, C; King, RG, 1989)	0.28
"7), whereas berberine, which differs basically from atropine, shifted the dose-response curve for acetylcholine non-parallelly to the right with its maximal response reduced concomitantly."	( Blocking action of berberine on various receptors in rat anococcygeus muscle. Fang, DC; Jiang, MX; Xia, GJ; Yao, WX, 1989)	0.28
" The doses for each drug were selected based on the results of dose-response curves."	( Adrenergic effects on internal cardiac defibrillation threshold. Jones, DL; Klein, GJ; Rattes, MF; Sharma, AD; Szabo, T, 1987)	0.27
" Denervation caused a shift to the left of the 86Rb efflux dose-response curve to carbachol and phenylephrine (3."	( Effect of parasympathetic denervation on K+ release by rat parotid slices. Adham, N; Templeton, D, 1987)	0.27
" DI and VE shifted dose-response curves for phenylephrine and clonidine to the right with suppression of maximal responses."	( Effects of calcium antagonists on alpha-adrenoceptor mediated vasoconstrictions of the canine intermediate auricular artery. Chiba, S; Ito, T, 1987)	0.27
" Phenylephrine (Phe) pressor dose-response curves were established prior to anesthesia, during fentanyl anesthesia, and during fentanyl anesthesia plus hypothermic cardiopulmonary bypass at the time of aortic cross-clamp (anes + CPB/AXC)."	( alpha 1-Adrenergic responsiveness during coronary artery bypass surgery: effect of preoperative ejection fraction. Hawkins, ED; Kates, RA; McIntyre, RW; Reves, JG; Schwinn, DA, 1988)	0.27
"0 mg/kg intravenously) was administered after the highest phenylephrine infusion dosage to assure complete beta-blockade."	( In vivo demonstration of maturational changes of the chronotropic response to alpha-adrenergic stimulation. Gelband, H; McCormack, J; Pickoff, AS; Stolfi, A; Villafañe, J; Xu, H, 1988)	0.27
"The effect of nifedipine on pressor dose-response curves to phenylephrine, alpha-methylnoradrenaline and angiotensin II was determined in anaesthetized cats pretreated with propranolol and atropine."	( Lack of differential inhibition by nifedipine of pressor responses induced by alpha 1- and alpha 2-adrenoceptor agonists and by angiotensin II in anaesthetized cats. Alabaster, VA; Solca, AM, 1985)	0.27
" Labetalol 400 mg significantly shifted the blood pressure dose-response curve to the right."	( Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man. Harron, DW; Riddell, JG; Shanks, RG, 1985)	0.27
"The effects of bucindolol a new nonselective beta blocker were studied after short-term dosing and for up to six months in eight patients with essential hypertension."	( Bucindolol in essential hypertension. Curzio, J; Reid, JL; Vincent, J, 1985)	0.27
" Studies of right ventricular papillary muscles from control and chronically beta-blocked cats demonstrated contractile and energetic properties as well as dose-response behavior and inotropic specificity suggestive of an increase in myocardial sensitivity to beta-adrenoceptor stimulation in the latter group."	( Beta adrenergic receptor blockade of feline myocardium. Cardiac mechanics, energetics, and beta adrenoceptor regulation. Cooper, G; Kent, RL; McGonigle, P; Watanabe, AM, 1986)	0.27
", once daily for 14 days) the dose-response curve of the isolated rat anococcygeal muscle to phenylephrine shifted to the left, and furthermore, the -log KA value (affinity) for phenylephrine was significantly increased without affecting the affinity for guanfacine."	( Enhancement of central and peripheral alpha 1-adrenoceptor sensitivity and reduction of alpha 2-adrenoceptor sensitivity following chronic imipramine treatment in rats. Hong, KW; Lee, WS; Rhim, BY, 1986)	0.27
" Although administered in a dosage range 100 to 1000 times that of alpha-1 agonists, the alpha-2 agonists (B-HT 920, UK 14,304 and guanabenz) produced only minimal renal vasoconstriction before systemic pressor effects."	( In vivo assessment of rat renal alpha adrenoceptors. Gesek, FA; Strandhoy, JW; Wolff, DW, 1987)	0.27
" In the rabbit the dose-response curve for phenylephrine was shifted to the right in parallel by prazosin (1 mg kg-1) and was unaffected by rauwolscine (1 mg kg-1)."	( Difference in the potency of alpha 2-adrenoceptor agonists and antagonists between the pithed rabbit and rat. Bulloch, JM; Docherty, JR; Flavahan, NA; McGrath, JC; McKean, CE, 1987)	0.27
" The phenylephrine, but not the angiotensin II or the nitroprusside, dose-response curves were shifted to the right after ethanol, indicating a decreased pressor responsiveness and suggesting that ethanol may have alpha-adrenergic blocking activity."	( Acute effects of ethanol on baroreceptor reflex control of heart rate and on pressor and depressor responsiveness in rats. Abdel-Rahman, AR; Russ, R; Strickland, JA; Wooles, WR, 1987)	0.27
"1 mg/kg) and of yohimbine (1 mg/kg) on the dose-response curves for cirazoline in the pithed rat, and for phenylephrine in the anaesthetized dog were compared, after various doses of phenoxybenzamine."	( Loss of selectivity of so-called selective alpha 1-adrenoceptor agonists after phenoxybenzamine. Gonçalves, J; Guimarães, S; Nunes, JP; Paiva, MQ, 1988)	0.27
" Dose-response studies (required to increase heart rate or systolic blood pressure by 25 beats/min and 20mm Hg, respectively) were performed with phenylephrine, angiotensin and isoprenaline after each drug, and placebo administration and the effects of physiological pressor stimuli were compared."	( Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Bompart, F; Graham, BR; Liu, JB; Prichard, BN; Tomlinson, B, 1988)	0.27
" Complete dose-response curves were generated to methoxamine, phenylephrine, and norepinephrine."	( Vascular catecholamine sensitivity during pregnancy in the ewe. Cooke, R; Keve, TM; McLaughlin, MK, 1989)	0.28
" Dose-response curves to acetylcholine (ACh), noradrenaline (NA), phenylephrine (Phen) and angiotensin II (AII), were obtained in 6 cholesterol-fed and 6 control rabbits before and after isradipine (code name PN200-110) 100 micrograms kg-1."	( Vasoconstrictor and vasodilator effects in normal and atherosclerotic conscious rabbits. Hof, A; Hof, RP, 1988)	0.27
" Pressor dose-response curves to the selective alpha 1-adrenergic agonist, phenylephrine, were constructed in groups of rabbits before, during and 2 hr after halothane anesthesia and the dose of phenylephrine that induced a 25 torr increase in mean arterial pressure (ED25) was derived by polynomial regression analysis."	( Prolonged hyporesponsiveness of vascular smooth muscle contraction after halothane anesthesia in rabbits. Hoffman, BB; Maze, M; Smith, CM; Spiss, CK; Tsujimoto, G, 1985)	0.27
" With histamine, no significant difference in the dose-response curves between the two muscle layers was found."	( Contraction and cyclic AMP-related relaxation of the intimal and medial smooth muscle layers of pig thoracic aorta. Andersson, RG; Lundholm, L; Wingren, G, 1985)	0.27
" HA-1004 shifted the dose-response curve for CaCl2 to the right in a competitive manner in depolarized rabbit renal arterial strips."	( Relaxation of vascular smooth muscle by HA-1004, an inhibitor of cyclic nucleotide-dependent protein kinase. Hidaka, H; Inagaki, M; Ishikawa, T; Watanabe, M, 1985)	0.27
" Dose-response studies of the effect of epinephrine on adenosine-deaminase or isoproterenol-stimulated fat-cells demonstrate an inhibitory effect of epinephrine on lipolysis promoted by stimulation of alpha 2-adrenoceptors which occurs before the commonly described beta 1-adrenergic effect which promotes stimulation of lipolysis."	( Fat cell adrenoceptors: inter- and intraspecific differences and hormone regulation. Berlan, M; Carpene, C; Lafontan, M, 1985)	0.27
" Prazosin caused a parallel shift to the right of the dose-response curve to phenylephrine."	( Pre- and postjunctional alpha-adrenoceptors at sympathetic neuroeffector junction in bovine mesenteric lymphatics. Azuma, T; Ohhashi, T, 1986)	0.27
" Dose-response studies indicate the beta-adrenergic component of cyclic AMP stimulation is enhanced and the alpha 1-adrenergic component of cyclic GMP stimulation is diminished in LL pinealocytes."	( See-saw signal processing in pinealocytes involves reciprocal changes in the alpha 1-adrenergic component of the cyclic GMP response and the beta-adrenergic component of the cyclic AMP response. Klein, DC; Sugden, D; Vanecek, J; Weller, JL, 1986)	0.27
" Dose-response measurements indicate that the potentiation of Ca2+ influx by glucagon occurs even at low (physiological) concentrations of the hormone."	( Synergistic stimulation of Ca2+ uptake by glucagon and Ca2+-mobilizing hormones in the perfused rat liver. A role for mitochondria in long-term Ca2+ homoeostasis. Altin, JG; Bygrave, FL, 1986)	0.27
" In addition, lack of Ca2+ caused a shift to the right in the dose-response curve for phenylephrine-induced IP formation whereas serotonin-induced IP formation was not affected by changes in Ca2+e."	( Influence of Ca2+e on 5-HT2- and alpha 1-induced arterial contraction and phosphoinositide metabolism. Berta, P; Chevillard, C; Haiech, J; Mathieu, MN; Seguin, J; Vidal, N, 1986)	0.27
"1% respectively; the dose-response curve for NE inhibitory action is described."	( Quantitative evaluation of alpha- and beta-adrenoceptor modulation of [3H]choline release in guinea pig superior cervical ganglia. Belluzzi, O; Bonifazzi, C; Perri, V; Travagli, RA, 1987)	0.27
" Urotensin I diminished the maximum increase in perfusion pressure and shifted the log dose-response curves to the right for all three agonists."	( Differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated pressor responses by urotensin I, a selective mesenteric vasodilator peptide. Bolt, GR; Itoh, H; Lederis, K; MacCannell, KL, 1987)	0.27
" In isolated aortic rings the dose-response curve for (-)metaraminol was not parallel to that of (-)epinephrine, (-)norepinephrine or (-)phenylephrine."	( Heterogeneity of alpha 1 receptors associated with vascular smooth muscle: evidence from functional and ligand binding studies. Babich, M; Butler, BT; Pedigo, NW; Piascik, MT, 1987)	0.27
" Whereas LV peak dP/dt and LV (dP/dt)/DP40 were significantly decreased after the low dosage of lidocaine, these indexes returned to control values after the 10th min of infusion of the high dosage."	( Effects of lidocaine on myocardial contractility and baroreflex control of heart rate in conscious dogs. Berdeaux, A; Edouard, A; Giudicelli, JF; Langloys, J; Noviant, Y; Samii, K, 1986)	0.27
" A dorsal hand vein was preconstricted with submaximally effective doses of phenylephrine and a dose-response curve with nitroglycerin was established."	( Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Blaschke, TF; Eichler, HG; Hiremath, A; Hoffman, BB; Katzir, D, 1987)	0.27
" In acute experiments the depression of the phenylephrine dose-response produced by ethanol in vitro was greater than that for angiotensin II."	( Effect of acute and chronic ethanol on the agonist responses of vascular smooth muscle. Strickland, JA; Wooles, WR, 1988)	0.27
" Furthermore, the norepinephrine dose-response curve was shifted to the right in the presence of cirazoline, without affecting the maximal response."	( Pharmacologic characterization of cirazoline-activated inositol phospholipid hydrolysis in rat brain cortical slices. Li, PP; Sibony, D; Warsh, JJ, 1988)	0.27
" Chronic focal inflammation of the liver, and inflammation of the prostate were increased in dosed rats."	( Toxicity and carcinogenicity studies of phenylephrine hydrochloride in F344/N rats and B6C3F1 mice. Bucher, JR; Haseman, JK; Huff, J, 1988)	0.27
" Denuding caused a parallel shift of the dose-response curve of adenosine to the right by a factor of five in comparison with intact aorta."	( Partially endothelium-dependent vasodilator effect of adenosine in rat aorta. Chiou, WF; Wu, CC; Yen, MH, 1988)	0.27
"In clinical pharmacological studies, where it is not possible to describe the full dose-response curve, the construction of dose-response relationships ideally depends upon achieving a reproducible and readily measurable response for each dose administered."	( A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man. Elliott, HL; Reid, JL; Sumner, DJ; Vincent, J, 1987)	0.27
" The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo."	( Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987)	0.27
"8% of the MER) without altering the EC50 value (5 X 10(-6) M) of the phenylephrine dose-response curve."	( Effects of neuropeptide Y on the isolated rabbit iris dilator muscle. Davis, M; Krupin, T; Littzi, J; Piccone, M; Stone, RA; Wax, MB, 1988)	0.27
" Maintaining local perfusion pressure at different values during the infusion of ANG II or PE produced a family of dose-response curves, with each exhibiting a different maximum change in resistance."	( Vasoconstriction is amplified by autoregulation during vasoconstrictor-induced hypertension. Meininger, GA; Trzeciakowski, JP, 1988)	0.27
" The slope of phenylephrine dose-response curves of diabetic and healthy vessels with intact endothelium was similar, whereas the slope of phenylephrine dose-response curves of endothelium-denuded diabetic arteries was significantly greater than that of the denuded healthy arteries."	( Contractile and relaxant responses of diabetic dog femoral arteries. Gebremedhin, D; Hadházy, P; Koltai, MZ; Pogátsa, G, 1988)	0.27
" Dose-response experiments indicate that norepinephrine is approximately 10,000 times more potent on a molar basis than carbachol in stimulating antral gastrin release."	( Comparison of adrenergic and cholinergic receptor-mediated stimulation of gastrin release from rat antral fragments. Harty, RF; Maico, DG; McGuigan, JE, )	0.13
" Dose-response curves obtained via this new method showed a high degree of correlation with data obtained by classical tissue bath techniques using ring segments."	( Use of two-dimensional ultrasonic imaging to measure pharmacologically induced vasomotion in rabbit aorta. Fischell, TA; Ginsburg, R, 1986)	0.27
" Following insulin administration, the dose-response curves for phenylephrine and angiotensin II were shifted to the right."	( Effects of insulin on pressor responsiveness and baroreflex function in diabetes mellitus. Hattori, N; Ikeda, T; Iwase, N; Kiyokawa, H; Noto, Y; Takata, S; Yagi, S; Yamamoto, M, 1986)	0.27
"We have demonstrated previously that phenylephrine, a selective postsynaptic alpha-1-adrenergic agonist, significantly potentiates the incidence of acetazolamide-induced right forelimb ectrodactyly in a dose-response manner."	( Reduction of uterine blood flow by phenylephrine, an alpha-adrenergic agonist, in the day 11 pregnant rat: relationship to potentiation of acetazolamide teratogenesis. Scott, WJ; Ugen, KE, 1987)	0.27
" The concentration of phenylephrine required to dilate the pupil 1 mm, obtained by interpolation on the dose-response curve, was taken as a measure of alpha-adrenergic sensitivity."	( Pupillary responses and airway reactivity in asthma. Davis, PB, 1986)	0.27
" This preparation was used to examine the intrinsic mechanical properties of the trout heart, the dose-response effects of catecholamines and extracellular calcium on these properties, and the effects of catecholamines and extracellular calcium during exposure to acidotic conditions."	( Intrinsic mechanical properties of the perfused rainbow trout heart and the effects of catecholamines and extracellular calcium under control and acidotic conditions. Chancey, B; Farrell, AP; MacLeod, KR, 1986)	0.27
" A dosing volume of 10 microliter was instilled into rabbit eyes and the pupillary diameter was measured over time."	( Improving the ocular absorption of phenylephrine. Chien, DS; Schoenwald, RD, )	0.13
" Dose-response curves indicated that there was a similar enhancement in pressor sensitivity to AVP, ANG II, and PE in the absence of the baroreceptors."	( Cardiovascular actions of vasopressin: baroreflex modulation in the conscious rat. Cowley, AW; Osborn, JW; Webb, RL, 1986)	0.27
" Dose-response curves were obtained using a non-specific vasoconstrictor (KCl) and an alpha-adrenergic agonist, phenylephrine."	( Attenuation of alpha-adrenergic responsiveness in hypoxic SHR. Henley, WN; Tucker, A, 1986)	0.27
"The rationale for the objective assessment of dose-response curves (DRCs) is presented."	( The analysis of dose-response curves--a practical approach. Jackson, SH; Jamieson, MJ; Johnston, A; Shepherd, AM, 1987)	0.27
" The dose-response lines to phenylephrine were shifted in a parallel manner by propranolol 10(-8)M and 10(-7)M, suggesting that the relaxations were mediated through beta-adrenoceptors."	( Actions of phenylephrine on beta-adrenoceptors in guinea-pig trachea. Chahl, LA; O'Donnell, SR, 1969)	0.25
" Dose-response curves were constructed correlating decreases in renal blood flow with doses of phenylephrine, clonidine, and guanabenz injected as boluses into renal arteries of anesthetized dogs."	( Renal alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in dogs: comparison of phenylephrine, clonidine, and guanabenz. Buckalew, VM; Strandhoy, JW; Wolff, DW, 1984)	0.27
" Then prazosin or yohimbine were administered intra-arterially and dose-response curves repeated."	( Renal alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in dogs. Buckalew, VM; Strandhoy, JW; Wolff, DW, 1984)	0.27
" Prazosin (PRZ), a selective alpha 1-receptor blocker, inhibited preferentially the positive phase of the inotropic response and displaced the dose-response curve of PE to the right in nanomolar concentrations, indicating a competitive mechanism of inhibition."	( Competitive blockade of alpha-adrenergic receptors in rat heart by prazosin. Osnes, JB; Oye, I; Skomedal, T, 1980)	0.26
"In 40 hypotensive patients with sympathicotonic orthostatic dysregulation and presenting the relevant subjective symptoms, a dosage of 3 times daily 2 mg dihydroergotamine or 20 mg etilefrine or the fixed combination of both drugs--Dihydergot plus--was compared inter-individually and by the double blind method."	( [Treatment of hypotensive circulatory dysregulation with a combination of dihydroergotamine and etilefrine (author's transl)]. Bracharz, H; Polzien, P, 1981)	0.26
" The time course of inhibition, the extent of inhibition, and the dose-response relationship did not differ between the groups."	( Normal alpha 2-adrenergic responses in platelets from patients with asthma. Davis, PB; Lieberman, P, 1982)	0.26
" (3) Whereas the hyperbolic relationship was inadequate in all circumstances, the hill-type function accommodated dose-response curves which exhibit no "auto-inhibitory" hook or bell-shaped feature."	( A kinetic analysis of the actions of L-noradrenaline and its related agonists and antagonists on in vitro lipolysis in rat adipose tissue. Cooper, DM; Davies, JI, 1982)	0.26
" Postsynaptic alpha-adrenoceptor antagonist activity was assessed by comparing cumulative noradrenaline and phenylephrine dose-response curves in the absence and in the presence of increasing concentrations of antagonist."	( [Action of dihydroergocristine at pre- and postsynaptic alpha-adrenoceptors in the rat isolated vas deferens]. Demichel, P; Gomond, P; Malek, A; Roquebert, J, )	0.13
" There was a transient increase in blood pressure, and plasma noradrenaline, 10-20 min after dosing and an associated reduction in heart rate."	( Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man. Elliott, HL; Reid, JL, 1983)	0.27
" Cocaine plus reserpine shift the dose-response curve for phenylephrine to the left."	( Mechanism of action of phenylephrine on isolated guinea-pig atria rate. Nigro, D; Scivoletto, R, 1983)	0.27
" However, the biphasic nature of the dose-response curves and the antagonist inhibition curves indicated additionally the presence of an alpha-component."	( Quantitative differentiation of alpha- and beta-adrenergic respiratory responses in isolated hamster brown fat cells: evidence for the presence of an alpha 1-adrenergic component. Cannon, B; Mohell, N; Nedergaard, J, 1983)	0.27
" However, the pressor effect of adrenaline and noradrenaline (NA) were significantly reduced in dogs, and the dose-response curves to NA in aortic strips and to the alpha-agonist, phenylephrine in rats was shifted to the right in a parallel manner by quinidine."	( Vascular alpha-adrenergic blocking properties of quinidine. Caldwell, RW; Elam, JT; Mecca, TE; Nash, CB, 1983)	0.27
" Trimethaphan (10(-4)-10(-3)M) shifted the dose-response curve for norepinephrine in mesenteric arteries to the right, but failed to influence the contractile response to 25 mM KCl."	( Trimethaphan is a direct arterial vasodilator and an alpha-adrenoceptor antagonist. Harioka, T; Hatano, Y; Mori, K; Toda, N, 1984)	0.27
" The reduction in alpha 1-adrenergic receptor density following phenoxybenzamine treatment was determined by Scatchard analysis of specific 125IBE binding sites and compared with the expected reduction (q values) calculated from the agonist dose-response curves before and after phenoxybenzamine treatment."	( "Spare" alpha 1-adrenergic receptors and the potency of agonists in rat vas deferens. Abel, PW; Minneman, KP, 1984)	0.27
" The ratios of beta 1- to alpha 1-adrenoceptor antagonism as calculated from the relative shifts of the isoprenaline and phenylephrine dose-response curves, were 3 to 1 for labetalol and about 7 to 1 for medroxalol."	( Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties. Elliott, HL; McLean, K; Meredith, PA; Reid, JL; Sumner, DJ, 1984)	0.27
" However, POB shifted the dose-response curve for NAT induction by norepinephrine (NE) to the left."	( Modulation of rat pineal acetyl-Co A:arylamine N-acetyltransferase induction by alpha adrenergic drugs. Alphs, L; Lovenberg, W, 1984)	0.27
" Prazosin (10(-8) M-10(-6) M, alpha 1-adrenoceptor antagonist) produced a rightward shift of the phenylephrine and clonidine dose-response curve in both the trigone and urethra."	( Alpha 1- and alpha 2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra. Satake, N; Shibata, S; Ueda, S, 1984)	0.27
" The pressor dose-response analysis for three agonists of varying selectivities for alpha 1 and alpha 2-adrenoceptors showed only modest changes with phenylephrine and noradrenaline with dose ratios less than 2, in contrast to the marked antagonism by RX781094 of the pressor response to the alpha 2 agonist, alphamethylnoradrenaline, dose ratio greater than 20."	( Peripheral pre and postjunctional alpha 2-adrenoceptors in man: studies with RX781094, a selective alpha 2 antagonist. Elliott, HL; Jones, CR; Reid, JL, 1983)	0.27
" Following the intravenous infusion of increasing doses of phenylephrine, log dose-response curves were deprived, and the dose required to raise mean arterial pressure by 20 mm Hg (PD20) was compared."	( Effect of age on the responsiveness of vascular alpha-adrenoceptors in man. Elliott, HL; McLean, K; Reid, JL; Sumner, DJ, )	0.13
" Unexpected differences, not previously reportd, were found in the shapes of the cAMP accumulation dose-response curves of norepinephrine and isoproterenol."	( Neonatal rat pinealocytes: typical and atypical characteristics of [125I]iodohydroxybenzylpindolol binding and adenosine 3',5'-monophosphate accumulation. Auerbach, DA; Aurbach, GD; Klein, DC; Woodard, C, 1981)	0.26
"The cardiovascular effects of repeated dosing with delta-9-tetrahydrocannabinol (THC) were examined in chronically catheterized, conscious rhesus monkeys."	( The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. Benowitz, NL; Fredericks, AB; Savanapridi, CY, 1981)	0.26
" PE log dose-response curves were shifted to the right in a non-parallel manner by 1 mM Mn2+ such that responses to lower PE concentrations were more inhibited."	( Inhibition of alpha-receptor-induced Ca2+ release and Ca2+ influx by Mn2+ and La3+. Deth, R; Lynch, C, 1981)	0.26
" To measure affinity, dose-response curves were first obtained for agonist alone and then for agonist in the presence of various concentrations of phentolamine, a reversible alpha-adrenergic antagonist."	( The effect of preload on the dissociation constant of phentolamine in isolated rabbit thoracic aorta. Raffa, RB; Tallarida, RJ, 1981)	0.26
" Dose-response curves to the racemate were always situated between the stereoisomers, approximately 2-fold to the right of (+)-dobutamine."	( Alpha and beta adrenergic effects of the stereoisomers of dobutamine. Murphy, PJ; Pollock, GD; Ruffolo, RR; Spradlin, TA; Waddell, JE, 1981)	0.26
" These recordings disclosed qualitative differences between the alpha-and Beta-inotropic response both in dose-response and time course experiments."	( Differences between alpha-adrenergic and beta-adrenergic inotropic effects in rat heart papillary muscles. Osnes, JB; Oye, I; Skomedal, T, 1982)	0.26
"The effect of oral prazosin on blood pressure and antagonism of phenylephrine-induce blood pressure increase was investigated in six healthy subjects during a dosing interval after the first dose and 3 days after the first dose of the drug."	( Alpha-receptor function changes after the first dose of prazosin. Lindström, B; Seideman, P; von Bahr, C, 1982)	0.26
" There was a shift to the left in pressor dose-response curves to the alpha 1-adrenoreceptor agonist phenylephrine and the mixed alpha 1/alpha 2-adrenoreceptor agonist noradrenaline in 6-hydroxydopamine-pretreated animals."	( The effects of intravenous 6-hydroxydopamine on peripheral alpha-adrenoreceptors. Hamilton, CA; Reid, JL, 1982)	0.26
" Increasing concentrations of thalistyline produced parallel shifts to the right in the dose-response curves of phenylephrine."	( A pharmacological study of two bisbenzylisoquinoline alkaloids, thalistyline and obamegine. Banning, JW; Patil, PN; Salman, KN, )	0.13
" Dose-response relation was obtained in terms of various doses of ISO and the increments of heart rate (deltaHR) produced by ISO."	( Estimated affinity of isoproterenol to cardiac chronotropic beta-receptor and of phenylephrine to vasoconstrictive alpha-receptor of the systemic resistance vessels in human borderline hypertension. Hirakawa, S; Ito, H; Tonai, N, 1983)	0.27
" It is concluded that in clinical dosage mianserin is devoid of effects upon muscarinic receptors, alpha 1 adrenoceptors and noradrenaline uptake in the pupil."	( Failure of mianserin to affect autonomic function in the pupils of depressed patients. Checkley, S; Delgado, I; Shur, E, 1983)	0.27
" Prazosin (a preferential alpha 1-antagonist) inhibited the dose-response curves to noradrenaline and phenylephrine 100 and 1000-times respectively more effectively than either phentolamine or rauwolscine (a preferential alpha 2-antagonist)."	( Pharmacological characterization of alpha-adrenoreceptor subtypes in rat isolated thoracic aorta. Charlton, KG; Clarke, DE; Hamed, AT; Johnson, TD, 1983)	0.27
" Prazosin caused a parallel shift to the right of the dose-response curve to phenylephrine, and not to clonidine in the vessels."	( [Characteristics of alpha adrenoceptors of lymphatics and their physiological significance]. Azuma, T; Ohhashi, T, 1983)	0.27
" In rat mesenteric artery, the pA2 value for yohimbine against clonidine was not statistically different from values obtained with the other agonists; however, in the presence of prazosin the dose-response curve to clonidine was biphasic, suggesting that the action of clonidine is mediated through two distinct sites to which prazosin has different affinities."	( Pharmacological characterization of the postsynaptic alpha adrenoceptors in vascular smooth muscle from canine and rat mesenteric vascular beds. Agrawal, DK; Daniel, EE; Triggle, CR, 1984)	0.27
" Conventional measurements of maximum isometric force and dose-response relations for l-phenylephrine in strips of ascending aorta in vitro were followed by radioligand studies on homogenates made from the same strips."	( Relation between alpha adrenergic receptor occupation and contractile response: radioligand and physiologic studies in canine aorta. Griendling, KK; Milnor, WR; Rusher, MM; Sastre, A, 1984)	0.27
"An impurity present in all commercial guaifenesin-containing dosage forms examined was isolated and identified as 2-(2-methoxyphenoxy) 1,3-propanediol (VI)."	( Determination of the structure of a synthetic impurity in guaifenesin: modification of a high-performance liquid chromatographic method for phenylephrine hydrochloride, phenylpropanolamine hydrochloride, guaifenesin, and sodium benzoate in dosage forms. Lubey, GS; Newby, DG; Schieffer, GW; Smith, WO, 1984)	0.27
" The dose-response curve for Phe was markedly shifted to the left by papaverine in 6W rats, but slightly in 7M rats."	( Age-dependent differences in the positive inotropic effect of phenylephrine on rat isolated atria. Hashimoto, H; Nakashima, M; Sugino, N, 1983)	0.27
" Treatment of strips with PCMB and DTNB did not alter the dose-response curves for GTN."	( Investigations into the role of sulfhydryl groups in the mechanism of action of the nitrates. Armstrong, PW; Marks, GS; Moffat, JA, 1982)	0.26
" The lowest dosage of fenoterol was as effective as the highest but had fewer adverse effects."	( Comparison of fenoterol, isoproterenol, and isoetharine with phenylephrine aerosol in asthma. Epstein, JD; Gruebel, BJ; Rotman, HH; Spellman, GG; Weg, JG, )	0.13
" Dose-response curves for various vasoactive agents were obtained before and after exposure to captopril (2 x 10(-4) M) for 30 minutes."	( Effect of in vitro administration of captopril on vascular reactivity of rat aorta. Fregly, MJ; Kikta, DC, )	0.13
" Adverse effects are often related to dosage or other factors."	( Mydriatic and cycloplegic drugs: a review of ocular and systemic complications. Doughty, CB; Rengstorff, RH, 1982)	0.26
" Phentolamine competitively antagonized ADR and PE-induced contractile responses of arteries while on veins, ISOP and PE dose-response curves (DRCs) were shifted to the right in the presence of propranolol."	( Autonomic and autacoid activity in antigen-sensitized and control ovine pulmonary vein and artery. Eyre, P; Mirbahar, KB, 1982)	0.26
" Males showed greater responsiveness to both drugs than females, this being reflected in significantly higher maxima of the dose-response curves for the males."	( Pharmacological responsiveness of sweat glands in anxious patients and healthy volunteers. Bradshaw, CM; Maple, S; Szabadi, E, 1982)	0.26
" Incubation of tissues with papaverine (1 hr) changed the usual dose-response curve to isoproterenol into a low, monotonous effect, independent of the agonist dose."	( Papaverine-induced changes on cardiac inotropism with special reference to a D-propranolol antagonism. Aramendía, P; Márquez, MT, 1982)	0.26
" Trifluoperazine significantly inhibited glycogenolytic effect of phenylephrine and angiotensin II by lowering maximal response, and that of vasopressin by shifting the dose-response curve to the right, while alpha-antagonist phentolamine was inhibitory only to phenylephrine."	( Inhibition by trifluoperazine of glycogenolytic effects of phenylephrine, vasopressin, and angiotensin II. Kimura, S; Koide, Y; Kugai, N; Tada, R; Yamashita, K, 1982)	0.26
"Cumulative dose-response curves were produced for the effect of different adrenergic agonists on the contractions of uterine strips from natural estrous and ovariectomized rats."	( Inhibitory effects of some catecholamines on contractions of uterine strips isolated from estrous and spayed rats. Influence of endogenous and exogenous prostaglandins on the action of methoxamine. Agostini, MC; Borda, E; Gimeno, AL; Gimeno, MF; Sterin-Borda, L, 1981)	0.26
" The chronotropic dose-response curves were made in both spontaneously beating atria while inotropic effects were derived from left atria driven at 1 Hz, 5 msec and voltage about 20 percent above threshold."	( Interactions between sympathomimetic agonists and blocking agents: cardiac effects of phenylephrine and isoproterenol. Aramendía, P; Márquez, MT; Mikulić, LE, )	0.13
" ETA did not affect the phenylephrine dose-response curves and nor did 8 micrograms/ml of indomethacin, whereas the high dose was inhibitory."	( Role of prostaglandins in contractile activity of the ampulla of the rabbit oviduct. Coons, LW; Harper, MJ; Hodgson, BJ; Radicke, DA; Valenzuela, G, 1980)	0.26
" A dose-response curve for white subjects showed a threshold mydriasis of less than 5 micrograms and a clinically useful mydriasis was obtained with one application of 50 micrograms."	( Mydriasis from topically administered phenylephrine HCl powder. Hanna, C; Thornton, CN, 1980)	0.26
" After obtaining dose-response curves to phenylephrine (PE) and carbachol or sodium nitroprusside (SNP), we exposed rings to the FR generating system or H2O2 for 30 min, either with or without a range of potentially protective agents."	( Effects of a xanthine oxidase/hypoxanthine free radical and reactive oxygen species generating system on endothelial function in New Zealand white rabbit aortic rings. Dowell, FJ; Hamilton, CA; McMurray, J; Reid, JL, 1993)	0.29
" Similarly, for both tissues, nitroprusside, ATP, and bethanechol induced similar dose-response relaxations of pre-stimulated tissue."	( Comparison of the pharmacological response of human corpus cavernosal tissue with the response of rabbit cavernosal tissue. Broderick, GA; Hypolite, JA; Levin, RM, 1995)	0.29
" When the endothelium was removed, however, the dose-response curves of both groups of rats were shifted to the left with an increase in maximum responses and they were no longer significantly different (max."	( Effect of swimming on vascular reactivity to phenylephrine and KC1 in male rats. Jansakul, C, 1995)	0.29
" We obtained dose-response curves for mean blood pressure and total peripheral resistance to phenylephrine."	( Plasma adrenaline modulates alpha 1-adrenoceptor mediated pressor responses and the baroreflex control in patients with borderline hypertension. Fujiwara, H; Hirakawa, S; Ishimura, K; Ito, H; Minatoguchi, S; Mori, M; Suzuki, T; Tonai, N, 1995)	0.29
" The dose-response relationship showed that less than an order of magnitude increase in ligand concentration led to maximal increase in [Ca2+]i from basal levels."	( Receptor-mediated calcium signals in astroglia: multiple receptors, common stores and all-or-nothing responses. McCarthy, KD; Shao, Y, 1995)	0.29
"This study indicates that a lower dosage (for example, one drop) is also efficacious and has the added benefit of fewer side effects."	( Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole. Crowder, AM; Dale, JL; Heiser, JF; Katz, BB; Wassom, NJ; Wilcox, CS, 1995)	0.29
"Full dose-response curves to histamine were constructed in 16 healthy volunteers (mean age, 47 +/- 20 years; age range, 21 to 80 years) by infusing histamine (2 to 136 ng/min) into dorsal hand veins preconstricted with the alpha-adrenergic selective agonist phenylephrine."	( H1- and H2-histamine receptor-mediated vasodilation varies with aging in humans. Bedarida, G; Blaschke, TF; Bushell, E; Hoffman, BB, 1995)	0.29
" Dose-response curves to histamine were repeated after infusion of the H2-selective antagonist cimetidine at a dose sufficient to completely block the H2-mediated response (49 micrograms/min)."	( H1- and H2-histamine receptor-mediated vasodilation varies with aging in humans. Bedarida, G; Blaschke, TF; Bushell, E; Hoffman, BB, 1995)	0.29
" By contrast, phenylephrine-induced dose-response curves in rabbit aorta were largely unaffected by tyrosine kinase inhibitors at 50 microM."	( Alpha 2-adrenoceptor-mediated vasoconstriction requires a tyrosine kinase. Deth, RC; Jinsi, A, 1995)	0.29
" Nifedipine (100 micrograms/kg, 300 micrograms/kg, and 1000 micrograms/kg) inhibited in a dose-dependent manner the pressor responses to the alpha 1- and alpha 2-adrenoceptor agonists, the dose-response curves to the alpha 2-adrenoceptor agonists being shifted further to the right."	( A comparison of the effects of TMB-8 and nifedipine on pressor responses to alpha 1- and alpha 2-adrenoceptor agonists in pithed rats. Aleixandre, MA; Pintado, A; Puerro, M, 1995)	0.29
" Dose-response curves to norepinephrine (NE) and phenylephrine (PE) were performed in thoracic aorta in the absence or presence of insulin (100 microU/ml) for 2 hrs."	( Insulin attenuates alpha-adrenergic aortic contraction in normotensive but not borderline hypertensive rats. Fuchs, LC; Tackett, RL; Winecoff, AP, 1995)	0.29
" Utilizing the dorsal hand vein technique, dose-response curves to bradykinin (maximum dose = 513 ng/min) were constructed in veins preconstricted with the alpha-adrenergic agonist phenylephrine in healthy young volunteers."	( Mechanism of bradykinin-induced venodilation in humans. Blaschke, TF; Dachman, WD; Ford, GA; Hoffman, BB, 1993)	0.29
" Although adverse sequelae to these episodes of hypertension were not noticed, this report documents the uptake of phenylephrine from topical ocular application and suggests the need for dose-response measurements for this adjunct to mydriatic treatment in dogs."	( Arterial hypertension associated with topical ocular use of phenylephrine in dogs. Ilkiw, JE; Pascoe, PJ; Smith, EM; Stiles, J, 1994)	0.29
" There were no significant differences between the dose-response curves of the diabetic group with normal urinary albumin excretion and the non-diabetic group."	( Selective enhancement of alpha 2-adrenoceptor-mediated vasoconstriction in insulin-dependent diabetic patients with microalbuminuria. Bodmer, CW; De Leeuw, PW; Janssen, M; Schaper, NC; Williams, G, 1995)	0.29
" However, vasoconstriction due to clonidine post-ENDT even at maximal dosage (10(-3) M), was greatly attenuated in all four branching orders as in group II."	( Attenuation of arteriolar alpha 2-adrenoceptor sensitivity during endotoxemia. Baker, CH; Nessellroth, S; Ortiz-Tweed, M; Price, JM; Sutton, ET, 1994)	0.29
" The correlation coefficient of the dose-response relationship was high, and significant only in the medial part of the nucleus tractus solitarii (NTS) in the medulla and periaqueductal gray (PAG) in the midbrain, whereas it was comparatively high but insignificant in the commissure and lateral parts of the NTS, caudal and rostral ventrolateral medulla, periambiguus nucleus, dorsal and ventral medullary reticular nuclei, lateral parabrachial nucleus, paraventricular nucleus thalamus, and dorsomedial nucleus hypothalamus."	( Neuronal expression of Fos protein in the rat brain after baroreceptor stimulation. Miura, M; Okada, J; Takayama, K, 1994)	0.29
" The pulmonary vascular dose-response relation to the sympathetic alpha-adrenoreceptor agonist phenylephrine also was investigated in conscious and isoflurane-anesthetized dogs (n = 6)."	( Isoflurane and the pulmonary vascular pressure-flow relation at baseline and during sympathetic alpha- and beta-adrenoreceptor activation in chronically instrumented dogs. Lennon, PF; Murray, PA, 1995)	0.29
" The dose-response curves produced by phenylephrine in the two groups were comparable."	( Forearm vascular responsiveness to alpha 1- and alpha 2-adrenoceptor stimulation in patients with congestive heart failure. Ceravolo, R; Chiariello, M; Condorelli, M; Esposito, G; Indolfi, C; Maione, A; Rapacciuolo, A; Rendina, V; Volpe, M, 1994)	0.29
" Liver injury measured by either method was essentially nonexistent for dosages < or = 50 mg/kg in male mice, and was only minimally evident in female mice at the highest dosage testable."	( Methylphenidate-induced hepatotoxicity in mice and its potentiation by beta-adrenergic agonist drugs. Harbison, RD; James, RC; Roberts, SM; Roth, L, 1994)	0.29
" In atherosclerotic aortas from WHHL rabbits, the dose-response curves of both tension and [Ca2+]i for 5-HT were shifted to the left at lower threshold concentrations and one-half maximally effective dose."	( Augmented receptor-mediated Ca2+ mobilization causes supersensitivity of contractile response to serotonin in atherosclerotic arteries. Hirata, K; Kawashima, S; Matsuda, Y; Miwa, Y; Suematsu, M; Yokoyama, M, 1994)	0.29
"1 mumol/site) appeared to produce greater shifts of the dose-response curve to BK (0."	( Cutaneous permeability responses to bradykinin and histamine in the guinea-pig: possible differences in their mechanism of action. Douglas, GJ; Khawaja, AM; Lawrence, L; Page, CP; Paul, W; Perez, AC; Schachter, M, 1994)	0.29
" The mean PGE1 dosage injected was 6 micrograms and mean duration of erection preceding aspiration 180 minutes."	( Pharmacologic erection: time-dependent changes in the corporal environment. Broderick, GA; Harkaway, R, 1994)	0.29
" The dose-response relation of NE-induced vasoconstriction was determined and compared for control (n = 5) and trained (n = 6) groups."	( Physical conditioning decreases norepinephrine-induced vasoconstriction in rabbits. Possible roles of norepinephrine-evoked endothelium-derived relaxing factor. Chen, CC; Chen, HI; Li, HT, 1994)	0.29
" In agonist dose-response studies, WO caused a noncompetitive inhibition of both alpha 1R and alpha 2R responses, but was more potent against alpha 2R."	( Effects of wortmannin on alpha-1/alpha-2 adrenergic receptor-mediated contractile responses in rabbit vascular tissues. Deth, RC; Waen-Safranchik, VI, 1994)	0.29
" Forearm blood flow was determined by venous occlusion plethysmography, and dose-response curves were generated for each drug."	( Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Creager, MA; Creager, SJ; Cusco, JA; Johnstone, MT; Lee, BK; Scales, KM, 1993)	0.29
" The nitric oxide (NO) synthase inhibitor, L-monomethyl-L-arginine (30 microM) shifted the dose-response curve for NECA to the right in all groups suggesting that the vascular response to NECA is partially mediated through the release of NO."	( Influence of aortic baroreceptor denervation on adenosine receptor-mediated relaxation of isolated rat aorta. Abdel-Rahman, AA; el-Mas, MM; Fahim, M; Mustafa, SJ, 1994)	0.29
" Left ventricular papillary muscles were isolated and mounted in an isolated bath and isometric, isotonic, and unloaded contractions were recorded during a phenylephrine dose-response curve."	( Age related changes in contractility and alpha 1 adrenergic responsiveness of myocardium from normal hamsters and hamsters with hereditary cardiomyopathy. Li, K; Rouleau, JL, 1993)	0.29
" This decrease was accompanied by a rightward shift in the dose-response curve."	( Age related changes in contractility and alpha 1 adrenergic responsiveness of myocardium from normal hamsters and hamsters with hereditary cardiomyopathy. Li, K; Rouleau, JL, 1993)	0.29
" Nitroglycerin pre-exposure (10 microM for 30 min) provoked a significant shift to the right of the dose-response curve to nitroglycerin in aortae isolated from rats of 8 weeks, 12 and 18 months."	( Nitrate tolerance and aging in isolated rat aorta. Berkenboom, G; Brékine, D; Fontaine, J; Unger, P, 1993)	0.29
" A control ring before endotoxin treatment and a ring after endotoxin treatment (blood pressure = 40 mmHg) were excised from the contralateral artery for length-tension and dose-response experiments with phenylephrine."	( Effect of muscle length on the in vitro comparison of femoral arteries before and after endotoxin shock. Baker, CH; Price, JM; Sutton, ET; Zhou, Z, 1993)	0.29
" Dose-response curves to PE were generated in the control and postexercise condition, with and without the NO synthase inhibitor L-NAME."	( Acute exercise enhances nitric oxide modulation of vascular response to phenylephrine. Collins, HL; DiCarlo, SE; Patil, RD, 1993)	0.29
" Identical dose-response curves were produced by PGF2 alpha in arteries from OH and LN dogs."	( Decreased potency of contraction to alpha-adrenoceptor stimulation in renal arteries from obese hypertensive dogs. Granger, JP; Ratz, PH; West, DB, 1993)	0.29
" PE shifted the ouabain dose-response curve toward lower ouabain concentrations; conversely, ouabain shifted the PE dose-response curve toward lower PE concentrations."	( Nanomolar ouabain augments caffeine-evoked contractions in rat arteries. Blaustein, MP; Heidrich, J; Podberesky, DJ; Weiss, DN, 1993)	0.29
" Dose-response curves to CPA were shallower and maximal responses were weaker than those produced by the other agonists."	( Interactions of adenosine A1 receptor-mediated renal vasoconstriction with endogenous nitric oxide and ANG II. Barrett, RJ; Droppleman, DA, 1993)	0.29
" The potentiating action of L-NNA on noradrenaline-induced contractions could also be observed in the presence of yohimbine or rauwolscine, although dose-response curves were shifted to the right."	( Involvement of alpha-adrenoceptors in the endothelium-dependent depression of noradrenaline-induced contraction in rat aorta. Kaneko, K; Sunano, S, 1993)	0.29
" KCl, phenylephrine (PHE) and arginine-vasopressin (AVP) dose-response curves (DR) were obtained at a preload of 500 mg which allowed the maximum response in control rings."	( In vitro femoral arterial responses to vasoconstrictor and vasodilator agents in endotoxin shock. Baker, CH; Price, JM; Sutton, ET; Zhou, Z, 1994)	0.29
" The dose-response curve for phenylephrine-induced increases in mesenteric or hindlimb vascular resistance was shifted only 2- to 10-fold to the right by CEC."	( The regulation of regional hemodynamics by alpha-1 adrenoceptor subtypes in the conscious rat. Barron, KW; Piascik, MT; Smith, MS; Soltis, EE, 1993)	0.29
" For AII, reduced vasoactivity with low chloride was evident both in terms of the threshold dose and on the linear part of the dose-response curve but not for the maximum response."	( Chloride anion concentration as a determinant of renal vascular responsiveness to vasoconstrictor agents. Lin, YS; McGiff, JC; Quilley, CP, 1993)	0.29
" The slopes of the dose-response curves for noradrenaline, phenylephrine and methoxamine and frequency-response curves for renal nerve stimulation generated at each dose level of BRL38227 could not be distinguished statistically."	( Effect of BRL 38227 on the adrenergic regulation of the kidney vasculature of the rat. Johns, EJ, 1993)	0.29
" The dose-response curve of endothelium-intact and -rubbed preparations to PE was shifted to the right by both high PCO2 and the pH-matched acidotic solution with normal PCO2."	( Endothelium dependence of effects of high PCO2 on agonist-induced contractility of rat aorta. Fukuda, S; Morioka, M; Shimoji, K; Taga, K; Tanaka, T, 1993)	0.29
" Samples from atria submitted to the highest tension shifted the dose-response curve of contraction induced by increasing cumulative doses of phenylephrine to the right."	( The vascular relaxing effect of a factor released by rat atria distension. Illanes, AG; Martinez, JL; Penna, M, 1993)	0.29
" The dose of isoprenaline required to increase heart rate by 25 beats min-1 (I25) and the dose of phenylephrine required to increase systolic and diastolic blood pressure by 20 mm Hg (PS20 and PD20) were calculated using a quadratic fit to individual dose-response curves."	( The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Guy, S; McDermott, BJ; Riddell, JG; Shanks, RG; Tham, TC, 1995)	0.29
" A calcium dose-response curve in normal and cardiomyopathic dog myocardium was also constructed."	( Tension-frequency relationships in normal and cardiomyopathic dog and hamster myocardium. Li, K; Rouleau, JL, 1995)	0.29
" L-NNA resulted in similar twofold leftward shifts in the PE dose-response curves for both groups."	( Contraction and endothelium-dependent relaxation in mesenteric microvessels from pregnant rats. Lindheimer, MD; Nalbantian-Brandt, C; Pascoal, IF; Umans, JG, 1995)	0.29
"In vitro, prospective, repeated-measures, dose-response study."	( Effect of halothane on phenylephrine-induced vascular smooth muscle contractions in endotoxin-exposed rat aortic rings. Bina, S; Grissom, TE; Hart, J; Muldoon, SM, 1996)	0.29
" Phenylephrine dose-response data (10(-10) to 10(-5) M) were determined for lipopolysaccharide- and nonlipopolysaccharide-treated rings."	( Effect of halothane on phenylephrine-induced vascular smooth muscle contractions in endotoxin-exposed rat aortic rings. Bina, S; Grissom, TE; Hart, J; Muldoon, SM, 1996)	0.29
" To this end, dose-response curves to phenylephrine and BaCl2 were studied in the renal vasculature under basal conditions and after the infusion of N(omega)-nitro-L-arginine methyl ester (L-NAME) and tetraethylammonium (TEA) in endothelium-intact and endothelium-denuded (CHAPS-treated) preparations."	( Modulatory role of endothelium-derived relaxing factors on the response to vasoconstrictors and flow-pressure curve in the isolated perfused rat kidney. Osuna, A; Vargas, F, )	0.13
"We used the dorsal hand vein compliance technique to construct full dose-response curves to the beta 2-agonist isoproterenol (2 to 270 ng/min) in hand veins preconstricted with phenylephrine in 11 young white subjects and in 11 young Asian Indian subjects."	( Impaired beta 2-adrenergic agonist-induced venodilation in Indians of Asian origin. Adubofour, KO; Dachman, WD; Kapoor, C; Singarajah, C; Takahashi, B; Vajo, Z; Zafar, H, 1996)	0.29
" In the controls the phenylephrine dose-response relationship remained unaffected by simultaneous administration of L-NMMA."	( Indirect evidence for stimulation of nitric oxide release by tumour necrosis factor-alpha in human veins in vivo. Haefeli, WE; Linder, L; Simper, D; Strobel, WM, 1995)	0.29
" The dose-response curve for ACh (0."	( Infusions of pressor agents selectively attenuate depressor responses to ACh in anesthetized dogs. Ishii, K; Nakahara, T; Nakayama, K; Tanaka, Y, 1996)	0.29
" On separate days, cumulative dose-response curves to phenylephrine alone and with coadministration of 1 or 30 pmol neuropeptide Y per minute were constructed, and the responses were fitted to a four-parameter logistic equation."	( Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo. Haefeli, WE; Lautenschlager, BM; Linder, L, 1996)	0.29
" dosing of nitroprusside."	( Non-invasive assessment of baroreflex sensitivity and relation to measures of heart rate variability in man. Brazzale, D; Jackman, G; Kamen, PW; Krum, H; Pellizzer, AM, )	0.13
" Dose-response relationships (ACh: 10(-9) to 10(-6)M; Phe: 3 x 10(-8) to 10(-4)M) and -log ED50 sensitivity to ACh and Phe before and after CPB were compared."	( Hyperglycemia during hypothermic cardiopulmonary bypass does not alter postbypass vascular endothelial responses in dogs. Feerick, AE; Johnston, WE; Lin, CY; O'Dwyer, C; Steinsland, OS; Wang, Y, 1996)	0.29
"05) in hyperglycemic animals, indicating similar and significant rightward shifts of the dose-response relationship to ACh after CPB in both groups."	( Hyperglycemia during hypothermic cardiopulmonary bypass does not alter postbypass vascular endothelial responses in dogs. Feerick, AE; Johnston, WE; Lin, CY; O'Dwyer, C; Steinsland, OS; Wang, Y, 1996)	0.29
" In the presence of chlorisondamine, McN-A-343 increased both RNA and BP in dose-related fashion, and the dose-response curves of McN-A-343 shifted to the right in the presence of pirenzepine."	( Role of muscarinic receptors in ganglionic transmission in rabbits. Kim, JH; Ro, YB, 1996)	0.29
" Dose-response curves were generated in the aorta in response to potassium chloride (KCl), AII and PE."	( Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance. Iyer, SN; Katovich, MJ, 1996)	0.29
" An escalating adenosine dosage schedule was planned to produce blood cardioplegia concentrations from 0 to 250 mumol/L, and the blocks were tested sequentially."	( Phase 1 human trial of adenosine-potassium cardioplegia. Christakis, GT; Cohen, EA; Deemar, KA; Feder-Elituv, R; Fremes, SE; Goldman, BS; Iazetta, J; Levy, SL; Mallidi, HR; Walker, SE; Wong, BI, 1996)	0.29
"10 ml in each puff with a dosage used in clinical practice."	( Effects of topical nasal decongestants on histology of nasal respiratory mucosa in rabbits. Chon, KM; Hong, SH; Jeong, CH; Min, YG; Suh, SH, 1995)	0.29
" To this end, we studied dose-response curves of phenylephrine (10(-9) to 10(-5) mol/L) in the presence and absence of losartan (10(-9), 10(-7), and 10(-5) mol/L) in SHR aortic rings."	( Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1996)	0.29
" Bk reduced the size of the pressor responses at relatively low concentrations (2-60 nM) but the dose-response curve was flat and the maximum inhibitory effect hardly exceeded 50 percent."	( Comparison of the vasodilatory effects of bradykinin in isolated dog renal arteries and in buffer-perfused dog kidneys. Hadházy, P; Koltai, MZ; Malomvölgyi, B; Pogátsa, G; Tekes, K, 1996)	0.29
" We speculate that the lack of a simple, linear dose-response effect of progesterone on blood pressure and baroreflex sensitivity can be explained by progesterone action at multiple receptor populations."	( Progesterone rapidly reduces arterial pressure in ewes. Keller-Wood, M; Roesch, DM, 1997)	0.3
" Dose-response curves to phenylephrine (PE) 10(-9) to 5 x 10(-6) M) were examined in PA rings as well as response to L-arginine analogues in isolated lungs from CH or normoxic (N) rats after various incubation times."	( Induction of nitric oxide synthase activity in pulmonary arteries from normoxic and chronically hypoxic rats. Adnot, S; Carville, C; Eddahibi, S; Raffestin, B; Rideau, D; Teiger, E, 1997)	0.3
"To determine the response of haemodynamic and oxygen-transport parameters to phenylephrine in a dose-response fashion in septic non-hypotensive, vasodilated surgical intensive care unit (ICU) patients."	( A dose-response study of phenylephrine in critically ill, septic surgical patients. Choban, P; Dasta, J; Dick, M; Flancbaum, L; Sinha, R, 1997)	0.3
" Dose-response trials are needed to determine the optimal dose of phenylephrine."	( A dose-response study of phenylephrine in critically ill, septic surgical patients. Choban, P; Dasta, J; Dick, M; Flancbaum, L; Sinha, R, 1997)	0.3
" Pretreatment with ACTH-(1-24) caused a pronounced, dose-dependent parallel shift to the right of the dose-response curve for the pressor and tachycardiac effects of gamma 2-MSH."	( Different cardiovascular profiles of three melanocortins in conscious rats; evidence for antagonism between gamma 2-MSH and ACTH-(1-24). De Wildt, DJ; Kleijne, JA; Van Bergen, P; Versteeg, DH, 1997)	0.3
" Rings were exposed to increasing concentrations of triiodothyronine (4 x 10(-12) to 1 x 10(-4) mol/L) to obtain dose-response curves."	( Direct effects of triiodothyronine on human internal mammary artery and saphenous veins. Carlsson, C; Chen, D; Cooper, SC; Eldridge, CJ; Hellmann, SK; Jeevanandam, V; Krasner, LJ; McClurken, JB; Wendling, WW, 1997)	0.3
" Changes in vessel internal diameter were measured and dose-response curves (DRC) for each vasoactive agent were determined."	( Nitric oxide inhibition simulates the enhancement of alpha 1 agonist-induced vasoconstriction in diabetes. Dresner, LS; Mueller, CM; Ponomarenko, IN; Wait, RB; Wang, SP; West, MW, 1997)	0.3
" In addition, a dose-response curve to PTHrP was constructed in a dorsal hand vein in eight subjects."	( Hemodynamic effects of parathyroid hormone-related peptide-(1-34) in humans. Dorner, G; Eichler, HG; Entlicher, J; Kapiotis, S; Schmetterer, L; Wolzt, M; Zelger, G, 1997)	0.3
" The recommended dosage for this indication is 2 drops followed 5 minutes later by 2 drops."	( Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. Bartlett, JD; Hart, KK; Hogan, TS; McDaniel, DD; Paggiarino, DA, 1997)	0.3
" Finally, to rule out the possibility that the conteracting effect of L-NMMA may not be specifically related to insulin action, dose-response curves to phenylephrine (0."	( Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm. Barbato, E; Fontana, D; Iaccarino, G; Izzo, R; Lembo, G; Trimarco, B; Vecchione, C, 1997)	0.3
" In the first group a dose-response curve to phenylephrine (PE) (0."	( Reactivity of the isolated perfused rat tail vascular bed. Amaral, SM; França, AS; Rossoni, LV; Vassallo, DV, 1997)	0.3
" CS contracts the smooth muscle of the aorta in a dose-response relation."	( Vasoconstrictor effect of Cissus sicyoides on guinea-pig aortic rings. Cartas-Heredia, L; García, X; Gijón, E; Lorenzana-Jímenez, M, 1997)	0.3
" Log dose-response curves for TNG, 10(-9) to 10(-5) M, were constructed for each tissue."	( Placental tissue enhances uterine relaxation by nitroglycerin. Csavoy, AN; Datta, S; Segal, S, 1998)	0.3
" However, administration of isoproterenol at either dosage had no significant effect on the incidence of gastric cancers and the labeling index of antral epithelial cells."	( Promotion by the alpha-adrenoceptor agonist phenylephrine, but not by the beta-adrenoceptor agonist isoproterenol, of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Baba, M; Iishi, H; Iseki, K; Nakaizumi, A; Sakai, N; Tatsuta, M; Uehara, H; Yano, H, 1998)	0.3
" Using the dorsal hand vein compliance technique, dose-response curves were constructed for the two vasoactive agents in 10 Mexican-American and 10 White American volunteers."	( Variability in vascular responsiveness between Mexican-Americans and White Americans. Adubofour, KO; Dachman, WD; Kapoor, C; Rackleff, D, 1998)	0.3
" Dose-response curves were constructed to intravenously infuse phenylephrine with and without coinfusion with two different doses of hNPY (1."	( Human neuropeptide Y potentiates alpha1-adrenergic blood pressure responses in vivo. Grouzmann, E; Haefeli, WE; Linder, LM; Schuerch, LV, 1998)	0.3
" In thoracic aortic rings from CH rats, cumulative dose-response curves to phenylephrine (PE) in the presence of the nitric oxide (NO) synthase inhibitor Nomega-nitro-L-arginine (L-NNA) and the HO inhibitor zinc protoporphyrin 9 (ZnPPIX) elicited increased contractility compared with CH rings treated with only L-NNA."	( Role of endothelial carbon monoxide in attenuated vasoreactivity following chronic hypoxia. Caudill, TK; Kanagy, NL; Resta, TC; Walker, BR, 1998)	0.3
"5 microg/kg/min, with further improvement as the dosage increased."	( Effects of dopamine, dobutamine, dopexamine, phenylephrine, and saline solution on intramuscular blood flow and other cardiopulmonary variables in halothane-anesthetized ponies. Alibhai, HI; Clarke, KW; Lee, YH; Song, D, 1998)	0.3
" The dose-response curves of vasoconstriction to phenylephrine and prostaglandin F2alpha were obtained in healthy male volunteers."	( Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity. Kimura, M; Kosuge, K; Nakashima, M; Nishimoto, M; Ohashi, K; Umemura, K, 1998)	0.3
"The ACEIs shifted the dose-response curve of phenylephrine to the right and raised the median effective dose (ED50; 189."	( Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity. Kimura, M; Kosuge, K; Nakashima, M; Nishimoto, M; Ohashi, K; Umemura, K, 1998)	0.3
" Cumulative dose-response curves to phenylephrine (PHE) and acetylcholine (ACH) were obtained."	( Altered vasoconstrictor and dilator responses after a "two-hit" model of sequential hemorrhage and bacteremia. Garrison, RN; Harris, PD; Price, SA; Spain, DA; Wilson, MA, 1999)	0.3
" Pretreatment with palmatine shifted the dose-response curves of PE both rightwards and downwards in a dose-dependent manner."	( Effects of palmatine on isometric force and intracellular calcium levels of arterial smooth muscle. Chang, YL; Hsieh, MT; Jiang, MJ; Usami, S, 1999)	0.3
" Apparent rate constants for methoxamine binding and unbinding gave Kd values in agreement with EC50 values measured from dose-response relations."	( Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2. Fedida, D; Li, Q; Parker, C, 1999)	0.3
" Vessel sensitivity (pD2) to phenylephrine, acetylcholine, and KCl was calculated from dose-response curves."	( Subacute sepsis impairs vascular smooth muscle contractile machinery and alters vasoconstrictor and dilator mechanisms. Garrison, RN; Harris, PD; Price, SA; Spain, DA; Wilson, MA, 1999)	0.3
" There was a significant decrease with age in the maximal relaxation to cholera toxin as well as a rightward shift in the dose-response curve."	( Impaired cholera toxin relaxation with age in rat aorta. Chapman, J; Mader, SL; Schutzer, WE; Watts, VJ, 1999)	0.3
" Dose-response curves were obtained with acetylcholine, sodium nitroprusside, and calcium ionophore A23187 following contraction with phenylephrine (10(-6) M) in the presence of indomethacin (10(-5) M)."	( A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? Cable, DG; Hisamochi, K; Schaff, HV, 1999)	0.3
" The least decrease of BP and minimal need of rescue ephedrine among all patients studied were recorded in the group receiving low dosage of lidocaine with intrathecal clonidine (L40-C100)."	( Enhancement of intrathecal lidocaine by addition of local and systemic clonidine. Dobrydnjov, I; Samarütel, J, 1999)	0.3
" m-2), a PE dose-response curve was generated by the cumulative injection of individual doses of PE (25 to 500 micrograms)."	( G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Benessiano, J; Desmonts, JM; Durand, G; Henrion, D; LeMarie, C; Levy, BI; Philip, I; Plantefeve, G; Poirier, O; Vicaut, E; Vuillaumier-Barrot, S, 1999)	0.3
" There were no differences in normalized dose-response curves to KCl among three groups."	( Different contractile properties between intralobar and extralobar pulmonary arteries of the rabbit. Earm, YE; Ho, WK; Kang, TM; Lee, SH; Lee, SJ; Park, MK; Uhm, DY, 1999)	0.3
" Indomethacin did not alter the dose-response curves to KCl or Phe in either swimming or control groups."	( Effects of exercise training on responsiveness of the mesenteric arterial bed to phenylephrine and KCl in male rats. Hirunpan, P; Jansakul, C, 1999)	0.3
"Phenylephrine dose-dependently contracted ciliary artery smooth muscle, and bunazosin (1 microM) shifted this dose-response curve to the right."	( Effects of beta antagonists on mechanical properties in rabbit ciliary artery. Hayashi, E; Hayashi-Morimoto, R; Ishikawa, H; Sato, Y; Yoshitomi, T, 1999)	0.3
"We investigated the dose-response effects of phenylephrine and antagonistic effects of prazosin on axial movement of the rat incisor and arterial blood pressure."	( Effects of phenylephrine and prazosin on axial movement of the rat incisor and arterial blood pressure. Ohyama, N; Yamaguchi, S, 1999)	0.3
" We administered intravenous bolus doses of either phenylephrine or saline after performing a dose-response curve to establish the amount of phenylephrine that produced a 20-mmHg increase in mean arterial pressure."	( Drug-induced arterial pressure elevation is associated with arousal from NREM sleep in normal volunteers. Anand, A; Kesler, B; Launois, SH; Weiss, JW, 1999)	0.3
" In contrast, the dose-response curve of the adrenergic agonist phenylephrine was significantly attenuated for the estradiol-replaced rats compared with the ovariectomized group (EC(50)=0."	( Effect of estrogen replacement on vasoconstrictor responses in rat mesenteric arteries. Davidge, ST; Zhang, Y, 1999)	0.3
" Dose-response curves to the PGI2 analogue iloprost on phenylephrine-preconstricted rings of diabetic rats and controls were comparable."	( Modification of vasodilator response in streptozotocin-induced diabetic rat. Bouchard, JF; Dumont, EC; Lamontagne, D, 1999)	0.3
" The dose-response curve of CpCr(NO)2Cl was displaced to the right by hemoglobin, as well as methylene blue, showing involvement of the NO/cGMP pathway."	( Vasodilator effects of organotransition-metal nitrosyl complexes, novel nitric oxide donors. Legzdins, P; Pang, CC; Poon, JS; Wang, YX, 2000)	0.31
" Dose-response curves to phenylephrine were significantly decreased and shifted to the right when aortic rings were incubated with 1 microM CGRP for 1 h followed by 2 h incubation without CGRP."	( Calcitonin gene-related peptide causes long-term inhibition of contraction in rat thoracic aorta through a nitric oxide-dependent pathway. Fiscus, RR; Lu, LF, 1999)	0.3
"The rabbit inferior vena cava (IVC) is a large-capacitance vessel that displays typical contractile dose-response curves for caffeine and phenylephrine (PE)."	( Asynchronous Ca(2+) waves in intact venous smooth muscle. Lee, CH; Poburko, D; Ruehlmann, DO; van Breemen, C, 2000)	0.31
" Dose-response curves were constructed before and during nicotine coinfusion at a rate of 40 ng/min, reproducing a plasma concentration of 15 ng/mL."	( Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Benowitz, NL; Blaschke, TF; Chalon, S; Hoffman, BB; Moreno, H, 2000)	0.31
" Experimental studies in pregnant rabbits using Primatene in both low and high dosage resulted in limb reduction defects and other malformations in a significant number of the offspring compared with controls."	( Association of sympathomimetic drugs with malformations. Drut, RM; Gilbert-Barness, E, 2000)	0.31
" A biphasic (low, then high) dose-response relation for mean arterial pressure, pulmonary arterial pressure, and vascular resistances, and an attenuation of the cold pressor response also were observed."	( The effects of increasing plasma concentrations of dexmedetomidine in humans. Barney, JA; Colinco, MD; Ebert, TJ; Hall, JE; Uhrich, TD, 2000)	0.31
" In isolated pulmonary arterial rings, 4-AP increased resting tension and caused a leftward shift in the KCl dose-response curve."	( K(+) channel inhibition, calcium signaling, and vasomotor tone in canine pulmonary artery smooth muscle. Damron, DS; Doi, S; Horibe, M; Murray, PA; Ogawa, K; Tanaka, S, 2000)	0.31
" Because endogenous steroids are known to play a role in the modulation of vasomotor tone, the purpose of our study was to investigate the phenylephrine-mean arterial pressure dose-response relationship in patients with septic shock and the effect of a physiological dose of hydrocortisone on it."	( Effect of hydrocortisone on phenylephrine--mean arterial pressure dose-response relationship in septic shock. Annane, D; Bellissant, E, 2000)	0.31
"5 g resting tensions, NOS inhibitors shifted the ACh dose-response curve to the right."	( Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips. Bani, D; Ciuffi, M; Failli, P; Franchi-Micheli, S; Mazzetti, L; Zilletti, L, 2000)	0.31
" The following experiments were conducted to determine the dose-response relationship of acutely administered estrogen on autonomic tone and reflex control of heart rate in ovariectomized Sprague-Dawley female rats."	( Acute injection of 17beta-estradiol enhances cardiovascular reflexes and autonomic tone in ovariectomized female rats. Connell, BJ; Saleh, MC; Saleh, TM, 2000)	0.31
" There was a clear dose-response relationship at one hour."	( Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence. Cheetham, MJ; Kamm, MA; Phillips, RK, 2001)	0.31
" In separate groups of animals, dose-response curves for increases in diastolic pressure produced by phenylephrine were generated after the administration of saline (control), ouabain (18 microg/kg), L-omega-N-nitro arginine methyl ester (L-NAME, 3 micromol/kg) and angiotensin II (15 ng/kg per min)."	( Acute pressor actions of ouabain do not enhance the actions of phenylephrine or norepinephrine in anesthetized rats. Barker, LA; Rossoni, LV; Vassallo, DV, 2001)	0.31
"To determine optimal dosage regimens of intranasal metered dose aerosolized surfactant with and without other medications in the treatment of otitis media with effusion (OME)."	( Dosage regimens of intranasal aerosolized surfactant on otitis media with effusion in an animal model. Chandrasekhar, SS; Connelly, PE; Mautone, AJ; Troublefield, YL; Venkatayan, N, 2001)	0.31
" Resolution with the once-daily dosage was longer for all conditions."	( Dosage regimens of intranasal aerosolized surfactant on otitis media with effusion in an animal model. Chandrasekhar, SS; Connelly, PE; Mautone, AJ; Troublefield, YL; Venkatayan, N, 2001)	0.31
" Twice-daily dosing was statistically superior."	( Dosage regimens of intranasal aerosolized surfactant on otitis media with effusion in an animal model. Chandrasekhar, SS; Connelly, PE; Mautone, AJ; Troublefield, YL; Venkatayan, N, 2001)	0.31
"This study reiterates the effectiveness of OME treatment with an aerosolized synthetic surfactant with and without steroids and establishes a superior twice-daily dosage schedule."	( Dosage regimens of intranasal aerosolized surfactant on otitis media with effusion in an animal model. Chandrasekhar, SS; Connelly, PE; Mautone, AJ; Troublefield, YL; Venkatayan, N, 2001)	0.31
" Dose-response curves to acetylcholine (10(-9)-10(-4) mol/l) and sodium nitroprusside (10(-9)-10(-4) mol/l) were studied in segmental arteries in the presence or absence of the thromboxane A2/PGH2 receptor antagonist ifetroban (10(-5) mol/l)."	( Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S, 2001)	0.31
" In separate experiments, cumulative dose-response curves to alpha- (phenylephrine) and beta- (isoproterenol) adrenoreceptor agonists were generated in conscious and propofol-anesthetized dogs."	( Pulmonary vascular effects of propofol at baseline, during elevated vasomotor tone, and in response to sympathetic alpha- and beta-adrenoreceptor activation. Kim, SO; Kondo, U; Murray, PA; Nakayama, M, 2001)	0.31
" In the preliminary session a dose-response curve to the vasoconstrictor effect of phenylephrine was constructed and the dose producing 50-75% maximal response was determined for each individual."	( Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man. Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E, 2001)	0.31
" Dose-response curves were obtained for the antinociceptive effect of diclofenac, phenylephrine, clonidine, desipramine, prazosin, and yohimbine administered both systemically and intrathecally, and ED(50)s were calculated."	( An isobolographic analysis of the adrenergic modulation of diclofenac antinociception. Miranda, HF; Pinardi, G; Sierralta, F, 2001)	0.31
" Therefore, we recommend the use of phenylephrine 10% in the described dosage as routine medication for cataract surgery."	( [Biochemical stress monitoring during cataract surgery; phenylephrine 10% shows no changes in serum-catecholamines in comparison with phenylephrine 5%]. Bartram, MC; Burkhardt, KU; Schlichtenbrede, FC; Wiedemann, R, 2001)	0.31
" We explore the toxicities of OTC cough and cold medications, discuss mechanisms of dosing errors, and suggest why physicians should be more vigilant in specifically inquiring about OTCs when evaluating an ill child."	( Toxicity of over-the-counter cough and cold medications. Gunn, VL; Liebelt, EL; Serwint, JR; Taha, SH, 2001)	0.31
"28) %, in the rings from SHR rats treated with OO, and were more pronounced than in WKY rats In the same way, OO attenuated the dose-response curves induced by phenylephrine (10(-8)-10(-5) m) from SHR rats, accompanied with a slower contraction."	( Effects of dietary oleic-rich oils (virgin olive and high-oleic-acid sunflower) on vascular reactivity in Wistar-Kyoto and spontaneously hypertensive rats. Herrera, MD; Marhuenda, E; Pérez-Guerrero, C; Ruiz-Gutiérrez, V, 2001)	0.31
" Dose-response curves were obtained for systemic and intrathecal antinociceptive effects of ketoprofen, phenylephrine, clonidine, desipramine, and prazosin; and ED50 were calculated."	( Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems. Miranda, HF; Pinardi, G; Sierralta, F, 2001)	0.31
" A dose-response curve of the effect of the beta2-adrenergic-receptor agonist isoproterenol was constructed (dose range, 4 to 480 ng per minute)."	( The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. Byrne, DW; Dishy, V; Kim, RB; Sofowora, GG; Stein, CM; Wood, AJ; Xie, HG, 2001)	0.31
" Constrictor dose-response curves to phenylephrine were generated before and after pretreatment with N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase."	( Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Dos Santos, N; Dubé, GP; McManus, BM; Rahimian, R; Toma, W; van Breemen, C, 2002)	0.31
" The purpose of this study was to determine and compare the potencies of the alpha(1)-adrenoceptor antagonists terazosin, doxazosin, tamsulosin, and fiduxosin, based on relationships between plasma drug concentrations and blockade of phenylephrine (PE)-induced intraurethral (IUP) and mean arterial pressure (MAP) responses after single oral dosing in conscious male beagle dogs."	( Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. Brune, ME; Hancock, AA; Hui, YH; Katwala, SP; Kerwin, JF; Marsh, KC; Meyer, MD; Milicic, I; Stolarik, D; Witte, DG, 2002)	0.31
"A rapid, precise, and specific high-performance liquid chromatographic method is described for the simultaneous determination of paracetamol, phenylephrine HCI, and chlorpheniramine maleate in combined pharmaceutical dosage forms."	( Simultaneous high-performance liquid chromatographic determination of paracetamol, phenylephrine HCl, and chlorpheniramine maleate in pharmaceutical dosage forms. Ozden, T; Senyuva, H, 2002)	0.31
" Dose-response curves to PE (3."	( Postexercise alpha-adrenergic receptor hyporesponsiveness in hypertensive rats is due to nitric oxide. Collins, HL; DiCarlo, SE; Rao, SP, 2002)	0.31
" In fetal, but not adult, MCA, UK-14304 induced a significant decrease in pD(2) for the phenylephrine dose-response relation."	( Pre- and postjunctional alpha(2)-adrenergic receptors in fetal and adult ovine cerebral arteries. Bishai, JM; Buchholz, JN; Gheorghe, CP; Longo, LD; Meulenaar, R; Nijland, R; Penninga, L; Zhang, L; Zhao, Y, 2002)	0.31
" Nomega-nitro-L-arginine methyl ester shifted the dose-response curves of adenosine, N6-cyclopentyladenosine, or 5'-N-ethylcarboxamidoadenosine to the right in both normal and hypothyroid vessels."	( Adenosine participates in regulation of smooth muscle relaxation in aortas from rats with experimental hypothyroidism. Baños, G; Franco, M; Grimaldo, JI; Martínez, F, 2002)	0.31
" Dose-response curves for acetylcholine-induced, endothelium-related relaxation of aortic rings (after previous exposure to phenylephrine) and for serotonin-induced vasoconstriction were conducted in the presence or absence of 10-5 mol/L melatonin."	( Vascular reactivity in diabetic rats: effect of melatonin. Albornoz, LE; Cardinali, DP; Damiano, PF; Linares, LM; Reyes-Toso, CF; Rosón, MI, 2002)	0.31
" Isolated rings of the thoracic aorta were obtained from rats immediately or 24 h after in vivo exposure to 60 min of hyperoxia (>95% O2), and the in vitro dose-response to phenylephrine (PHE), prostaglandin F2alpha (PGF2alpha) and endothelin-1 (ET-1), acetylcholine (Ach) and sodium nitroprusside (SNP) was assessed."	( Exposure of rats to hyperoxia enhances relaxation of isolated aortic rings and reduces infarct size of isolated hearts. Eha, I; Elfström, P; Kals, J; Starkopf, J; Taal, G; Tähepõld, P; Talonpoika, A; Vaage, J; Valen, G, 2002)	0.31
" Dose-response curves for alpha-adrenoceptor agonists in testosterone-treated animals showed a leftward shift, indicating increased sensitivity of tissue to alpha-adrenoceptor agonists."	( Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Kaul, CL; Ramarao, P; Thiyagarajan, M, 2002)	0.31
" The proposed methods are successfully applied to the determination of drugs I and II in their dosage forms using the standard addition technique."	( Spectrophotometric determination of phenylephrine HCl and orphenadrine citrate in pure and in dosage forms. Shama, SA, 2002)	0.31
"In dose-response curves to alpha stimulation, BBI mediated a shift to the right (decreased receptor sensitivity in bladder/urethra as well as corpora with no change in the maximal response)."	( Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity. Broderick, GA; Kennedy, AR; Levin, RM; Liu, SP; Malkowicz, SB; Wein, AJ, 2003)	0.32
" Hemodynamic studies were undertaken with the determination of dose-response curve for MAP and renal cortical blood flow (RCF) in response to U46619, angiotensin-II, phenylephrine and endothelin-1, as well as the systemic hemodynamic response to acetylcholine and L-NG nitro-arginine methylester (L-NAME)."	( Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Ajayi, AA; Cory, J; Hayes, BE; Hercule, H; Oyekan, AO, 2003)	0.32
"6) was examined to evaluate the dose-response effect and time course on pupil diameter, of ibopamine, phenylephrine, and tropicamide."	( Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment. Babighian, S; Bonomi, L; Marchini, G; Perfetti, S; Tosi, R, 2003)	0.32
" The method was applied to the quantitation of the three components in a commercial dosage form."	( Simultaneous determination of naphazoline, diphenhydramine and phenylephrine in nasal solutions by capillary electrophoresis. Goicoechea, HC; Mantovani, VE; Marchesini, AF; Robles, JC; Williner, MR, 2003)	0.32
" These results indicate that factors that can influence alpha-adrenergic receptors may be critical in assessing dose-response data used in the risk assessment process."	( Activation of alpha(1)-adrenergic receptors potentiates the nephrotoxicity of ethylene dibromide. Banasik, M; Harbison, RD; Mosquera, DI; Muro-Cacho, C; Stedeford, T, 2003)	0.32
" Dose-response curves were made with gradually increasing doses of Phe using an isolated kidney preparation in the presence of a NO synthase (NOS) inhibitor (L-NAME, 1 microM), a PG-synthesis inhibitor (indomethacin, 1 microM), both, or neither."	( Pregnancy influence on the vascular interactions between nitric oxide and other endothelium-derived mediators in rat kidney. Anguiano, L; Bobadilla, RA; López Sanchez, P; Pérez-Alvarez, V, 2003)	0.32
" Phenylephrine (25 to 250 microg) caused a similar increase in BP in a dose-response fashion before and during SNP infusion."	( Role of nitric oxide in the regulation of cerebral blood flow in humans: chemoregulation versus mechanoregulation. Egbarya, R; Jacob, G; Lavi, R; Lavi, S, 2003)	0.32
" Contraction dose-response curves were generated to determine maximal contraction force (F(max)) and pD2 (sensitivity) to phenylephrine in each experimental group."	( Sepsis alters vessel contraction by adrenoceptor-induced nitric oxide and prostanoid. Garrison, RN; Harris, PD; Kawabe, T; Zakaria, EL, 2003)	0.32
" In contrast, it is unclear whether vascular superoxide increases during eccentric administration of oral nitrates, which is a widely used therapeutic dosing regimen."	( Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance. Kojda, G; Laber, U; Meyer, W; Müllenheim, J; Müller, S, 2003)	0.32
" The mean dosage and the total amount of Pethidine at 24 hours were significantly lower in G2 compared with G1."	( Postoperative pain relief after laparoscopic cholecystectomy: a randomised prospective double-blind clinical trial. Goroshina, J; Lepner, U; Samarütel, J, 2003)	0.32
" The fluctuation of the dose-response relaxation curves for the contraction of KCl induced by tetrandrine was observed with isolated rabbit corpus cavernosum tissue."	( [The relaxation effects of tetrandrine on the corpus cavernosum tissue of rabbit in vitro]. Chen, J; Chen, Z; Liu, JH; Sun, CL; Wang, T; Xiao, HJ, 2003)	0.32
" The dose-response curves of KCl were shifted to the right nonparallelly, and the maximal responses were depressed to (73."	( [The relaxation effects of tetrandrine on the corpus cavernosum tissue of rabbit in vitro]. Chen, J; Chen, Z; Liu, JH; Sun, CL; Wang, T; Xiao, HJ, 2003)	0.32
" In addition, dose-response relationships of alpha- and beta-adrenergic receptor stimulation were evaluated after application of an alpha- and beta-adrenergic receptor agonist, respectively in different dosages."	( Milking characteristics and their relation to adrenergic receptor mRNA expression and ligand binding in the mammary gland of dairy cows. Bruckmaier, RM; Inderwies, T; Pfaffl, MW, 2003)	0.32
" Dose-response curves were obtained sequentially with a wash-out of 20 min between each concentration; the maximum contractility of an individual muscle ring was set at 100%."	( Involvement of signal transducing GTP-binding proteins in renal artery alpha 1-adrenoceptor mediated smooth muscle contraction. Eckert, RE; Karsten, AJ, 2004)	0.32
" Dose-response curves for acetylcholine-induced, endothelium-related relaxation of aortic rings (after previous exposure to phenylephrine) and for phenylephrine-induced vasoconstriction were conducted."	( Effect of melatonin on vascular reactivity in pancreatectomized rats. Arán, M; Cardinali, DP; Linares, LM; Pinto, JE; Reyes-Toso, CF; Ricci, CR; Rodríguez, RR, 2004)	0.32
" Complete dose-response curves to MgSO4 (0."	( Magnesium-induced vasodilation in the dorsal hand vein. Landau, R; Scott, JA; Smiley, RM, 2004)	0.32
" The main difference seen between SMRA and aorta was that PM did not modify the phenylephrine-induced dose-response vasoconstriction in SMRA, while it did do so in the aorta."	( The effect of particulate matter on resistance and conductance vessels in the rat. Bagaté, K; Borm, PJ; Cassee, FR; Meiring, JJ, 2004)	0.32
" Dose-response curves were fit with nonlinear regression analysis to calculate the EC(50) and slope."	( Acidosis attenuates P2X purinergic vasoconstriction in skeletal muscle arteries. Buckwalter, JB; Clifford, PS; Hamann, JJ; Kluess, HA, 2005)	0.33
"Initially a dose-response curve of phenylephrine was constructed at dose strengths of 1-16 microg/kg in a cumulative manner."	( Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs. Ahuja, VM; Fahim, M; Sharma, R, 2004)	0.32
" In endothelium-intact rings precontracted with phenylephrine 10(-6) M, dose-response curves for acetylcholine (10(-9) to 10(-5) M) and calcium ionophore (10(-9) to 10(-6) M) were generated in the presence and absence of etomidate (5 x10(-6) 10(-5) M)."	( Effect of etomidate on endothelium-dependent relaxation induced by acetylcholine in rat aorta. Cho, HC; Chung, YK; Kim, HJ; Lee, HK; Shin, IW; Sohn, JT, 2004)	0.32
" Infusions of phenylephrine at 3 microg/kg/min for 120 min shifted the dose-response curve for the depressor responses produced by acetylcholine (0."	( Accelerated acetylcholine metabolism in the lung after infusion of phenylephrine in dogs. Ishii, K; Nakahara, T; Nakayama, K; Nejishima, H, 2003)	0.32
" Thoracic aorta was isolated and the dose-response curve of phenylephrine (PE) in the presence or absence of Nomega-nitro-L-arginine-methyl ester (L-NAME) was recorded."	( Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Balaraman, R; Majithiya, JB; Paramar, AN, 2005)	0.33
" The presence of pioglitazone at higher concentrations (>10 muM), but not at lower concentrations, significantly changed the dose-response curve of PE or Ach."	( Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Balaraman, R; Majithiya, JB; Paramar, AN, 2005)	0.33
" A second dose-response curve was obtained during NOS inhibition with a subpressor dose of N- nitro-L-arginine-methyl ester (L-NAME) (5 microg/kg per min) or during a systemic NO clamp using combined systemic infusions of L-NAME (12."	( Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. Boomsma, F; van den Meiracker, AH; van der Linde, NA, 2005)	0.33
" Methylene blue (MB) but not N(omega)-nitro-L-arginine methylester (L-NAME) or ODQ (1H-[1,2,4]oxadiazol-[4,3-]quinoxsalin-1-one) modified the dose-response curve of ginsenoside Rg(3)."	( Relaxation of canine corporal smooth muscle relaxation by ginsenoside saponin Rg3 is independent from eNOS activation. Chang, KC; Kang, YJ; Sohn, JT, 2005)	0.33
"5-g preload, cumulative dose-response curves were generated with six doses of the alpha1-adrenergic receptor-selective agonist L-phenylephrine (L-Phe, 10(8)-3 x 10(-6) M) and relaxed with one dose of acetylcholine (3 x 10(-6) M) to assess intact endothelium."	( Wild blueberry-rich diets affect the contractile machinery of the vascular smooth muscle in the Sprague-Dawley rat. Harris, PD; Kalea, AZ; Klimis-Zacas, DJ; Norton, C, 2005)	0.33
" Dose-response curves for the alpha1-adrenoceptor agonist phenylephrine were generated in the absence and presence of fentanyl."	( Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contraction. Ding, X; McCune, DF; Murray, PA; Perez, DM; Sohn, JT, 2005)	0.33
" Particle suspensions (EHC-93), particle filtrates (particle-free) and Cu(2+)- or Zn(2+)-containing solutions were used to obtain cumulative dose-response curves of relaxation in normal and endothelium-denuded rings."	( Signal transduction pathways involved in particulate matter induced relaxation in rat aorta--spontaneous hypertensive versus Wistar Kyoto rats. Bagate, K; Borm, PJ; Cassee, FR; Gerlofs-Nijland, ME; Meiring, JJ, 2006)	0.33
" Two days after the last training session, the animals were killed and blood samples for lipoprotein dosage were obtained."	( Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment. Bernardes, CF; Cunha, TS; Marcondes, FK; Moura, MJ; Tanno, AP, 2005)	0.33
" Long-term terbutaline treatment also desensitized venous Thr164Ile beta2-AR; after terbutaline treatment, dose-response curves for terbutaline-induced venodilation were superimposable in WT and Thr164Ile beta2-AR subjects."	( Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Brodde, OE; Bruck, H; Heusch, G; Leineweber, K; Park, J; Philipp, T; Weber, M, 2005)	0.33
" Dose-response curves were evaluated under basal conditions, after inhibition of haeme oxygenase with chromium-mesoporphyrin, after inhibition of nitric oxide synthase (NOS) with N(G)-nitro-L-arginine-methyl-ester (L-NAME), and then after inhibition of both NOS and haeme oxygenase."	( Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Angeli, P; Bolognesi, M; Di Pascoli, M; Gatta, A; Merkel, C; Pontisso, P; Quarta, S; Sacerdoti, D; Sticca, A, 2005)	0.33
" Twelve to 24 hrs following this stimulation, phenylephrine was infused in a stepwise manner to establish the phenylephrine-mean arterial pressure dose-response curve before and after intravenous hydrocortisone administration (50 mg)."	( Hydrocortisone increases the sensitivity to alpha1-adrenoceptor stimulation in humans following hemorrhagic shock. Asehnoune, K; Benhamou, D; Brailly-Tabard, S; Edouard, AR; Hoen, S; Mazoit, JX; Moine, P, 2005)	0.33
" A phenylephrine dose-response structure (E0, ED50, and Emax) was described without influence of the group and the sequence."	( Hydrocortisone increases the sensitivity to alpha1-adrenoceptor stimulation in humans following hemorrhagic shock. Asehnoune, K; Benhamou, D; Brailly-Tabard, S; Edouard, AR; Hoen, S; Mazoit, JX; Moine, P, 2005)	0.33
" We examined dose-response relationships to pressor and depressor agents to determine cardiovascular reactivity."	( Contribution of baroreflex sensitivity and vascular reactivity to variable haemodynamic responses to cocaine in conscious rats. Aochi, T; Kawada, T; Knuepfer, MM; Shishido, T; Sunagawa, K; Traub, M, 2005)	0.33
" In study 1, CV alpha1-adrenoceptor antagonism was assessed by measuring the inhibition of phenylephrine (PE)-induced increases in diastolic blood pressure (DBP) and total peripheral resistance (TPR) before and after dosing with placebo, tamsulosin OCAS, and alfuzosin XL in 18 young subjects."	( Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Chapple, CR; Michel, MC, 2006)	0.33
"In study 1, tamsulosin OCAS induced statistically significantly less inhibition of PE-induced increases in DBP at 2 h after dosing and in TPR at 2 and 4 h after dosing than alfuzosin XL."	( Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Chapple, CR; Michel, MC, 2006)	0.33
" The beta1-adrenoceptor agonist, dobutamine, and the alpha1-adrenoceptor agonist, phenylephrine, induced learning, and both exhibited an inverted U-curve dose-response relationship to odor preference learning."	( Beta1-adrenoceptor or alpha1-adrenoceptor activation initiates early odor preference learning in rat pups: support for the mitral cell/cAMP model of odor preference learning. Darby-King, A; Harley, CW; McCann, J; McLean, JH, )	0.13
" BSO shifted the phenylephrine (PE) dose-response curve to the left (p=0."	( Glutathione depletion in vivo enhances contraction and attenuates endothelium-dependent relaxation of isolated rat aorta. Denniss, SG; Ford, RJ; Graham, DA; Quadrilatero, J; Rush, JW, 2006)	0.33
" This was accompanied by potentiation of the response to PHE as demonstrated by a left shift in the dose-response curve and a decrease in the EC50."	( Thermographic study of in vivo modulation of vascular responses to phenylephrine and endothelin-1 by dexamethasone in the horse. Berney, CA; Cornelisse, CJ; Derksen, FJ; Eberhart, S; Hauptman, JE; Robinson, NE, 2006)	0.33
"IV drug infusion has the potential for dosing errors, which arise from complex interactions between carrier flows and the infusion set dead volume."	( The delivery of drugs to patients by continuous intravenous infusion: modeling predicts potential dose fluctuations depending on flow rates and infusion system dead volume. Kinnealley, ME; Lovich, MA; Peterfreund, RA; Sims, NM, 2006)	0.33
" In NPUA sheep, PDBu produced a concentration-dependent potentiation of phenylephrine-induced contractions and shifted the dose-response curve to the left."	( Regulation of alpha1-adrenoceptor-mediated contractions of uterine arteries by PKC: effect of pregnancy. Longo, LD; Xiao, D; Zhang, H; Zhang, L, 2006)	0.33
" The phenylephrine dose-forearm blood flow response curve was used to determine alpha1-vascular reactivity (slope of the dose-response curve) and sensitivity, EC50 (phenylephrine dose inducing 50% maximal response)."	( Mechanism of lipid enhancement of alpha1-adrenoceptor pressor sensitivity in hypertension. Egan, BM; Gadegbeku, CA; Shrayyef, MZ; Taylor, TP, 2006)	0.33
"The Food and Drug Administration (FDA) is issuing a final rule to amend the final monograph (FM) for over-the-counter (OTC) nasal decongestant drug products (drug products used to relieve nasal congestion due to a cold, hay fever, or other upper respiratory allergies) to add phenylephrine bitartrate (PEB), both individually and in combination drug products in an effervescent dosage form, as generally recognized as safe and effective (GRASE)."	( Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of monograph for OTC nasal decongestant drug products. Final rule. , 2006)	0.33
" Dose-response curves were determined for phenylephrine and for several imidazoline ligands, using endothelium denuded, isolated ring segments, of tail arteries from adult male Sprague-Dawley rats."	( Centrally acting imidazolines stimulate vascular alpha 1A-adrenergic receptors in Rat-Tail Artery. Crane, L; Edwards, LP; George, OK; Gonzalez, RR; Kennedy, WB, )	0.13
" In a first experiment, dose-response curves for acetylcholine-induced relaxation of aortic rings were conducted."	( Effect of melatonin on vascular responses in aortic rings of aging rats. Cardinali, DP; Linares, LM; Obaya-Naredo, D; Pinto, JE; Planells, FM; Reyes-Toso, CF; Ricci, CR, 2007)	0.34
" In addition, the dose-response curve to 8-BrcGMP was shifted to the right in the presence of iberiotoxin, an inhibitor of large conductance, voltage-dependent, and calcium-sensitive potassium channel (BK(Ca))."	( Nitric oxide pathway counteracts enhanced contraction to membrane depolarization in aortic rings of rats on high-sodium diet. Cordaillat, M; Elghozi, JL; Fort, A; Jover, B; Richard, S; Virsolvy, A, 2007)	0.34
" Statistical significance at 30 and 60 minutes after dosing (the primary time points) and a >or=20% reduction in NAR from baseline were considered indicative of a clinically meaningful difference."	( Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. Kollar, C; Krusinska, E; Schneider, H; Waksman, J, 2007)	0.34
" Acetylcholine dose-response relaxation curves revealed that SAM-R1 vessels were slightly more sensitive than those of SAM-P8."	( The senescence-accelerated mouse (SAM-P8) as a model for the study of vascular functional alterations during aging. de Cabo, C; de Mera, RM; Jordán, J; Lloréns, S; Mendizábal, Y; Nava, E; Pascual, A; Prieto-Martín, A, 2007)	0.34
" Dose-response curves for acetylcholine-induced, endothelium-related relaxation of aortic rings (after previous exposure to phenylephrine) were conducted in a high glucose solution (44 mmol/L)."	( Antioxidants restore aortic ring relaxation in pancreatectomized rats. Cardinali, DP; Linares, LM; Reyes-Toso, CF; Ricci, CR; Vázquez, MB; Witriw, A, 2007)	0.34
" At 10(-7) M of ST-91, the antagonism was characterized by a rightward shift of isoproterenol dose-response curve (A50=6."	( alpha2B-adrenoceptor agonist ST-91 antagonizes beta2-adrenoceptor-mediated relaxation in rat mesenteric artery rings. Gyires, K; Kató, E; Lipták, L; Mátyus, P; Rónai, AZ; Shujaa, N, 2008)	0.35
" Although prazosin (10 microg/kg/min) markedly shifted the phenylephrine (alpha(1)-agonist) dose-response curve to the right, it did not have any effect on clofilium-induced prolongation of QTc and MAPD(90) (43 +/- 7 and 53 +/- 9%, respectively) or the occurrence of TdP (seven of eight)."	( Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. Belardinelli, L; Dhalla, AK; Robertson, C; Wang, WQ, 2008)	0.35
"A simple and reliable high-performance liquid chromatographic method was developed for the simultaneous determination of mixture of phenylephrine hydrochloride (PHENYL), guaifenesin (GUAIF), and chlorpheniramine maleate (CHLO) either in pure form or in the presence of methylparaben and propylparaben in a commercial cough syrup dosage form."	( Simultaneous determination of phenylephrine hydrochloride, guaifenesin, and chlorpheniramine maleate in cough syrup by gradient liquid chromatography. Abbas, SS; Ali, NM; Amer, SM; Shehata, MA, )	0.13
" Endothelium-dependent and -independent vasorelaxation were measured by generating dose-response curves to acetylcholine (10(-8)M - 10(-4)M) and sodium nitroprusside (10(-9)M - 10(-5)M)."	( Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Crisostomo, PR; Lahm, T; Markel, TA; Meldrum, DR; Tan, J; Wang, M; Wang, Y, 2008)	0.35
" Preincubation with 300 and 1000 microM SCU significantly suppressed the contractile dose-response to phenylephrine, causing both a significant rise in half maximal effective concentration and a decrease in the maximal developed force."	( Nitric oxide and catalase-sensitive relaxation by scutellarin in the mouse thoracic aorta. Bofferding, A; Lust, RM; Wingard, CJ; Yang, W, 2009)	0.35
" Patients were dosed with immediate-release formulations of phenylephrine, 12 mg, pseudoephedrine, 60 mg, as a control, or placebo."	( A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Danzig, M; Horak, F; Lemell, P; Staudinger, H; Yao, R; Zieglmayer, P; Zieglmayer, R, 2009)	0.35
"There is denervation supersensitivity in PD patients that is, however, insufficient to shift the dose-response curve to the left."	( Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy. Lipp, A; Low, PA; Sandroni, P, 2009)	0.35
"Under the conditions of this study, we have shown that when phenylephrine or ephedrine were used to prevent post-spinal hypotension, the dosing requirement of hyperbaric bupivacaine was similar for intrathecal anaesthesia."	( Effect of i.v. phenylephrine or ephedrine on the ED50 of intrathecal bupivacaine with fentanyl for caesarean section. Barnes, J; Belavadi, P; Columb, MO; Hennebry, MC; Lyons, G; Stocks, GM; Wray, S, 2009)	0.35
" Our results indicate that daily gastric feeding of euthyrox to rat with dosage of 100 microg group (H1) or 200 microg group (H2) for 25 days was sufficient to induce a thyrotoxicosis."	( Changes in vasoreactivity of rat large- and medium-sized arteries induced by hyperthyroidism. Deng, J; Wang, J; Zhang, Z; Zhao, R, 2010)	0.36
" NOX-1 also significantly antagonized cumulative dose-response effect of norepinephrine, phenylephrine, KCl or calcium with reduction in submaximal contractions."	( Vasorelaxant effect in rat aortic rings through calcium channel blockage: a preliminary in vitro assessment of a 1,3,4-oxadiazole derivative. Bankar, GR; Chamallamudi, MR; Nampurath, GK; Nandakumar, K; Nayak, PG; Thakur, A, 2009)	0.35
" Dose-response curves to phenylephrine (PE) were established in abdominal aortic rings."	( Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Chatterjee, S; De Winter, B; Francque, S; Herman, A; Jung, A; Michielsen, P; Pelckmans, P; Ramon, A; Van Marck, E; Vermeulen, W; Wamutu, S, 2010)	0.36
"3 x 10(-3) mol/L) produced a significant rightward shift in the phenylephrine dose-response curve, but had no effects on the potassium chloride-induced contraction."	( Relaxant effects of matrine on aortic smooth muscles of guinea pigs. Dai, GD; Fu, XY; Yan, L; Zheng, J; Zheng, P; Zhou, R; Zhou, X, 2009)	0.35
" In patients with intracranial pathology, for whom hypocapnia is frequently induced, phenylephrine dosage may need to be appropriately reduced."	( Hypocapnia enhances the pressor effect of phenylephrine during isoflurane anesthesia in monkeys. Adams, DC; Schwartz, AE, 2010)	0.36
" The inhibition of dose-response curves by bumetanide was much greater in SHR than in Wistar Kyoto (WKY) normotensive rats."	( Promoter hypomethylation upregulates Na+-K+-2Cl- cotransporter 1 in spontaneously hypertensive rats. Baek, I; Cho, HM; Hong, SH; Kim, IK; Lee, DY; Lee, HA; Seok, YM; Yang, E, 2010)	0.36
" The ideal dosing regimen for this purpose is not known."	( A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. Allen, TK; George, RB; Habib, AS; Muir, HA; White, WD, 2010)	0.36
"Taken together, the MTG-containing ZnO can be a more effective and convenient delivery system for the treatment of hemorrhoid with a reduced dosage interval."	( Effect of zinc oxide on the rheological and mucoadhesive properties of poloxamer 407-based mucoadhesive thermosensitive gel. Choi, HG; Kim, CK; Kim, HT; Kim, ST; Park, JS; Park, TH, 2010)	0.36
"Results show that phenylephrine injected intracamerally does not have a linear mydriatic dose-response relationship in humans."	( Mydriatic response to different concentrations of intracameral phenylephrine in humans. Behndig, A; Lundberg, B, 2010)	0.36
" From individual dose-response curves, we calculated the dose of phenylephrine and dexmedetomidine that produced 50% (ED50) of maximum venoconstriction (Emax) for each patient."	( Independent regulation of α1 and α2 adrenergic receptor-mediated vasoconstriction in vivo. Kurnik, D; Muszkat, M; Sofowora, GG; Stein, CM; Wood, AJ, 2011)	0.37
" Dose-response curves were evaluated under basal conditions and after inhibition of HO with chromium-mesoporphyrin (CrMP)."	( Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats. Bolognesi, M; Di Pascoli, M; Gatta, A; Merkel, C; Quarta, S; Sacerdoti, D; Zampieri, F, 2011)	0.37
" The endothelium-dependent dose-response vasorelaxation was determined with endothelium-dependent vasodilators while arterial preconstriction was induced with vasoconstrictors at a submaximal dose."	( Assessment of endothelial function of large, medium, and small vessels: a unified myograph. Kassab, GS; Lu, X, 2011)	0.37
" Dose-response relationships for the elevation of mean arterial pressure or change in heart rate (HR) in response to intravenous injections of noradrenaline (NA), phenylephrine (PE), methoxamine (ME) and Ang II were determined."	( The effect of losartan and carvedilol on vasopressor responses to adrenergic agonists and angiotensin II in the systemic circulation of Sprague Dawley rats. Abdulla, MH; Abdullah, NA; Anand Swarup, KR; Johns, EJ; Khan, MA; Sattar, MA, )	0.13
" Vessel function was assessed using KCl, sodium nitroprusside (SNP), phenylephrine (PE) and ACh dose-response curves to characterize non-receptor- and receptor-mediated vasocontraction and vasorelaxation."	( Human skeletal muscle feed arteries studied in vitro: the effect of temperature on α(1)-adrenergic responsiveness. Amann, M; Andtbacka, RH; Ives, SJ; McDaniel, J; Noyes, RD; Richardson, RS; Symons, JD; Witman, MA; Wray, DW, 2011)	0.37
"The aim of the current study was to develop osmotically controlled release system of freely water soluble drug phenylephrine hydrochloride by use of asymmetric membrane capsules to reduce the dosing frequency and consequently improve the patient compliance."	( Asymmetric membrane capsules of phenylephrine hydrochloride: an osmotically controlled drug delivery system. Kumar, A; Pathak, K; Philip, AK, 2011)	0.37
" The optimized phenylephrine nanosuspension was then freeze dried and incorporated into a multi-layered buccal patch, consisting of a small tablet adhered to a mucoadhesive film, yielding a phenylephrine buccal product with good dosage accuracy and improved mucosal permeability."	( Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Evans, AM; Peddie, F; Rao, S; Song, Y, 2011)	0.37
" The optimum dosing regimen for phenylephrine administration is also discussed."	( A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. Habib, AS, 2012)	0.38
" Phenylephrine dose-response contraction was obtained after 1, 2, and 3 h in segments pre-incubated with DETA-NONOate or papaverine for 30 min."	( Effect of DETA-NONOate and papaverine on vasodilation of human internal mammary artery. Ansari, M; Dehpour, AR; Javadi-Paydar, M; Rabbani, S; Rahimi, N; Sohanaki, H; Tafti, SH, 2011)	0.37
" Comparison of DR(10) values (the dose required to shift the dose-response curve 10-fold to the right) in both tissues showed that the inhibitory effect of silodosin was significantly more potent in the salivary gland than in the urethra (18-fold), but tamsulosin (2."	( Effects of α1-adrenoceptor antagonists on phenylephrine-induced salivary secretion and intraurethral pressure elevation in anesthetized rats. Hatanaka, T; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Suzuki, M; Ueshima, K; Yanai-Inamura, H, 2012)	0.38
" Dose-response curves for phenylepherine (PE) - and acetylcholine (Ach) -induced relaxation were constructed for rings pre-contracted with PE."	( Experimental malaria: the in vitro and in vivo blood pressure paradox. Ajayi, IO; Ebeigbe, AB; Nwokocha, CR; Nwokocha, MI; Owu, DU, 2012)	0.38
" After stabilization, maximal tissue contractions were obtained by the application of phenylepinephrine to the urethra strips, and a dose-response curve for ginseng saponin was constructed (10(-6)-10(-2)M)."	( The relaxant effect of ginseng saponin on the bladder and prostatic urethra: an in vitro and in vivo study. Bae, JH; Cheon, J; Cho, S; Jang, HA; Kang, SG; Kang, SH; Kim, JJ; Ko, YH; Lee, JG, 2012)	0.38
" Bolus injections of GA elicited dose-response vasodilation, which was abolished after endothelium removal."	( Endothelium-dependent vascular relaxation induced by Globularia alypum extract is mediated by EDHF in perfused rat mesenteric arterial bed. Ben Cheikh, R; Chokri, A; El Abida, K; Zegzouti, YF, 2012)	0.38
" Since there continues to be disagreement about the utility of fludrocortisone in septic shock, we assessed the effects of a single administration of low doses of hydrocortisone (50 mg intravenously) and fludrocortisone (50 μg orally), given either alone or in combination, on phenylephrine mean arterial pressure and cardiac systolic and diastolic function dose-response relationships in 12 healthy male volunteers with hypo-aldosteronism induced by intravenous sodium loading."	( Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers. Bellissant, E; Donal, E; Lainé, F; Laviolle, B; Le Maguet, P, 2013)	0.39
"0-10 mg/mL relaxed high K+ (80 mM) and phenylephrine (PE, 1 μM)-induced contractions and shifted Ca++ dose-response curves to right, similar to that caused by verapamil."	( Hypotensive effect of Gentiana floribunda is mediated through Ca++ antagonism pathway. Khan, AU; Murugan, DD; Mustafa, MR, 2012)	0.38
" However, the optimal dosing regimen remains unclear."	( Closed-loop double-vasopressor automated system to treat hypotension during spinal anaesthesia for caesarean section: a preliminary study. Sia, AT; Sng, BL; Tan, HS, 2012)	0.38
"In this study, a simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination of nimesulide (NS), phenylephrine hydrochloride (PE), chlorpheniramine maleate (CPM) and caffeine anhydrous (CF) in pharmaceutical dosage forms."	( Development and validation of RP-HPLC method for simultaneous estimation of nimesulide, phenylephrine hydrochloride, chlorpheniramine maleate and caffeine anhydrous in pharmaceutical dosage form. Kumar, A; Nair, A; Saini, G; Sharma, R, )	0.13
" Dose-response curves were also constructed for pre-incubation of vascular rings with Nω-nitro-L-arginine methyl ester (L-NAME) (a non-specific nitric oxide synthase inhibitor), indomethacin (an unspecific cyclooxygenase inhibitor), and 1H-[1,2,4] oxadiazolo [4,3-a]quinoxalin-1-one (ODQ) (a guanylyl cyclase inhibitor)."	( The lignan (-)-cubebin inhibits vascular contraction and induces relaxation via nitric oxide activation in isolated rat aorta. Andrade E Silva, ML; Bastos, JK; Carvalho, MT; Celotto, AC; Cunha, WR; Evora, PR; Rezende, KC, 2013)	0.39
" Thereafter, the nurse was interviewed and a dosing error was identified: she had mistakenly given the patient 1 mg of phenylephrine (1 mL) instead of 100 mcg (1 mL of the standard dilution, 1mg in 10 mL)."	( [Phenylephrine dosing error in Intensive Care Unit. Case of the trimester]. , )	0.13
" Pharmacological modeling (EC50, Emax, and Hill coefficient) and individual dose-response curve were tested."	( Activated protein C improves macrovascular and microvascular reactivity in human severe sepsis and septic shock. Alves, I; Duburcq, T; Favory, R; Guerry, MJ; Lemyze, M; Mathieu, D; Parmentier-Decrucq, E; Poissy, J, 2013)	0.39
" The method was applied successfully on tablet dosage form."	( Gradient HPLC-DAD determination of paracetamol, phenylephrine hydrochloride, cetirizine in tablet formulation. Bakal, RL; Chandewar, AV; Dewani, AP; Jaybhaye, SS; Patra, S; Shelke, PG, 2014)	0.4
" In contrast with traditional dose-response studies, it was possible to quantify separately the underlying changes in α1 AR binding and signal transduction."	( Effect of disease states on α1 -adrenoceptor binding and signal transduction parameters in isolated perfused heart: quantification by pharmacokinetic-pharmacodynamic modelling. Arendt, P; Hassna, R; Weiss, M, 2014)	0.4
" Dose-response curves were obtained with phenylephrine, acetylcholine and sodium nitroprusside."	( Influence of decompression sickness on vasomotion of isolated rat vessels. Belhomme, M; Buzzacott, P; Guerrero, F; Lambrechts, K; Mansourati, J; Mazur, A; Theron, M; Wang, Q, 2014)	0.4
"Prophylactic variable rate phenylephrine infusion and rescue phenylephrine bolus dosing is more effective than relying on rescue phenylephrine bolus dosing with respect to limiting clinician workload and maternal symptoms during spinal anesthesia for cesarean delivery."	( A randomized controlled trial of variable rate phenylephrine infusion with rescue phenylephrine boluses versus rescue boluses alone on physician interventions during spinal anesthesia for elective cesarean delivery. Aouad, MT; Kanazi, GE; Siddik-Sayyid, SM; Taha, SK, 2014)	0.4
" These agents are rarely absorbed to systemic circulation and in some cases result with serious side effects like skin rash, tachycardia, feeding intolerance, discomfort, apnea, gastric dilatation and ileus, despite different treatment models and dosage reducing strategies."	( Fatal necrotising enterocolitis due to mydriatic eye drops. Demet, T; Mehmet, Y; Murat, S; Nilgun, K; Ozge, KA; Ozgun, U; Zafer, D, 2014)	0.4
" In abdominal aorta, alamandine (1 μM) was added 30 min before a dose-response curve to angiotensin II or AngA (1 nM-1 μM), and immunohistochemistry was used to identify MrgD receptors and eNOS."	( Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7). Alsaadon, H; Habiyakare, B; Hayes, A; Mathai, ML; Zulli, A, 2014)	0.4
" Our hypothesis was that the ADRB2 genotype altered the ephedrine dose-response and that we would not see this effect if phenylephrine was the vasopressor used to maintain blood pressure because phenylephrine does not act via the β2-adrenoceptor."	( The Effect of β2-Adrenoceptor Genotype on Phenylephrine Dose Administered During Spinal Anesthesia for Cesarean Delivery. Blouin, JL; Brodow, D; Landau, R; Odekon, L; Smiley, RM; Wang, S, 2015)	0.42
" After fasting overnight, subjects were dosed with oral phenylephrine HCl 10, 20, or 30 mg or placebo."	( Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Gelotte, CK; Zimmerman, BA, 2015)	0.42
" Dose-response curves were obtained with phenylephrine and endothelin-1."	( Influence of decompression sickness on vasocontraction of isolated rat vessels. Belhomme, M; Buzzacott, P; Guerrero, F; Lambrechts, K; Mazur, A; Theron, M; Wang, Q, 2016)	0.43
"A validated and highly selective high-performance thin-layer chromatography (HPTLC) method was developed for the determination of ketorolac tromethamine (KTC) with phenylephrine hydrochloride (PHE) (Mixture 1) and with febuxostat (FBX) (Mixture 2) in bulk drug and in combined dosage forms."	( Development and Validation of a High-Performance Thin-Layer Chromatographic Method for the Simultaneous Determination of Two Binary Mixtures Containing Ketorolac Tromethamine with Phenylephrine Hydrochloride and with Febuxostat. El Yazbi, FA; Hamdy, MM; Hassan, EM; Khamis, EF; Ragab, MA, )	0.13
" The optimal dosage regimen is still undetermined."	( Hemodynamics of Phenylephrine Infusion Versus Lower Extremity Compression During Spinal Anesthesia for Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Study. Dahl, V; Hauge, TH; Kuhn, JC; Langesæter, E; Rosseland, LA, 2016)	0.43
" Studies with more subjects are warranted to define optimal dosing strategies of these medications in an acute pulmonary hypertensive crisis."	( Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children With Pulmonary Hypertension: A Pilot Study. Feinstein, JA; Ogawa, MT; Peng, LF; Ramamoorthy, C; Siehr, SL; Yang, W, 2016)	0.43
"We recorded cardiopulmonary dynamics in supine syncope patients and healthy volunteers (aged 15-27 years) challenged with a dose-response using the α1-agonist phenylephrine (PE), with and without the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine, monoacetate salt (L-NMMA)."	( Postsynaptic α1-Adrenergic Vasoconstriction Is Impaired in Young Patients With Vasovagal Syncope and Is Corrected by Nitric Oxide Synthase Inhibition. Medow, MS; Merchant, S; Stewart, JM; Suggs, M; Sutton, R; Terilli, C; Visintainer, P, 2016)	0.43
" Patients' charts were reviewed to record the dosing of phenylephrine and the outcomes and circumstances of the presentation."	( Use of High-Dose Phenylephrine in the Treatment of Ischemic Priapism: Five-Year Experience at a Single Institution. Munarriz, R; Phillips, EA; Ridyard, DG; Vincent, W, 2016)	0.43
"The use of high concentration and dosing of intracavernous phenylephrine demonstrates a high success rate in the treatment of ischemic priapism."	( Use of High-Dose Phenylephrine in the Treatment of Ischemic Priapism: Five-Year Experience at a Single Institution. Munarriz, R; Phillips, EA; Ridyard, DG; Vincent, W, 2016)	0.43
" However, the release kinetic was significantly influenced by the method used, highlighting the need for optimization and standardization of in vitro models for the evaluation of drug release from ophthalmic dosage forms."	( Mydriatics release from solid and semi-solid ophthalmic formulations using different in vitro methods. Gioia, GA; Macaluso, C; Nicoli, S; Padula, C; Pescina, S; Santi, P, 2017)	0.46
"Five simple, sensitive, and eco-friendly LC and UV spectrophotometric methods have been developed for the simultaneous determination of phenylephrine hydrochloride (PHE) and prednisolone acetate (PRD) in their combined dosage form."	( Development and Validation of Eco-Friendly Liquid Chromatographic and Spectrophotometric Methods for Simultaneous Determination of Coformulated Drugs: Phenylephrine Hydrochloride and Prednisolone Acetate. El Mously, DA; Elsayed, GM; Hassan, NY; Mostafa, NM, 2017)	0.46
"In a random-allocation, graded dose-response study, 180 healthy patients undergoing spinal anesthesia for elective cesarean delivery received a single bolus of norepinephrine in one of six different doses ranging from 4 to 12 µg or phenylephrine in one of six different doses ranging from 60 to 200 µg to treat the first episode of hypotension."	( A Random-allocation Graded Dose-Response Study of Norepinephrine and Phenylephrine for Treating Hypotension during Spinal Anesthesia for Cesarean Delivery. Ngan Kee, WD, 2017)	0.46
"Comparative dose-response analysis was completed for norepinephrine and phenylephrine given as a bolus to treat the first episode of hypotension in patients undergoing spinal anesthesia for cesarean delivery."	( A Random-allocation Graded Dose-Response Study of Norepinephrine and Phenylephrine for Treating Hypotension during Spinal Anesthesia for Cesarean Delivery. Ngan Kee, WD, 2017)	0.46
" We compared the incidence of intraoperative nausea and vomiting (IONV) in obese patients who received a prophylactic phenylephrine infusion vs those who received bolus dosing for the treatment of spinal-induced hypotension."	( A randomized trial of phenylephrine infusion versus bolus dosing for nausea and vomiting during Cesarean delivery in obese women. Allen, TK; Dominguez, JE; Doyle, PA; George, RB; Habib, AS; McKeen, DM, 2018)	0.48
"0 minimum alveolar concentration [MAC]: T1, T2, and T3, respectively) with a fixed remifentanil dosage (1."	( Isoflurane's Effect on Intraoperative Systolic Left Ventricular Performance in Cardiac Valve Surgery Patients. Bang, J; Kang, H; Kim, JD; Kim, K; Kim, TY; Kwon, WK; Lee, DK; Sidik, H; Son, I; Sung, TY; Yeo, GE, 2018)	0.48
" In mesenteric arteries, the dose-response curves for phenylephrine-induced contractions shifted to the left and the EC50 (mean ± SD) was significantly lower in the HS-NormK (0."	( Effects of High Salt-Low Potassium Diet on Blood Pressure and Vascular Reactivity in Male Sprague Dawley Rats. Michel, FS; Millen, AME; Mokotedi, L; Norton, GR; Woodiwiss, AJ, 2018)	0.48
" Previously marketed prescription products contained phenylephrine tannate, an extended-release salt, which allowed dosing every 8-12 h."	( An open-label, randomized, four-treatment crossover study evaluating the effects of salt form, acetaminophen, and food on the pharmacokinetics of phenylephrine. Gelotte, CK, 2018)	0.48
" Commercial intracameral phenylephrine products would address dosage concerns and could improve surgical outcomes in cases of poor pupil dilation and/or floppy iris syndrome."	( Assessing the accuracy of intracameral phenylephrine preparation in cataract surgery. Guthrie, S; Hartley, RC; Jensen, T; Lockington, D; Ramaesh, K, 2018)	0.48
"The administration of prophylactic phenylephrine infusion results in higher intrathecal hyperbaric bupivacaine dosing requirements in parturients undergoing cesarean delivery."	( Comparison of the ED50 and ED95 of Intrathecal Bupivacaine in Parturients Undergoing Cesarean Delivery With or Without Prophylactic Phenylephrine Infusion: A Prospective, Double-Blind Study. Chen, X; Drzymalski, D; Liu, L; Wang, L; Xiao, F; Zhang, Y, 2018)	0.48
" In a subset of eight participants, an infusion of phenylephrine hydrochloride was administered at a dosage of 30 µg/l of predicted blood volume at each altitude."	( Spleen reactivity during incremental ascent to altitude. Day, TA; James, MA; Keess, JL; Ondrus, P; Purdy, GM; Rees, JL; Steinback, CD, 2019)	0.51
" We applied conventional meta-analysis, trial sequential analysis, computing the required information size that would exclude type I and II errors, contour-enhanced funnel plot testing for publication bias, meta-regression to assess the dose-response relationship, and the Grading of Recommendations Assessment, Development, and Evaluation system (GRADE)."	( Ephedrine versus phenylephrine as a vasopressor for spinal anaesthesia-induced hypotension in parturients undergoing high-risk caesarean section: meta-analysis, meta-regression and trial sequential analysis. Heesen, M; Hilber, N; Klimek, M; Ngan Kee, WD; Rijs, K; Rossaint, R; van der Marel, C, 2019)	0.51
" Meta-regression showed no dose-response relationship."	( Ephedrine versus phenylephrine as a vasopressor for spinal anaesthesia-induced hypotension in parturients undergoing high-risk caesarean section: meta-analysis, meta-regression and trial sequential analysis. Heesen, M; Hilber, N; Klimek, M; Ngan Kee, WD; Rijs, K; Rossaint, R; van der Marel, C, 2019)	0.51
"Two chromatographic methods (high performance thin layer chromatography (HPTLC) and high performance liquid chromatography-diode array detector (HPLC-DAD)), were addressed for the analysis of a mixture consisted of phenylephrine hydrochloride and ibuprofen in two forms bulk and their combined dosage form."	( Determination of Ibuprofen and Phenylephrine in Tablets by High-Performance Thin Layer Chromatography and in Plasma by High-Performance Liquid Chromatography with Diode Array Detection. Abdel-Hay, MH; Ahmed, HM; Mohyeldin, SM; Ragab, MAA, 2019)	0.51
" Parallel rightward shift of dose-response curves for trazodone recorded in higher phenylephrine concentrations (10-100 μM) indicated competitive antagonism at α1-adrenoceptors."	( Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and α1-adrenoceptor antagonism. Bonfiglio, F; Corradetti, R; Magnani, M; Mlinar, B; Montalbano, A; Polenzani, L, 2019)	0.51
"In a tertiary women's hospital in Nanjing, China, 102 women were allocated with computer derived randomized number to receive prophylactic 8 μg norepinephrine (group N; n = 52) or 100 μg phenylephrine (group P; n = 50) immediately post-spinal anesthesia, followed by an extra bolus of the same dosage until delivery whenever maternal systolic blood pressure became lower than 80% of the baseline."	( Bolus norepinephrine and phenylephrine for maternal hypotension during elective cesarean section with spinal anesthesia: a randomized, double-blinded study. Mao, M; Shen, XF; Wang, X; Wang, ZH; Xu, SQ; Zhang, SS, 2020)	0.56
" This allowed us to predict specific dosing thresholds of phenylephrine required to maintain systolic blood pressure above 90 mmHg."	( The application of a neural network to predict hypotension and vasopressor requirements non-invasively in obstetric patients having spinal anesthesia for elective cesarean section (C/S). Allen, I; Baruch, M; Deal, E; Gratz, I; McEniry, B; Seaman, J; Takla, M, 2020)	0.56
" Issues related to their use in the treatment of hypotension caused by spinal anaesthesia in the elderly, including the features of both drugs, their method of administration and dosage based on the literature and own experience are the subject of this study."	( [Hypotension - a complication of subarachnoid anesthesia especially dangerous in patients aged]. Abukhouskaya, N; Górniewski, G; Janiak, M; Kosson, D; Kowalczyk, R; Trzebicki, J, 2020)	0.56
"A stability-indicating high performance liquid chromatography method with diode array detection (HPLC-DAD) was developed and validated for simultaneous determination of phenylephrine hydrochloride (PHR), dimetindene maleate (DMD) and benzalkonium chloride (BZM) in nasal drops and gel dosage forms."	( Analytical investigation of ternary mixture of phenylephrine hydrochloride, dimetindene maleate and benzalkonium chloride using validated stability indicating HPLC-DAD method. Abdel-Khalek, MM; Abdelhamid, AG; Belal, TS; El-Kafrawy, DS, 2020)	0.56
"We performed an open controlled one-arm clinical trial to assess whether preoperative anxiety influences phenylephrine dosage required to maintain normotension during cesarean section under spinal anesthesia."	( The effect of preoperative anxiety on phenylephrine dose during cesarean delivery: An open controlled one-arm clinical trial. Danon, E; Eidelman, L; Heesen, P; Kornilov, E; Orbach-Zinger, S; Ronen, A; Weiniger, C, 2020)	0.56
" Secondary outcomes included changes in blood pressure, adverse effects, dosing errors, fluid and vasopressor requirements, ICU and hospital lengths of stay (LOS), and in-hospital mortality."	( Comparison of push-dose phenylephrine and epinephrine in the emergency department. Fitter, S; Moussavi, K; Nam, E, 2022)	0.72
" Dosing errors occurred more frequently in patients that received PDP-E (5/39 [12."	( Comparison of push-dose phenylephrine and epinephrine in the emergency department. Fitter, S; Moussavi, K; Nam, E, 2022)	0.72
" However, dosing errors occurred more frequently in those receiving PDP-E."	( Comparison of push-dose phenylephrine and epinephrine in the emergency department. Fitter, S; Moussavi, K; Nam, E, 2022)	0.72
" Many adverse events associated with PDP have been due to dosing errors highlighting the importance of education surrounding the use of these agents."	( A Review of Push-Dose Vasopressors in the Peri-operative and Critical Care Setting. Garavaglia, JM; Greco, AR; Hays, WB; Kovacic Scherrer, NL; McPherson, KL, 2023)	0.91
" After exposure, blood was collected to measure dosage of cadmium, in male and female, and estrogen in females."	( Sex-dependent vascular effects of cadmium sub-chronic exposure on rats. Almenara, CCP; Carneiro, MTWD; da Costa, CS; de Oliveira, TF; Graceli, JB; Krause, M; Padilha, AS; Rossi, EM, 2023)	0.91
" The advantages of the proposed method qualify it for routine analysis of the studied drugs either in single or co-formulated dosage form in quality control labs."	( A quality-by-design eco-friendly UV-HPLC method for the determination of four drugs used to treat symptoms of common cold and COVID-19. Abdallah, NA; El-Brashy, AM; Fathy, ME; Ibrahim, FA; Tolba, MM, 2023)	0.91
" Future research will be required to balance vasopressor agent dosage in view of colorectal anastomotic leakage."	( Fluid management and vasopressor use during colorectal surgery: the search for the optimal balance. Bootsma, BT; Daams, F; Huisman, DE; Ingwersen, EW; Reudink, M; Slooter, GD; Stens, J, 2023)	0.91
"Based on this study, 5-10 mg ephedrine and 13-16 μg norepinephrine prophylactic bolus injection may be the optimum dosage of three drugs prevent spinal-induced hypotension, which has the least impact on maternal and neonatal outcomes."	( Prevention of spinal hypotension during cesarean section: A systematic review and Bayesian network meta-analysis based on ephedrine, phenylephrine, and norepinephrine. Lv, X; Ma, X; Xue, X; Yang, Z; Yu, N; Zhou, Y, 2023)	0.91
" Vasoconstriction to phenylephrine and vasodilation to acetylcholine (endothelial dependent) and sodium nitroprusside (endothelial independent) were assessed by cumulative dose-response curves."	( Isometric myography is a feasible method to identify and quantify endothelial dysfunction in dogs with myxomatous mitral valve disease. Culshaw, GJ; Jones, NK; Mazzarella, MO, 2023)	0.91

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
alpha-adrenergic agonist	An agent that selectively binds to and activates alpha-adrenergic receptors.
cardiotonic drug	A drug that has a strengthening effect on the heart or that can increase cardiac output.
mydriatic agent	Agent that dilates the pupil. Used in eye diseases and to facilitate eye examination. It may be either a sympathomimetic or parasympatholytic. The latter cause cycloplegia or paralysis of accommodation at high doses and may precipitate glaucoma.
protective agent	Synthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.
vasoconstrictor agent	Drug used to cause constriction of the blood vessels.
sympathomimetic agent	A drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
nasal decongestant	A drug used to relieve nasal congestion in the upper respiratory tract.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
phenylethanolamines	An ethanolamine compound having a phenyl (substituted or unsubstituted) group on the carbon bearing the hydroxy substituent.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
phenols	Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Physiological and pathological hypertrophy of the heart	0	2

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
dopamine D1 receptor	Homo sapiens (human)	Potency	1.8356	0.0052	1.3022	8.1995	AID624455
glp-1 receptor, partial	Homo sapiens (human)	Potency	0.7308	0.0184	6.8060	14.1254	AID624148
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	1.1220	0.1000	20.8793	79.4328	AID588453
NFKB1 protein, partial	Homo sapiens (human)	Potency	3.5481	0.0282	7.0559	15.8489	AID895; AID928
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.2512	0.0013	7.7625	44.6684	AID914; AID915
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	19.9526	0.0013	18.0743	39.8107	AID926
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0264	0.0013	10.1577	42.8575	AID1259252
D(1A) dopamine receptor	Homo sapiens (human)	Potency	5.6234	0.0224	5.9449	22.3872	AID488983
ras-related protein Rab-9A	Homo sapiens (human)	Potency	91.9997	0.0002	2.6215	31.4954	AID485297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.3900	0.0001	0.8074	10.0000	AID36055
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	6.1000	0.0001	0.9490	10.0000	AID32954
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	0.3900	0.0002	0.7257	10.0000	AID36055
Beta-1 adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	13.0000	0.0000	0.6673	10.0000	AID33078
Alpha-1A adrenergic receptor	Bos taurus (cattle)	Ki	0.9333	0.0000	0.5072	3.7020	AID36463
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.3900	0.0003	0.4834	10.0000	AID36055
Alpha-1B adrenergic receptor	Mesocricetus auratus (golden hamster)	Ki	1.2589	0.0000	2.0167	9.6000	AID37185
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.3300	0.0000	0.9296	10.0000	AID32956; AID35187
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.3300	0.0000	0.9708	10.0000	AID32956; AID35187
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.3300	0.0000	0.9375	10.0000	AID32956; AID35187
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	3.1311	0.0000	0.5751	10.0000	AID32954; AID35739
Alpha-1A adrenergic receptor	Homo sapiens (human)	Ki	0.1622	0.0000	0.2726	10.0000	AID35739
Alpha-1B adrenergic receptor	Homo sapiens (human)	Ki	1.2589	0.0000	0.4713	10.0000	AID37185
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	3.1311	0.0000	0.9650	10.0000	AID32954; AID35739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alpha-1B adrenergic receptor	Cricetulus griseus (Chinese hamster)	EC50 (µMol)	0.0100	0.0100	0.3444	0.9430	AID1342011
Beta-2 adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	6.0000	0.0000	0.3111	10.0000	AID41160
Beta-1 adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	6.0000	0.0001	0.4914	6.0000	AID41160
Alpha-2A adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.3060	0.0008	0.3733	6.7100	AID1342005
Beta-3 adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	6.0000	0.0001	0.4553	10.0000	AID41160
Alpha-1A adrenergic receptor	Bos taurus (cattle)	EC50 (µMol)	0.0090	0.0090	0.3740	1.1320	AID1342009
Alpha-2C adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.3400	0.0005	0.5541	6.7100	AID1342007
Alpha-1A adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.0555	0.0001	0.5098	7.1000	AID1194508; AID1323688
Alpha-1B adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.0034	0.0001	1.3010	5.6000	AID1194509; AID1323690
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
POU domain, class 2, transcription factor 1	Homo sapiens (human)	Km	221.2000	2.1000	5.3900	8.6000	AID1769498
Alpha-2B adrenergic receptor	Mus musculus (house mouse)	IC40 (µMol)	0.0780	0.0037	0.0408	0.0780	AID36357
Alpha-2C adrenergic receptor	Mus musculus (house mouse)	IC40 (µMol)	0.0780	0.0037	0.0408	0.0780	AID36357
Alpha-2A adrenergic receptor	Mus musculus (house mouse)	IC40 (µMol)	0.0780	0.0037	0.0408	0.0780	AID36357
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
diet induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
regulation of sodium ion transport	Beta-2 adrenergic receptor	Homo sapiens (human)
transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor-mediated endocytosis	Beta-2 adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome to lysosome transport	Beta-2 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase A signaling	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of bone mineralization	Beta-2 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-2 adrenergic receptor	Homo sapiens (human)
bone resorption	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of mini excitatory postsynaptic potential	Beta-2 adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of autophagosome maturation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of lipophagy	Beta-2 adrenergic receptor	Homo sapiens (human)
cellular response to amyloid-beta	Beta-2 adrenergic receptor	Homo sapiens (human)
response to psychosocial stress	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of AMPA receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-1 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-1 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-1 adrenergic receptor	Homo sapiens (human)
fear response	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of circadian sleep/wake cycle, sleep	Beta-1 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor-mediated endocytosis	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
carbohydrate metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Beta-3 adrenergic receptor	Homo sapiens (human)
energy reserve metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-3 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-3 adrenergic receptor	Homo sapiens (human)
eating behavior	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-3 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	POU domain, class 2, transcription factor 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	POU domain, class 2, transcription factor 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	POU domain, class 2, transcription factor 1	Homo sapiens (human)
positive regulation of miRNA transcription	POU domain, class 2, transcription factor 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	POU domain, class 2, transcription factor 1	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-1A adrenergic receptor	Bos taurus (cattle)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Bos taurus (cattle)
regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Bos taurus (cattle)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
apoptotic process	Alpha-1A adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
activation of phospholipase C activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1A adrenergic receptor	Homo sapiens (human)
adult heart development	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to hormone	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of autophagy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of action potential	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
calcium ion transport into cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase C signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
pilomotor reflex	Alpha-1A adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-1B adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of cardiac muscle contraction	Alpha-1B adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1B adrenergic receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amyloid-beta binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta2-adrenergic receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase binding	Beta-2 adrenergic receptor	Homo sapiens (human)
potassium channel regulator activity	Beta-2 adrenergic receptor	Homo sapiens (human)
identical protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein-containing complex binding	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
beta1-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-1 adrenergic receptor	Homo sapiens (human)
PDZ domain binding	Beta-1 adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-1 adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Beta-1 adrenergic receptor	Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta3-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-3 adrenergic receptor binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-3 adrenergic receptor	Homo sapiens (human)
epinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	POU domain, class 2, transcription factor 1	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	POU domain, class 2, transcription factor 1	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	POU domain, class 2, transcription factor 1	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	POU domain, class 2, transcription factor 1	Homo sapiens (human)
DNA binding	POU domain, class 2, transcription factor 1	Homo sapiens (human)
protein binding	POU domain, class 2, transcription factor 1	Homo sapiens (human)
sequence-specific DNA binding	POU domain, class 2, transcription factor 1	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Bos taurus (cattle)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Beta-2 adrenergic receptor	Homo sapiens (human)
lysosome	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
Golgi apparatus	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
apical plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Beta-1 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-3 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
nucleus	POU domain, class 2, transcription factor 1	Homo sapiens (human)
nucleoplasm	POU domain, class 2, transcription factor 1	Homo sapiens (human)
endoplasmic reticulum	POU domain, class 2, transcription factor 1	Homo sapiens (human)
intracellular membrane-bounded organelle	POU domain, class 2, transcription factor 1	Homo sapiens (human)
chromatin	POU domain, class 2, transcription factor 1	Homo sapiens (human)
RNA polymerase II transcription regulator complex	POU domain, class 2, transcription factor 1	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Bos taurus (cattle)
cytoplasm	Alpha-1A adrenergic receptor	Bos taurus (cattle)
plasma membrane	Alpha-1A adrenergic receptor	Bos taurus (cattle)
caveola	Alpha-1A adrenergic receptor	Bos taurus (cattle)
nuclear membrane	Alpha-1A adrenergic receptor	Bos taurus (cattle)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1B adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID36783	50% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID56378	Effect of zero uM external [Ca2+] on the contractions induced by compound in the canine saphenous vein at EC100 concentration experimented in the presence of 2 mM EGTA and expressed as percent of control response in 2.5 mM Ca+ physiological salin	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	N-[2-hydroxy-5-[2-(methylamino)ethyl]phenyl]methanesulfonamide. A potent agonist which releases intracellular calcium by activation of alpha 1-adrenoceptors.
AID36055	Compound was tested for its ability to displace [3H]clonidine form alpha-2 adrenergic receptor site in guinea pig cerebral cortical membranes.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID36715	Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported.	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID1194509	Agonist activity at alpha-1B adrenergic receptor (unknown origin) after 5 hrs by CCF4-AM staining-based cellular assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one.
AID1194508	Agonist activity at alpha-1A adrenergic receptor (unknown origin) after 5 hrs by CCF4-AM staining-based cellular assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one.
AID73730	Effective concentration for stimulation of [3H]phosphoinositide formation in guinea pig synaptoneurosomes expressing alpha-1 receptor	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.
AID197169	Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID32956	Displacement of [3H]clonidine from adrenergic alpha 2 receptor of rat cerebral cortical membranes	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.
AID32954	Displacement of [3H]WB-4101 from adrenergic alpha 1 receptor of rat cerebral cortical membranes	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.
AID75503	Stimulation of [3H]phosphatidylinositol turnover in synaptoneurosomes at a concentration of 100 uM	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID36641	post-synaptic Alpha-2 adrenergic receptor agonist activity in rat anococcygeus	1983	Journal of medicinal chemistry, Jun, Volume: 26, Issue:6	alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID22293	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID35187	Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes	1982	Journal of medicinal chemistry, Dec, Volume: 25, Issue:12	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs.
AID35160	In vitro agonist potency towards Alpha-1B adrenergic receptor in rat spleen	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID1769501	Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID197171	Agonist potency of phenylephrine in rat isolated anococcygeus muscle	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID1323688	Intrinsic activity at alpha1A adrenergic receptor (unknown origin) after 5 hrs in presence of CCF4-AM by cell based beta lactamase reporter gene assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID35739	Binding affinity towards rat clonal Alpha-1D adrenergic receptor	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID56380	Effect of zero uM external [Ca2+] on the contractions induced by compound in the canine saphenous vein at EC50 concentration experimented in the presence of 2 mM EGTA and expressed as percent of control response in 2.5 mM Ca+ physiological saline	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	N-[2-hydroxy-5-[2-(methylamino)ethyl]phenyl]methanesulfonamide. A potent agonist which releases intracellular calcium by activation of alpha 1-adrenoceptors.
AID36470	In vitro agonist potency towards Alpha-1A adrenergic receptor in canine prostate	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID36927	Inhibitory activity against Alpha-2 adrenergic receptor in rat vas deferens	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Heteroaromatic analogues of the alpha 2-adrenoreceptor partial agonist clonidine.
AID36493	Presynaptic alpha-2 adrenergic receptor agonist activity in isolated mouse vas deferens	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity.
AID60508	Percent response towards alpha 1A adrenergic receptor in canine prostate using phenylephrine as control agonist	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID35984	Compound was tested for its ability to displace [3H]-prazosin form alpha-1 adrenergic receptor site in guinea pig cerebral cortical membranes.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID310711	Clearance in human	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
AID397122	Inhibition of HIV1 RT
AID37185	Binding affinity towards hamster clonal Alpha-1B adrenergic receptor	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID36463	Binding affinity towards bovine clonal Alpha-1A adrenergic receptor	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID56368	Effect of 1 uM external [Ca2+] on the contractions induced by compound in the canine saphenous vein at EC25 concentration and expressed as percent of control response in 2.5 mM Ca	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	N-[2-hydroxy-5-[2-(methylamino)ethyl]phenyl]methanesulfonamide. A potent agonist which releases intracellular calcium by activation of alpha 1-adrenoceptors.
AID234298	Selectivity is the ratio of binding affinities of alpha 1A adrenergic receptor to alpha 1d adrenergic receptor	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID70530	Free energy of binding to turkey erythrocyte beta receptor	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Mapping the turkey erythrocyte beta receptor: a distance geometry approach.
AID73703	Compound was evaluated for its agonist potency by measurement of contraction of guinea pig aortic strips	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID177376	In vivo ED40 is the raising diastolic blood pressure by 40 mm Hg in pithed rats. (postjunctional)	1988	Journal of medicinal chemistry, May, Volume: 31, Issue:5	Indoline analogues of idazoxan: potent alpha 2-antagonists and alpha 1-agonists.
AID1323700	Selectivity ratio of EC50 for human alpha1B adrenergic receptor expressed in CHOK1 cells co-expressing aequorin to EC50 for alpha1A adrenergic receptor (unknown origin)	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID1769500	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID41160	Evaluated for Beta adrenergic receptor agonistic property in isolated guinea pig atria	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols.
AID36357	Inhibition of alpha-2 adrenergic receptor	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity.
AID234297	Selectivity is the ratio of binding affinities of alpha 1A adrenergic receptor to alpha 1b adrenergic receptor	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID37044	Binding affinity towards Alpha-1A adrenergic receptor in rat submaxillary glands	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID1769498	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID180025	Percent response towards alpha 1A adrenergic receptor in rat vas deferens using phenylephrine as control agonist	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID56370	Effect of 1 uM external [Ca2+] on the contractions induced by compound in the canine saphenous vein at EC50 concentration and expressed as percent of control response in 2.5 mM Ca	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	N-[2-hydroxy-5-[2-(methylamino)ethyl]phenyl]methanesulfonamide. A potent agonist which releases intracellular calcium by activation of alpha 1-adrenoceptors.
AID33078	Displacement of [3H]dihydroalprenolol from adrenergic beta 1 receptor of rat cerebral cortical membranes	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID215613	Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly Beta adrenergic receptor was determined	1982	Journal of medicinal chemistry, Dec, Volume: 25, Issue:12	Correlation between affinity toward adrenergic receptors and approximate electrostatic potentials of phenylethylamine derivatives. 1. Effects of the side chain.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID180026	Percent response towards alpha 1B adrenergic receptor in rat spleen using phenylephrine as control agonist	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID26304	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID35618	In vitro agonist potency towards Alpha-1D adrenergic receptor in rat aorta	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID73704	Compound was evaluated for its agonist potency by measurement of potentiation of 2-chloroadenosine stimulation of cyclic AMP accumulation in guinea pig cerebral cortical synaptoneurosomal preparations.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID1769499	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID41317	Compound was tested for its ability to displace [3H]dihydroalprenolol form beta adrenergic receptor site in guinea pig cerebral cortical membranes.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID37036	In vitro agonist potency towards Alpha-1A adrenergic receptor in rat vas deferens	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID35983	Compound was tested for its ability to displace [3H]WB-4101 form alpha-1 adrenergic receptor site in guinea pig cerebral cortical membranes.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and adrenergic activity of ring-fluorinated phenylephrines.
AID56375	Effect of zero external [Ca2+] on the contractions induced by compound in the canine saphenous vein in the presence of 2 mM EGTA and expressed as percent of control response in 2.5 mM Ca+ physiological saline	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	N-[2-hydroxy-5-[2-(methylamino)ethyl]phenyl]methanesulfonamide. A potent agonist which releases intracellular calcium by activation of alpha 1-adrenoceptors.
AID1323690	Intrinsic activity at human alpha1B adrenergic receptor expressed in CHOK1 cells co-expressing aequorin assessed as calcium mobilization measured for 20 secs in presence of coelenterazine H by luminescence assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID56366	Effect of 1 uM external [Ca2+] on the contractions induced by compound agonist in the canine saphenous vein at EC100 concentration and expressed as percent of control response in 2.5 mM Ca	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	N-[2-hydroxy-5-[2-(methylamino)ethyl]phenyl]methanesulfonamide. A potent agonist which releases intracellular calcium by activation of alpha 1-adrenoceptors.
AID180028	Percent response towards alpha 1D adrenergic receptor in rat aorta using phenylephrine as control agonist	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346000	Human alpha1B-adrenoceptor (Adrenoceptors)	1994	Molecular pharmacology, Nov, Volume: 46, Issue:5	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
AID1346000	Human alpha1B-adrenoceptor (Adrenoceptors)	1997	British journal of pharmacology, Jul, Volume: 121, Issue:6	Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
AID1345908	Human alpha1A-adrenoceptor (Adrenoceptors)	1999	British journal of pharmacology, Jun, Volume: 127, Issue:4	Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells.
AID1345920	Rat alpha1D-adrenoceptor (Adrenoceptors)	1994	Molecular pharmacology, Nov, Volume: 46, Issue:5	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4441 (33.89)	18.7374
1990's	3496 (26.68)	18.2507
2000's	2847 (21.73)	29.6817
2010's	1878 (14.33)	24.3611
2020's	442 (3.37)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	857 (6.21%)	5.53%
Reviews	210 (1.52%)	6.00%
Case Studies	394 (2.86%)	4.05%
Observational	32 (0.23%)	0.25%
Other	12,304 (89.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (280)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phenylephrine Versus Tranexamic Acid to Control Bleeding in Patients Undergoing Inferior Turbinoplasty by Coblation [NCT05841251]		80 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
A Single-dose, Randomized, Crossover Bioequivalence Study to Compare Two Formulations of Paracetamol/Phenylephrine [NCT01112462]	Phase 1	40 participants (Actual)	Interventional	2010-03-31	Completed
Comparison of the Hemodynamic Effects of Phenylephrine and Norepinephrine in Patients Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Surgery. [NCT03872570]	Phase 4	40 participants (Anticipated)	Interventional	2019-06-01	Recruiting
ED90 of Norepinephrine and Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive Treatment During Cesarean Section [NCT06158048]		80 participants (Anticipated)	Interventional	2025-01-01	Not yet recruiting
ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section [NCT06158035]		80 participants (Anticipated)	Interventional	2025-07-01	Not yet recruiting
ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment During Cesarean Section [NCT06158009]		80 participants (Anticipated)	Interventional	2025-04-01	Not yet recruiting
Novel Role of Acetylcholine in Regulating Vascular Tone: Effects of Age and Exercise Training [NCT03972683]	Early Phase 1	0 participants (Actual)	Interventional	2019-04-16	Withdrawn(stopped due to no participants enrolled)
Preoperative Cataract Pupillary Dilation: Inpatient vs Outpatient [NCT01169688]		50 participants (Actual)	Interventional	2007-12-31	Completed
A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil [NCT03751098]	Phase 3	76 participants (Actual)	Interventional	2018-12-01	Completed
Comparison of Continuous Infusion of Noradrenaline Versus Phenylephrine During Cesarean Section Under Spinal Anesthesia. A Randomized Controlled Trial [NCT03842046]		82 participants (Actual)	Interventional	2019-02-16	Completed
Simultaneous Quantification of Dynamic and Static Cerebral Autoregulation (CA) at Different Steady-state Mean Blood Pressures Under Anaesthesia. [NCT03816072]		66 participants (Actual)	Interventional	2019-01-07	Completed
Cardiovascular Changes and Tetracaine Pharmacokinetics Following Intranasal Administration of Standard and High Doses of Kovacaine Mist (Tetracaine Hydrochloride With Oxymetazoline Hydrochloride) in Healthy Volunteers [NCT01304316]	Phase 2	12 participants (Actual)	Interventional	2010-09-30	Completed
Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea [NCT04153188]	Phase 4	34 participants (Actual)	Interventional	2019-01-15	Completed
Randomized Double-blinded Comparison of Norepinephrine and Phenylephrine in Bolus for Maintenance of Blood Pressure During Spinal Anesthesia for Cesarean Delivery [NCT03702400]	Phase 2	72 participants (Actual)	Interventional	2018-10-01	Completed
Neuro-Ox 2018: Assessment of Cerebral Oxygenation Under Three Clinically Relevant Conditions [NCT03682198]		18 participants (Actual)	Interventional	2018-09-24	Completed
The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction [NCT03680404]	Phase 1	24 participants (Actual)	Interventional	2018-10-01	Completed
A Phase I Safety Study of Phenylephrine Applied Topically to the Oral Mucosa in Cancer Patients Receiving Radiation to Sub-mandibular Lymph Nodes [NCT01092975]	Phase 1	1 participants (Actual)	Interventional	2010-03-31	Terminated(stopped due to formulation/dose changes; planned changes to safety monitoring/reporting)
Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea [NCT03380390]	Phase 4	46 participants (Actual)	Interventional	2017-12-04	Completed
Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia. [NCT03638726]	Phase 4	40 participants (Anticipated)	Interventional	2018-09-28	Recruiting
Open Label, 2-Way Crossover Study to Assess the PK of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride on the PK of Intranasal Ketorolac Tromethamine in Healthy Male Subjects [NCT01363089]	Phase 1	21 participants (Actual)	Interventional	2007-01-31	Completed
Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study [NCT04053478]		144 participants (Anticipated)	Interventional	2019-07-08	Recruiting
Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure [NCT01333891]		1 participants (Actual)	Interventional	2012-12-31	Terminated
Pretreatment With Topical Anesthesia or Decongestant for Reducing Pain and Discomfort During Fiberoptic Nasal Pharyngoscopy and Laryngoscopy: A Double Blind Randomized Study [NCT03620513]	Phase 4	160 participants (Actual)	Interventional	2018-09-01	Completed
The Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery and From the Nasal Mucosa During Operative Dentistry [NCT02062996]	Phase 2	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Could not receive FDA approval for IND)
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension [NCT02245230]	Phase 1	34 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03139708]	Phase 1	5 participants (Actual)	Interventional	2016-09-30	Completed
Comparison of Norepinephrine and Phenylephrine in Cesarean Section by Transesophageal Ultrasound [NCT02759510]	Early Phase 1	106 participants (Anticipated)	Interventional	2016-06-30	Not yet recruiting
Randomized, Double-blind, Controlled Clinical Trial for Comparison of Continuous Phenylephrine Versus Norepinephrine Infusion for Maintenance of Hemodynamic Stability During Cesarean Section Under Spinal Anesthesia [NCT03849508]	Phase 4	124 participants (Actual)	Interventional	2019-02-27	Completed
Influence of a Bolus Administration of Ephedrine and Phenylephrine on the Spinal Oxygen Saturation, Measured With NIRS. [NCT03767296]	Phase 4	33 participants (Actual)	Interventional	2017-02-06	Completed
Sex Differences in Sympathetic Vascular Reactivity at High Altitude [NCT05525416]		17 participants (Actual)	Interventional	2022-07-28	Completed
Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation [NCT02201121]		94 participants (Actual)	Interventional	2014-03-31	Completed
Phase 1, Randomized, Double-Blind, Placebo-Controlled, 4-Period, Complete Cross-Over Comparison of the Anesthetic Efficacy of Bilateral and Unilateral Application of Kovacaine Mist in Healthy Volunteers [NCT02457806]	Phase 1	48 participants (Actual)	Interventional	2011-08-31	Completed
The Effect of Epinephrine, Norepinephrine and Phenylephrine on Intraoperative Hemodynamic Performance - a Prospective Double-blinded Randomized Clinical Trial [NCT05492968]	Phase 4	225 participants (Anticipated)	Interventional	2022-09-01	Recruiting
A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients [NCT02299557]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2014-11-30	Completed
Preventive Intramuscular Phenylephrine in Elective Cesarean Section Under Spinal Anesthesia: A Randomized Controlled Tiral [NCT03507387]		99 participants (Actual)	Interventional	2018-04-01	Completed
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension [NCT05439460]	Phase 4	15 participants (Actual)	Interventional	2012-01-31	Completed
A Pilot Study to Evaluate the Effect of Changing Physiological Conditions on the Amplitude and/or Frequency of Myogenic Oscillations [NCT03719001]	Early Phase 1	40 participants (Actual)	Interventional	2018-10-23	Completed
Pulpal Blood Flow With the Use of Intra-nasal Anesthetic: a Randomized Double-blind Crossover Study [NCT03368391]	Phase 4	25 participants (Anticipated)	Interventional	2018-01-03	Not yet recruiting
Combination Therapy With Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy Concomitant With Allergic Rhinitis [NCT02559440]	Phase 4	240 participants (Actual)	Interventional	2014-02-28	Completed
Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II [NCT02560805]	Phase 2	134 participants (Anticipated)	Interventional	2015-10-31	Suspended(stopped due to Enrollment and study activities are temporarily suspended due to COVID-19.)
Norepinephrine or Phenylephrine for Hypotension in Non-elective Cesarean Section [NCT04367103]		180 participants (Actual)	Interventional	2021-04-10	Completed
A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems [NCT03098680]	Phase 1	18 participants (Actual)	Interventional	2017-04-24	Terminated(stopped due to Unable to recruit in time before end of PhD studentship)
Comparison of Prophylactic Norepinephrine and Phenylephrine Infusion for Hemodynamic Effects in Patients With Preeclampsia During Cesarean Section: a Randomized, Controlled Trial [NCT05035498]		72 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
ED90 of Norepinephrine and Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section [NCT06158022]		80 participants (Anticipated)	Interventional	2025-01-01	Not yet recruiting
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold: a Prospective, Randomized, Double-blind, Controlled Trial [NCT05070650]	Phase 3	1,002 participants (Anticipated)	Interventional	2024-09-20	Not yet recruiting
Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery [NCT02101047]		0 participants (Actual)	Interventional	2015-08-31	Withdrawn(stopped due to lack of eligible participant)
A Randomized, Dose-ranging, Placebo-controlled Trial to Evaluate the Effects of Phenylephrine HCl Immediate Release Tablets on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis [NCT01330017]	Phase 2	539 participants (Actual)	Interventional	2011-03-31	Completed
The Effects of Nasal Airflow on Upper Airway Dilator Muscles During Sleep [NCT03506178]		30 participants (Anticipated)	Interventional	2017-09-12	Recruiting
Evaluation of Costs and Consequences of Alternative Strategies of Intraoperative Fluid and Pharmacological Optimization. A Randomized Clinical Trial [NCT01141894]		150 participants (Actual)	Interventional	2010-03-31	Terminated(stopped due to slow recruitment)
A Randomized Crossover Bioequivalence Study Comparing a Single Dose of Phenylephrine HCl 30 mg Extended Release Tablet to Three Phenylephrine HCl 10 mg Immediate Release Tablets Each Consecutively Dosed Four Hours Apart Under Fed and Fasting Conditions [NCT01354418]	Phase 1	24 participants (Actual)	Interventional	2011-05-31	Completed
An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Pheniramine Maleate 20 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With [NCT02730364]	Phase 3	0 participants (Actual)	Interventional	2017-02-01	Withdrawn(stopped due to The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.)
Randomized, Double-blind, Placebo-Controlled Study of the Efficacy of Phenylephrine HCL Extended-Release 30 mg and Phenylephrine HCL Immediate-Release 12 mg Capsules in Subjects With Nasal Congestion Due to the Common Cold [NCT03339726]	Phase 2	193 participants (Actual)	Interventional	2017-11-30	Terminated(stopped due to did not enroll enough subjects in the 2017/2018 cold season, so the study was terminated)
Phenylephrine Versus Ephedrine to Treat Spinal Anesthesia-Induced Hypotension in Preeclamptic Patients During Cesarean Delivery [NCT00458003]		110 participants (Actual)	Interventional	2006-07-31	Completed
Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial [NCT04623684]	Phase 4	25 participants (Actual)	Interventional	2020-03-24	Completed
A Double-Masked, Active-Controlled Study of the Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil [NCT03751631]	Phase 3	70 participants (Actual)	Interventional	2018-11-15	Completed
Phenylephrine Versus Norepinephrine in Septic Shock: Effects on Systemic and Regional Hemodynamics. A Randomized, Controlled, Trial [NCT00639015]	Phase 2	32 participants (Actual)	Interventional	2007-11-30	Completed
Effect of Noradrenaline Infusuion Versus Phenyephrine Infusion in Improving Tissue Perfusion in HIPEC [NCT04144465]		30 participants (Actual)	Interventional	2019-11-01	Completed
Efficacy and Tolerance of Ophthalmic Insert Mydriasert® Versus Reference Treatment (Phenylephrine and Tropicamide Eyedrops) in Premature Newborns, Neonates and Infants Justifying a Mydriasis for a Bilateral Diagnosis Fundus [NCT00642135]	Phase 3	80 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to The total number of patients has been reached.)
The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction [NCT01850511]		60 participants (Actual)	Interventional	2013-05-31	Completed
Intraoperative Phenylephrine Infusion to Reduce Postoperative Shivering in Lower Segment Caesarean Section [NCT04133961]		118 participants (Actual)	Interventional	2019-06-12	Completed
Norepinephrine Versus Phenylephrine Continuous Variable Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Double-blinded Trial [NCT03328533]	Phase 4	123 participants (Actual)	Interventional	2017-11-10	Completed
Autoimmune Basis for Postural Tachycardia Syndrome [NCT02725060]		58 participants (Anticipated)	Interventional	2016-02-29	Enrolling by invitation
Comparison of the Potency of Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension in Patients With Severe Preeclampsia During Caesarean Section [NCT05035472]		80 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
Comparison of Different Protocols of Phenylephrine Infusion for Prophylaxis Against Post-spinal Hypotension During Cesarean Delivery [NCT03248817]	Phase 4	255 participants (Anticipated)	Interventional	2017-09-28	Recruiting
A Study Evaluating Pupil Dilation Speed With the Micro-Array Print (MAP) Dispenser Comparing 2 Dosing Regimens of Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution [NCT04907474]	Phase 4	60 participants (Actual)	Interventional	2021-05-24	Completed
Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study) [NCT04839224]	Phase 3	40 participants (Anticipated)	Interventional	2021-04-05	Recruiting
Sympathetic Nerve Activity and Vascular Function in Women With Uterine Leiomyomata [NCT02123069]		28 participants (Actual)	Observational	2013-04-30	Completed
An Observational Study to Test the Effect of the Vasoactive Drugs Phenylephrine and Ephedrine on the Stroke Volume and Microvascular Blood Flow of Healthy Volunteers [NCT02252627]		8 participants (Anticipated)	Observational	2014-08-31	Recruiting
Effects of Vasopressors on Cerebral Hemodynamics in Patients With Carotid Endarterectomy Under General Anesthesia(MRI Part): a Randomized Controlled Study [NCT05414877]		60 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
A New More Efficient Cycloplegia Scheme [NCT02177539]	Phase 4	30 participants (Anticipated)	Interventional	2014-05-31	Recruiting
Cerebral Hemodynamic and Metabolic Responses to Anesthesia and Vasopressors in Adult Surgery: A 2x2 Factorial Design Randomized Controlled Trial With Light-based Neuromonitoring (CHEM-FACT Study) [NCT05941494]	Phase 4	80 participants (Anticipated)	Interventional	2023-10-03	Recruiting
Phase III Clinical Trial - Efficacy and Safety Assessment of a Compound Acetaminophen, Chlorpheniramine and Phenylephrine Combination in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome in Adults [NCT00940836]	Phase 3	146 participants (Anticipated)	Interventional	2009-06-30	Recruiting
"A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product Oxymetazoline Hydrochloride Cream, 1% to Reference Product RHOFADETM Cream, 1% in the Trea [NCT03954444]	Phase 3	1,105 participants (Actual)	Interventional	2019-04-15	Completed
Up-down Determination of the ED90 of Phenylephrine for Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery [NCT00781157]	Phase 4	66 participants (Actual)	Interventional	2008-01-31	Completed
Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes [NCT01097551]		38 participants (Actual)	Observational	2011-01-31	Completed
Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans [NCT00806741]		18 participants (Actual)	Interventional	2009-09-30	Completed
Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia for Cesarean Section [NCT02854787]	Phase 4	120 participants (Anticipated)	Interventional	2016-05-31	Completed
The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study [NCT02675868]	Phase 4	40 participants (Actual)	Interventional	2016-01-31	Completed
An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respir [NCT02678234]	Phase 3	0 participants (Actual)	Interventional	2017-02-01	Withdrawn(stopped due to The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.)
[NCT02802683]	Phase 4	72 participants (Actual)	Interventional	2015-09-30	Completed
Comparison of Conventional Instillation and Lower Conjunctival Fornix Packing in Mydriasis for Premature Infants [NCT00877175]	Phase 4	25 participants (Actual)	Interventional	2009-03-31	Completed
Impact of Targeted Blood-pressure Management on Incidence of Acute Kidney Injury After Off-pump Coronary Artery Bypass Surgery: A Randomized Controlled Trial [NCT03629418]		612 participants (Anticipated)	Interventional	2018-08-14	Recruiting
Evaluation of Ophthalmic Oxymetazoline as an Adjunct Treatment for Acquired Blepharoptosis Due to Periocular Synkinesis. [NCT05945615]	Phase 3	48 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide [NCT00356265]		18 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Futility: Impossible to recruit enough hypertensive participants to match Chronic Kidney Disease (CKD) participants on needed parameters.)
Effects of Vasopressors on Cerebral Hemodynamics in Patients With Carotid Endarterectomy Under General Anesthesia(TCD Part): a Randomized Controlled Study [NCT05665881]		60 participants (Anticipated)	Interventional	2022-11-01	Recruiting
An Open-label Study to Assess the Effects of Allergic Rhinitis and Coadministration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine [NCT02154334]	Phase 1	47 participants (Actual)	Interventional	2014-06-30	Completed
A Phase 1 Study to Evaluate the Effects of Common Cold and of Concomitant Administration of Nasal Decongestant on the Pharmacokinetics and Pharmacodynamics of a Novel Glucagon Formulation in Otherwise Healthy Subjects [NCT02778100]	Phase 1	36 participants (Actual)	Interventional	2013-03-31	Completed
A Single-Center, Study Evaluating The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of Kovacaine Mist To Healthy Pediatric Subjects [NCT01952990]	Phase 2	18 participants (Actual)	Interventional	2013-09-30	Completed
Up-down Determination of the ED90 of the Initial Rate of Infusion of Phenylephrine for the Prophylaxis of Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery [NCT00796328]	Phase 4	45 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Results Invalid, study closed, analysis cannot proceed.)
Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans [NCT00914394]		12 participants (Actual)	Interventional	2010-10-31	Terminated
Comparison of the Effects of Norepinephrine and Phenylephrine on Tissue Oxygenation and Hemodynamic Stability During an Stroke Volume Variations(SVV) Fluid Guided Therapy in Elderly Undergoing Major Abdominal Surgery [NCT04067817]	Phase 3	100 participants (Anticipated)	Interventional	2019-10-06	Recruiting
A Randomized, Crossover, Double-Blind Study To Evaluate The Safety Of An Association Of Phenylephrine Hydrochloride 10mg + Acetaminophen 500mg + Dimethindene Maleate 1 Mg Compared To Phenylephrine Hydrochloride 10mg In Healthy Volunteers [NCT01026961]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2010-09-30	Withdrawn(stopped due to Study is no longer required by Brazil health authority.)
Role of Angiotensin II in Insulin-induced Microvascular Activity [NCT01024543]		18 participants (Actual)	Interventional	2006-10-31	Completed
The Pathophysiology of Orthostatic Hypotension [NCT00748059]	Phase 1	10 participants (Actual)	Interventional	1996-12-31	Completed
Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors [NCT02713087]	Phase 4	48 participants (Actual)	Interventional	2015-09-30	Completed
Effect of Phenylephrine Infusion for Preventing Hypotension During Shoulder Arthroscopic Surgery in the Beach Chair Position [NCT02585570]		66 participants (Actual)	Interventional	2015-10-31	Completed
An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Phenylephrine in Children and Adolescents [NCT00762567]	Phase 1	36 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized, Two-Way Crossover, Multicenter, Consumer Preference Study of Two Oral Formulations of Phenylephrine Hydrochloride. [NCT00976209]	Phase 3	331 participants (Actual)	Interventional	2009-08-31	Completed
Vasopressor Outcomes in Spine Surgery [NCT06053398]		120 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Multicenter, Phase III, Randomized, Open, Parallel, Comparative to Evaluate the Efficacy and Safety of the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis and Allergic Reactions, in Pediatric Patients [NCT01393548]	Phase 3	879 participants (Actual)	Interventional	2014-08-31	Completed
Phenylephrine Versus Upper Eyelid Taping For Muller's Muscle Conjunctival Resection Evaluation [NCT05890027]	Phase 4	30 participants (Anticipated)	Interventional	2024-02-15	Not yet recruiting
Use of the Hypotension Prediction Index Algorithm (HPI) for the Prevention of Intraoperative Hypotension (IOH) in Adult Patients Undergoing Spinal Surgery: Study Protocol for a Randomized Clinical Trial [NCT05341167]		40 participants (Anticipated)	Interventional	2022-06-06	Recruiting
Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study [NCT01006863]	Phase 2	150 participants (Actual)	Interventional	2004-03-31	Completed
Prophylactic Phenylephrine and Fluid Co-administration to Reduce Spinal Hypotension During Elective Caesarean Section in a Resource-limited Setting: a Prospective Alternating Intervention Study [NCT04005664]		300 participants (Actual)	Interventional	2018-05-01	Completed
A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants [NCT01054027]		15 participants (Actual)	Interventional	2007-03-31	Completed
Clinical Evaluation of Safety and Efficacy of Pediatric Naridrin in Comparison to Afrin on the Improval of Nasal Congestion. [NCT02601235]	Phase 3	292 participants (Actual)	Interventional	2018-01-16	Completed
The Dynamic Effects of Phenylephrine on Preload and Cardiac Output in Patients Under General Anaesthesia [NCT02739399]	Phase 4	26 participants (Actual)	Interventional	2016-02-29	Completed
A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU [NCT02118467]	Phase 4	836 participants (Anticipated)	Interventional	2014-05-31	Recruiting
Study to Determine the Best Regimen for Administration of Phenylephrine During Spinal Anesthesia for Cesarean Delivery, as Determined by Maternal Blood Pressure and Cardiac Output [NCT00996190]	Phase 4	60 participants (Actual)	Interventional	2009-11-30	Completed
Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital [NCT05706727]	Phase 3	42 participants (Anticipated)	Interventional	2023-03-23	Recruiting
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03959176]	Phase 4	13 participants (Actual)	Interventional	2019-07-20	Completed
A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa [NCT00584987]	Phase 4	64 participants (Actual)	Interventional	2007-06-30	Completed
Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber [NCT00276016]	Phase 3	39 participants (Actual)	Interventional	2006-01-31	Completed
The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment [NCT00585091]		15 participants (Actual)	Interventional	2003-10-31	Completed
Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring During Spinal Anaesthesia for Cesarean Section:A Prospective,Randomized, Controlled Study [NCT02532270]		100 participants (Anticipated)	Interventional	2015-09-30	Recruiting
The Phenylephrine vs. Norepinephrine Infusion by Lidico Monitoring With Pregnancy Patients Undergoing Cesarean Section [NCT03833895]	Phase 2/Phase 3	238 participants (Actual)	Interventional	2019-02-20	Completed
A Phase I/IIa Safety and Efficacy Study of Topical Phenylephrine Applied to Oral Mucosa in Bone Marrow Transplant Patients Receiving Cytoxan Plus Total Body Irradiation [NCT02434146]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2015-05-14	Terminated(stopped due to A company in China has decided to license the product)
Effect of Preventive Medicine on the Postreperfusion Syndrome [NCT01080625]		96 participants (Actual)	Interventional	2010-04-30	Completed
Effect of Three Weight-adjusted Vasopressors for With Combined Spinal-Epidural Anesthesia for Elective Cesarean Delivery: A Randomized Controlled Trial [NCT04991662]	Phase 4	78 participants (Actual)	Interventional	2021-10-10	Completed
Cardiovascular Hyporeactivity and Fatiguing Illness in Gulf War Veterans [NCT00100412]		0 participants	Interventional	1999-10-31	Completed
Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia in Neurosurgical Patients [NCT06083948]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2023-12-20	Recruiting
Stage 2, Double-blind, Randomized, Parallel Groups, One Centre Study in Patients With Allergic Rhinitis Treated With Nasal Oxymetazoline in Combination With Nasal Hydroxyl-propyl-methyl Cellulose (HPMC) or Placebo [NCT01986582]	Phase 2	40 participants (Anticipated)	Interventional	2013-10-31	Completed
Evaluation and Treatment of Autonomic Failure. [NCT00223691]	Phase 1	389 participants (Actual)	Interventional	2002-03-31	Completed
Effect of Phenylephrine or Dopamine Infusion on Cerebral Oxygen Saturation in Thoracic Surgery Patients [NCT02009007]	Phase 1	50 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Comparsion of the Effect of High Versus Low Mean Arterial Pressure (MAP) Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery Under General Anesthesia [NCT02857153]		322 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Efficacy and Safety of Difluprednate Ophthalmic Emulsion vs. a Fixed-Combination of Prednisolone Acetate - Phenylephrine Ophthalmic Suspension on Post-operative Inflammation Following Cataract Surgery. [NCT04631315]	Phase 4	255 participants (Actual)	Interventional	2019-03-24	Completed
A Multicenter, Consumer Product Evaluation of a Single Dose of Phenylephrine Hydrochloride 30 mg Extended Release Tablets (Sinus Comfort™) [NCT04534452]	Phase 3	347 participants (Actual)	Interventional	2012-05-12	Completed
Comparison of the Effects of Phenylephrine and Norepinephrine on Hemodynamics and Tissue Oxygenation in Patients Undergoing Ophthalmic Surgery [NCT01609491]		60 participants (Actual)	Interventional	2012-01-31	Completed
Safety and Efficacy of Therapeutic Induced Hypertension in Patients With Acute Non-cardioembolic Ischemic Stroke: A Multicenter, Randomized, Open Label, Prospective, Phase 3 Study [NCT01600235]	Phase 3	170 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Effect of Phenylephrine Infusion on Pulse Pressure Variability [NCT05011357]	Early Phase 1	6 participants (Anticipated)	Interventional	2021-09-10	Recruiting
A Pilot Study of the Effects of Nebulized Epoprostenol (Flolan) and Systemic Phenylephrine on Arterial Oxygenation During One Lung Ventilation [NCT02748265]	Phase 4	8 participants (Actual)	Interventional	2016-03-31	Completed
Blood Pressure or Cardiac Output - the Influence on Cerebral Perfusion During Cardiopulmonary Bypass [NCT02806492]		15 participants (Actual)	Interventional	2016-01-31	Completed
Exploration of Pupil Dilation in Horner's Patients Taking Flomax [NCT03615508]	Phase 4	1 participants (Actual)	Interventional	2018-09-21	Terminated(stopped due to incomplete enrollment)
Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C [NCT02885168]	Phase 4	30 participants (Actual)	Interventional	2008-02-29	Completed
Acoustic Rhinometry: Impact of External Nasal Dilator on the Two First Notches of the Rhinogram [NCT01411969]		16 participants (Actual)	Observational	2010-06-30	Completed
A Double-blind, Randomised, Placebo-controlled Study to Evaluate Topical 10% Phenylephrine Gel in the Management of Ileal Pouch Anal Anastomosis (IPAA)-Related Faecal Incontinence [NCT00420797]	Phase 3	0 participants (Actual)	Interventional	2007-02-28	Withdrawn(stopped due to Terminated, new protocol to be developed)
The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery [NCT01431612]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2008-11-30	Completed
Development of Advanced Double Intravenous Vasopressor Automated (ADIVA) System With Improved Hemodynamic Trend Control During Spinal Anaesthesia for Caesarean Section [NCT03620942]		173 participants (Actual)	Interventional	2018-11-07	Active, not recruiting
A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries: a Randomized Controlled Study [NCT02962986]		112 participants (Actual)	Interventional	2017-01-31	Completed
Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure [NCT00874120]	Phase 3	116 participants (Actual)	Interventional	2008-12-31	Completed
The Effect of Phenylephrine, Norepinephrine and Vasopressin on Cerebral Oxygentaion During Off Pump CABG: A Pilot Study [NCT04214145]		90 participants (Actual)	Interventional	2020-01-07	Completed
The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope [NCT04972123]	Phase 2	140 participants (Actual)	Interventional	2021-07-20	Completed
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction During Spinal Anesthesia for Cesarean Section and Its Relation to the Effect of Prophylaxis Phenylephrine [NCT02958215]	Phase 2	980 participants (Actual)	Interventional	2016-06-30	Completed
PET Detection of the Effects of Aging on the Human Heart. Aim#1-Impact of Aging on Myocardial Remodeling: Role of Nitric Oxide [NCT00603720]		54 participants (Actual)	Interventional	2005-09-30	Completed
A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability to Improve Perioperative Outcome During Spinal Anaesthesia for Caesarean Section [NCT02277730]	Phase 2/Phase 3	252 participants (Actual)	Interventional	2013-05-31	Completed
Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean [NCT02245191]		60 participants (Actual)	Interventional	2014-07-31	Active, not recruiting
Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris [NCT04040790]		10 participants (Actual)	Interventional	2019-09-16	Terminated(stopped due to Several reasons: Financing ended before all study assessments were performed, covid-19 delayed design, production and shipment of IMD, experience gained during the study made it clear that lens design should be changed)
Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia. [NCT05001048]		14 participants (Actual)	Interventional	2019-08-04	Completed
A Proof of Concept Study to Evaluate Differential Tachyphylaxis of Alpha 1 and Alpha 2 Adrenoreceptor Mediated Decongestant Response to Oxymetazoline and Its Acute Reversal by Corticosteroid in Healthy Volunteers [NCT00487032]	Phase 4	19 participants (Actual)	Interventional	2008-05-31	Completed
Randomised, Double-blind, Phase IV Study to Compare the Incidence of ECG Changes During Elective Caesarean Section Under Spinal Anaesthesia When Using Phenylephrine or Ephedrine Infusion to Maintain Baseline Systolic Blood Pressure [NCT01243970]	Phase 4	29 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Change in clinical practice since the start of the trial in 2011 (phenylephrine superior))
2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides [NCT00501878]	Phase 4	100 participants (Actual)	Interventional	2007-05-31	Completed
A Double-blind, Randomized, Placebo Controlled Study, Comparing Oxymetazoline 1% Cream TO RHOFADE in the Treatment of Moderate to Severe Persistent Facial Erythema Assocoated With Rosacea [NCT05148689]	Phase 1	82 participants (Actual)	Interventional	2018-02-23	Completed
Epinephrine Versus Phenylephrine Infusion for Prophylaxis Against Maternal Hypotension After Spinal Anesthesia for Cesarean Delivery: a Randomized Controlled Trial. [NCT05881915]		196 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury [NCT00624650]	Phase 2	33 participants (Actual)	Interventional	2008-02-29	Completed
Comparison of Phenylephrine and Ephedrine in the Treatment of Hemodynamic Disorders After Spinal Anesthesia in the Elderly [NCT03858465]		50 participants (Actual)	Interventional	2019-02-01	Completed
Variability in Adrenergic Response [NCT00838695]		106 participants (Actual)	Interventional	2009-01-31	Completed
A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults [NCT01660893]	Phase 3	26 participants (Actual)	Interventional	2012-08-31	Terminated
Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity [NCT00240058]		22 participants (Actual)	Interventional	2005-07-31	Completed
Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation [NCT00120432]	Phase 3	80 participants (Actual)	Interventional	2004-12-31	Completed
Evaluating the Severity of Mitral Regurgitation Using Phenylephrine During Transesophageal Echocardiography [NCT04500899]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2020-12-01	Recruiting
Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions [NCT00431392]	Phase 2	42 participants	Interventional	2001-09-30	Completed
The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section [NCT01216410]		306 participants (Actual)	Interventional	2008-12-31	Completed
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences [NCT05997732]	Phase 4	30 participants (Anticipated)	Interventional	2023-10-31	Recruiting
National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment of Symptoms Associated With Common Cold [NCT02904304]	Phase 3	150 participants (Anticipated)	Interventional	2020-12-31	Suspended(stopped due to the viability of the study is being analyzed)
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion [NCT00584662]		42 participants (Actual)	Interventional	2005-01-31	Terminated
Induced Hypertension for Acute Ischemic Stroke [NCT00227448]	Phase 2	60 participants	Interventional	2003-06-30	Completed
Effects of Phenylephrine on Systemic and Regional Hemodynamics in Patients With Septic Shock: a Crossover Pilot Study [NCT00481442]	Phase 2	15 participants (Actual)	Interventional	2007-01-31	Completed
Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery or Adenoidectomy [NCT02453841]		30 participants (Actual)	Interventional	2015-12-31	Completed
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study [NCT04838665]	Phase 4	60 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized Controlled Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients [NCT02203630]	Phase 4	17 participants (Actual)	Interventional	2014-08-31	Terminated(stopped due to Slow enrollment; Lack of support and equipoise)
Phase 2 Study Evaluating the Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia for Lower Limb Orthopedic Surgery in the Elderly Patients [NCT01533662]	Phase 2	64 participants (Actual)	Interventional	2011-03-31	Completed
A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea [NCT02095158]	Phase 3	440 participants (Actual)	Interventional	2014-04-30	Completed
Mechanisms of Vasovagal Syncope [NCT01791816]	Early Phase 1	90 participants (Anticipated)	Interventional	2013-02-28	Active, not recruiting
Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size [NCT02895035]	Phase 4	59 participants (Actual)	Interventional	2016-09-01	Terminated(stopped due to Data analysis was never performed by sub-investigator)
Norepinephrine and Phenylephrine for Cesarean Section [NCT02969239]	Phase 4	50 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel for Control of Pain of Dental Needle Insertion in the Palate [NCT00846690]	Phase 4	20 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Comparison of Phenylephrine Infusion With Colloids vs. Crystalloids for Reduction of Spinal-induced Hypotension During Cesarean Section [NCT00846651]	Phase 4	82 participants (Actual)	Interventional	2009-02-28	Completed
A Proof of Concept Study to Evaluate if Concomitant Topical Intranasal Steroid Prevents Tolerance and Rebound Congestion Due to Regular Oxymetazoline in Persistent Allergic Rhinitis. [NCT00846326]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to The suppliers were unable to provide the investigational medicinal product (IMP))
A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke (HOPE Study) [NCT04892511]	Phase 4	814 participants (Anticipated)	Interventional	2021-06-01	Recruiting
[NCT00225043]		60 participants (Actual)	Interventional	2005-06-30	Completed
Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant [NCT03590912]	Phase 4	160 participants (Actual)	Interventional	2018-09-05	Completed
Closed-loop Double-vasopressor Automated System vs Manual Bolus Vasopressor to Treat Hypotension During Spinal Anaesthesia for Caesarean Section [NCT04025918]	Phase 2/Phase 3	216 participants (Actual)	Interventional	2011-10-31	Completed
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients [NCT02701582]		66 participants (Actual)	Interventional	2014-03-31	Completed
Decision Support for Intraoperative Low Blood Pressure [NCT02726620]		22,435 participants (Actual)	Interventional	2017-01-05	Completed
Comparison of the Effects of Norepinephrine and Phenylephrine on Tissue Oxygenation and Hemodynamic Stability During an SVV Fluid Guided Therapy in Elderly Undergoing Radical Resection of Colon Cancer Surgery [NCT03215797]	Phase 3	40 participants (Actual)	Interventional	2016-09-30	Completed
Comparison of Two Different Doses of Intramuscular Phenylephrine HCL for Prevention of Spinal Anesthesia Induced Hypotension During Cesarean Section: A Prospective Randomized Double-blinded Parallel Study [NCT05348980]	Phase 4	60 participants (Actual)	Interventional	2020-01-01	Completed
Maternal Cardiac Output Response to Rescue Norepinephrine and Phenylephrine Boluses During Spinal Anesthesia for Caesarean Section in Patients With Severe Preeclampsia: a Randomized, Controlled Trial [NCT05035485]		32 participants (Anticipated)	Interventional	2022-09-13	Recruiting
Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia [NCT02025426]	Phase 4	13 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Significant challenges recruiting a difficult patient population with most surgeries occurring out of hours)
Antitussive Effect of a Naturally Flavored, Multi-Component Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo [NCT02062710]	Phase 4	22 participants (Actual)	Interventional	2014-01-31	Completed
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial. [NCT02285634]		68 participants (Actual)	Interventional	2014-11-30	Completed
Camillian Saint Mary's Hospital Luodong [NCT05348148]		450 participants (Anticipated)	Interventional	2020-06-16	Recruiting
Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia [NCT00199784]	Phase 4	80 participants (Anticipated)	Interventional	2005-06-30	Completed
Comparison of the Effects of Phenylephrine and Norepinephrine on Cardiac Function During Carotid Cross-Clamping During Carotid Endarterectomy Under General Anesthesia [NCT00294606]		86 participants	Interventional	2006-02-28	Recruiting
A Comparison Between Phenylephrine and Norepinephrine Boluses in Prevention of Post-spinal Hypotension During Cesarean Delivery [NCT03015857]	Phase 2	200 participants (Actual)	Interventional	2017-01-31	Completed
The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine [NCT01509521]	Phase 4	24 participants (Anticipated)	Interventional	2012-02-29	Completed
Open Label, Three-Way Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride and Multiple Doses of Fluticasone Propionate on the Absorption and Tolerab [NCT01365650]	Phase 1	24 participants (Actual)	Interventional	2007-12-31	Completed
A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies [NCT01332578]	Phase 4	25 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis [NCT01848041]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2013-05-31	Completed
Descemet Endothelial Thickness Comparison Trial [NCT02373137]	Phase 4	38 participants (Actual)	Interventional	2015-01-22	Active, not recruiting
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea [NCT03352323]	Phase 3	50 participants (Actual)	Interventional	2017-10-18	Completed
Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With [NCT00552110]	Phase 2	707 participants (Actual)	Interventional	2007-07-31	Completed
Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy [NCT01048125]		2 participants (Actual)	Interventional	2009-08-31	Terminated(stopped due to Due to difficulty in recruitment and resource restraints)
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening: a Non-inferiority Crossover Randomized Controlled Trial (MyMiROPS Trial) [NCT05043077]	Phase 4	83 participants (Actual)	Interventional	2021-09-07	Completed
A Phase 2, Single-Center, Open-Label, Randomized, Parallel-Groups, Dose-Ranging Study to Assess the Efficacy and Safety of Intranasally Administered Kovacaine Mist for Anesthetizing Maxillary Teeth in Pediatric Subjects [NCT01701505]	Phase 2	48 participants (Actual)	Interventional	2012-10-31	Completed
A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults [NCT01710787]	Phase 3	110 participants (Actual)	Interventional	2012-10-31	Completed
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) [NCT01275105]	Phase 2	68 participants (Actual)	Interventional	2011-01-31	Completed
Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes [NCT02965924]		20 participants (Actual)	Interventional	2016-10-31	Completed
A Randomized, Double-Blind, Single-Center, 5 Way Cross-Over Study to Assess the Effect of Adding Oral Phenylephrine and Oral Sorbitol to Low Dose (1.5 mg) Plain Oral Morphine in Human Volunteers: Analgesia and Side Effect Assessment. [NCT00374881]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2006-09-30	Completed
The Effect of Phenylephrine Versus Ephedrine on Cerebral Perfusion During Carotid Endarterectomy [NCT01451294]		40 participants (Anticipated)	Interventional	2011-11-30	Not yet recruiting
Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery [NCT03228914]	Phase 4	20 participants (Actual)	Interventional	2018-06-14	Completed
[NCT02132117]	Phase 3	445 participants (Actual)	Interventional	2014-06-30	Completed
Norepinephrine Versus Phenylephrine Infusion for Prophylaxis Against Spinal Induced Hypotension in Elderly Undergoing Hip Arthroplasty Under Spinal Anesthesia: A Randomized Comparative Trial [NCT04195321]	Phase 4	62 participants (Actual)	Interventional	2020-01-01	Completed
A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing U [NCT02132312]	Phase 3	78 participants (Actual)	Interventional	2014-07-31	Completed
A Phase I, Open-Label, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intra-anal Application of Topical Oxymetazoline Gel in Healthy Adult Volunteers [NCT03529487]	Phase 1	40 participants (Anticipated)	Interventional	2018-08-20	Active, not recruiting
A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients [NCT01302483]	Phase 2	45 participants (Actual)	Interventional	2008-12-31	Completed
Middle Ear Pressure Regulation in Health and Disease -- Gas Supply, Demand and Middle Ear Gas Balance -- Specific Aim 2 [NCT01925729]	Phase 1	84 participants (Actual)	Interventional	2013-10-01	Completed
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Palpebral Fissure Height, Eye Redness, and Patient-reported Eye Appearance [NCT04831047]	Phase 4	114 participants (Actual)	Interventional	2021-06-08	Completed
The Effects of Height and Weight Adjusted Dose of Local Anesthetic Compared to Standard Dose for Spinal Anesthesia in Elective Cesarean Section [NCT02635555]		160 participants (Actual)	Interventional	2016-04-30	Completed
A Single-Center, Open-Label, Observer-Masked, Active-Controlled, Phase 2 Study of the Safety, Efficacy and Pharmacokinetics of EYN-1601 in Dilation of the Pupil [NCT02946125]	Phase 2	12 participants (Actual)	Interventional	2016-10-31	Completed
An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respirator [NCT01576809]	Phase 3	51 participants (Actual)	Interventional	2012-03-31	Completed
Methylene Blue as a Third-line Vasopressor in Septic Shock to Maintain Hemodynamics [NCT04089072]	Phase 2	250 participants (Anticipated)	Interventional	2019-12-01	Recruiting
[NCT01813149]		128 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. There is no data collected)
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis [NCT02436759]	Phase 3	140 participants (Actual)	Interventional	2015-05-31	Completed
A SingleDose Rand, TwoPeriod, Crossover Bioequivalence Study Between a Combination Tablet With Paracetamol, Guaifenesin and Penylephrine HCL (Wrafton Lab Ltd, UK) and Vicks Active SymptoMax Plus, Powder for Oral Solution (Wrafton Lab Ltd, UK) in Healthy A [NCT03213353]	Phase 1	72 participants (Actual)	Interventional	2017-07-03	Completed
Optimal Method for Mydriasis in Cataract Surgery [NCT02909140]		3 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to insufficient patient recruitment)
Effects of Norepinephrine vs. Phenylephrine on the Graft Blood Flow Measured by Transit Time Flowmetry in Breast Reconstruction With Free Flap Transfer Surgery: a Pilot Study [NCT05049278]		20 participants (Actual)	Interventional	2021-09-24	Completed
Effectivenes of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery: a Randomised Controlled Trial [NCT02979405]	Phase 4	140 participants (Actual)	Interventional	2017-01-17	Completed
Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial [NCT01731444]	Phase 1	24 participants (Anticipated)	Interventional	2014-12-01	Recruiting
Cardiac Index Changes With Ephedrine, Phenylephrine, Ondansetron and Norepinephrine During Spinal Anesthesia for Cesarian Section [NCT03421860]	Phase 4	120 participants (Actual)	Interventional	2017-02-23	Completed
A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients [NCT01481740]	Phase 4	178 participants (Actual)	Interventional	2010-11-30	Completed
Phenylephrine Dose-Finding Study to Minimize Hypotension Due to Spinal Anesthesia for Cesarean Section [NCT00379691]		50 participants	Interventional	2006-08-31	Completed
Optimal Vasopressor Titration Pilot Randomized Controlled Trial [NCT01800877]		120 participants (Actual)	Interventional	2013-04-30	Completed
Effectiveness of Oxymetazoline Added on Intranasal Steroid in the Treatment of Allergic and Nonallergic Rhinitis With Persistent Nasal Obstruction [NCT01847131]	Phase 4	50 participants (Actual)	Interventional	2013-04-30	Completed
Phenylephrine vs. Norepinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Delivery [NCT02354833]	Phase 4	85 participants (Actual)	Interventional	2014-08-31	Completed
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors [NCT03592121]	Early Phase 1	3 participants (Actual)	Interventional	2018-07-09	Completed
Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain [NCT04829799]	Phase 4	0 participants (Actual)	Interventional	2022-02-28	Withdrawn(stopped due to Per study team, the study will not proceed)
A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis [NCT00373802]	Phase 2	50 participants	Interventional	2005-01-31	Completed
A Single Dose, Open Label, Randomized Scintigraphic Study to Investigate the Gastrointestinal Behavior of 2 Triple Combination Products (Acetaminophen, Phenylephrine and Dextromethorphan) in Healthy Male Volunteers [NCT03415243]	Phase 1	28 participants (Actual)	Interventional	2018-03-01	Completed
Comparison of the Effect of Epinephrine, Norepinephrine and Phenylephrine on Spinal Anesthesia Induced Hypotension [NCT03163914]	Phase 4	160 participants (Actual)	Interventional	2017-07-19	Completed
Maternal Microcirculation & SDF Imaging: A Novel Assessment of the Microcirculation During Cesarean Delivery With Spinal Anesthesia and the Impact of Phenylephrine Prophylaxis to Prevent Spinal Anesthesia-induced Hypotension. [NCT02376192]	Phase 4	32 participants (Actual)	Interventional	2014-01-31	Completed
Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity [NCT04436731]	Early Phase 1	104 participants (Anticipated)	Interventional	2020-12-09	Recruiting
Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery. Prospective Randomised Controlled and Single Centre Trial [NCT01794273]	Phase 4	80 participants (Actual)	Interventional	2012-07-31	Completed
Comparison of Pilocarpine, Brimonidine, Oxymetazoline, Hialuronic Acid, Bromfenac Ophthalmic Compound With Pilocarpine and Brimonidine to Improve Uncorrected Visual Acuity in Healthy Presbyopic Individuals [NCT05001243]	Phase 1	11 participants (Anticipated)	Interventional	2021-08-10	Recruiting
Three Protocols for Phenylephrine Administration for Prophylaxis Against Post-spinal Hypotension During Cesarean Delivery [NCT03302039]	Phase 4	217 participants (Actual)	Interventional	2017-10-06	Completed
Ephedrine Versus Phenylephrine Infusion for Prevention of Spinal Hypotension During Cesarean Section: Effect on Maternal Cardiodynamics and Fetal Circulation: Randomized Double-blind Study [NCT03047109]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2017-02-07	Completed
Comparison of Intravenous Phenylephrine and Norepinephrine for Treatment of Spinal-induced Hypotension in Caesarian Deliveries [NCT04789005]	Phase 3	80 participants (Actual)	Interventional	2019-11-10	Completed
Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support, a Randomized Controlled Double- [NCT02414555]	Phase 4	60 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Patient Safety)
Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia Undergoing Cesarean Section: a Randomized, Controlled Trial [NCT04556357]		138 participants (Actual)	Interventional	2020-09-22	Completed
A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congesti [NCT01448057]	Phase 3	341 participants (Actual)	Interventional	2013-07-31	Completed
NIRS-Based Cerebral Oximetry Monitoring in Elderly Thoracic Surgical Patients Undergoing Single Lung Ventilation Procedures: A Single Center, Prospective, Randomized Controlled Pilot Study Assessing the Clinical Impact of NIRS-Guided Intervention [NCT01866657]		74 participants (Actual)	Interventional	2013-06-30	Terminated(stopped due to Funding)
Colloid Co-hydration and Vasoconstrictor Infusion for Prevention of Postspinal Hypotension During Elective Cesarean Section. A Comparative Study [NCT04404946]		120 participants (Actual)	Interventional	2020-05-23	Completed
GUARDIAN (NCT04884802) Sub-study Comparing Phenylephrine and Norepinephrine [NCT04934748]	Phase 4	6,254 participants (Anticipated)	Interventional	2021-07-15	Enrolling by invitation
"Haemodynamic Stability During Induction of General Anesthesia With Propofol and Remifentanil: A Randomized, Controlled, Double-blind Study Comparing Equipotent Prophylactic Doses of Ephedrine, Phenylephrine, Norepinephrine vs Placebo." [NCT03864094]	Phase 4	99 participants (Anticipated)	Interventional	2022-03-15	Recruiting
The Choice of Vasopressor for Treating Hypotension During General Anesthesia: a Pilot Pragmatic Cluster Cross-over Randomized Trial (the VEGA-1 Trial) [NCT04789330]	Phase 4	2,000 participants (Actual)	Interventional	2021-07-01	Completed
Hemodynamic Effect of Prophylactic Phenylephrine Versus Lower Limb Compression in Women During Caesarean Section Under Spinal Anaesthesia [NCT01278238]		120 participants (Actual)	Interventional	2010-01-31	Completed
Phenylephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia Undergoing Cesarean Section: a Randomized, Placebo-controlled Dose-finding Trial [NCT04576663]		95 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia [NCT05006911]	Phase 1	11 participants (Anticipated)	Interventional	2021-08-14	Recruiting
A Randomized, Placebo- and Benchmark-controlled, Double-blind Clinical Trial of Anusol Topical Ointment to Evaluate Symptom Relief in Patients With Haemorrhoids [NCT05157711]	Phase 3	66 participants (Actual)	Interventional	2021-11-25	Completed
Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery [NCT04602767]	Phase 4	260 participants (Anticipated)	Interventional	2020-10-15	Recruiting
A Single Center, Pilot Study of Induced Hypertension for Minimizing Infarct Progression in Patients With Acute Large-vessel Occlusion Ischemic Stroke Undergoing Endovascular Therapy [NCT04218773]	Early Phase 1	40 participants (Anticipated)	Interventional	2020-09-11	Enrolling by invitation
A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis [NCT01413958]	Phase 3	575 participants (Actual)	Interventional	2011-08-31	Completed
Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension in Patients Undergoing Caesarean Section: A Randomized Sequential Allocation Dose-finding Study. [NCT05035888]		80 participants (Actual)	Interventional	2022-09-05	Completed
The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of The Highest Phase 3 Dose Of Kovacaine™ Mist To Healthy Volunteers [NCT01807624]	Phase 2	24 participants (Actual)	Interventional	2013-03-31	Completed
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Tri [NCT02630121]	Phase 4	52 participants (Anticipated)	Interventional	2023-04-30	Recruiting
A Non-randomized Experimental Study of Optically Registered Pharmacodynamic Responses During Iontophoresis of Vasoactive Substances to the Skin of Healthy Volunteers [NCT04777383]		90 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment [NCT03502135]	Phase 4	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to study drug not available in time)
Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (≥12 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia [NCT02323399]	Phase 4	100 participants (Anticipated)	Interventional	2015-02-28	Recruiting
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery [NCT05158699]	Phase 3	808 participants (Anticipated)	Interventional	2021-10-13	Recruiting
The Impact of Carbon Monoxide and Altitude on Vascular Function [NCT04928183]		19 participants (Actual)	Interventional	2021-06-10	Completed
Crystalloid Coload Combined With Variable Rate Phenylephrine Infusion for Prevention of Hypotension During Spinal Anesthesia for Elective Cesarean Delivery vs Crystalloid Coload Alone [NCT01378325]	Phase 4	80 participants (Actual)	Interventional	2012-07-31	Completed
Maternal Haemodynamic Changes After Crystalloid Co-loading and Phenylephrine Versus Phenylephrine Alone During Spinal Anaesthesia for Elective Caesarean Delivery: a Double-blind, Randomised Controlled Trial Using the Non Invasive Cardiac Output Monitor St [NCT04026685]		66 participants (Actual)	Interventional	2020-01-09	Completed
The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2) [NCT02673996]		125 participants (Anticipated)	Observational	2016-01-31	Recruiting
90% Effective Dose of Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive and Standard Treatment in Preeclamptic Patients During Cesarean Section [NCT06151470]		80 participants (Anticipated)	Interventional	2025-07-01	Not yet recruiting
Comparison of Two Vasopressor Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Trial [NCT03248791]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-20	Recruiting
A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and Cold [NCT05118672]	Phase 3	478 participants (Anticipated)	Interventional	2024-08-30	Not yet recruiting
Effect of Target Intraoperative Blood Pressure on the Incidence of Post-operative Cognitive Dysfunction in Patients Aged 75 and Older Undergoing General Anesthesia for Non-cardiac Surgery: an International Multicenter Randomized Controlled Trial [NCT02428062]	Phase 2/Phase 3	1,812 participants (Anticipated)	Interventional	2014-10-31	Suspended(stopped due to Pending Pilot study results evaluation)
Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS). [NCT03846765]	Phase 4	36 participants (Actual)	Interventional	2019-07-04	Completed
A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients [NCT01844830]	Phase 3	90 participants (Actual)	Interventional	2013-05-31	Completed
A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Placebo for Anesthetizing Maxillary Teeth in Adults [NCT01745380]	Phase 3	150 participants (Actual)	Interventional	2013-02-28	Completed
Evaluation of Patients After Cardiac Surgery: Novel Ultrasound Parameters for Quantification of Renal Perfusion & Analysis of Phenylephrines' Effect on Invasive Haemodynamics and Echocardiographic Measures [NCT04419662]	Phase 4	30 participants (Actual)	Interventional	2020-05-25	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00276016 (2) [back to overview]	The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Pseudoephedrine and Placebo.
NCT00276016 (2) [back to overview]	The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo
NCT00356265 (1) [back to overview]	α1-adrenoceptor Vasoreactivity With L-NMMA
NCT00458003 (2) [back to overview]	The Umbilical Artery pH
NCT00458003 (2) [back to overview]	The Umbilical Artery Blood Base Excess
NCT00552110 (2) [back to overview]	Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score
NCT00552110 (2) [back to overview]	Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15
NCT00584987 (6) [back to overview]	RQLQ Score [6 Weeks]
NCT00584987 (6) [back to overview]	RQLQ Score [Baseline]
NCT00584987 (6) [back to overview]	Total Nasal Congestion Symptom Score
NCT00584987 (6) [back to overview]	Total NPIF
NCT00584987 (6) [back to overview]	RQLQ Score [2 Weeks]
NCT00584987 (6) [back to overview]	RQLQ Score [4 Weeks]
NCT00603720 (1) [back to overview]	Effect of NO Inhibition on Myocardial Substrate Metabolism in Humans
NCT00796328 (1) [back to overview]	Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension
NCT00838695 (2) [back to overview]	ED50 After Phenylephrine
NCT00838695 (2) [back to overview]	Change in Blood Pressure
NCT00846651 (5) [back to overview]	APGAR Scores
NCT00846651 (5) [back to overview]	Dosage of Phenylephrine Used
NCT00846651 (5) [back to overview]	Incidence of Maternal Bradycardia
NCT00846651 (5) [back to overview]	Incidence of Maternal Hypotension
NCT00846651 (5) [back to overview]	Incidence of Maternal Nausea and Vomiting
NCT00874120 (1) [back to overview]	Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).
NCT00976209 (2) [back to overview]	Percentage of Participants That Preferred the Convenience of Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets
NCT00976209 (2) [back to overview]	Percentage of Participants That Preferred Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets for the Relief of Nasal Congestion
NCT01080625 (1) [back to overview]	Occurrence of Postreperfusion Syndrome (PRS)
NCT01216410 (5) [back to overview]	Pruritus
NCT01216410 (5) [back to overview]	Maternal Hemodynamics
NCT01216410 (5) [back to overview]	Intraoperative Nausea and Vomiting
NCT01216410 (5) [back to overview]	Satisfaction
NCT01216410 (5) [back to overview]	Postoperative Nausea and Vomiting (PONV)
NCT01302483 (5) [back to overview]	Maximum Change in Pulse Oximetry From Baseline
NCT01302483 (5) [back to overview]	Pulpal Anesthesia
NCT01302483 (5) [back to overview]	Maximum Change in Pulse From Baseline
NCT01302483 (5) [back to overview]	Maximum Change in Blood Pressure From Baseline
NCT01302483 (5) [back to overview]	Soft Tissue Anesthesia Duration
NCT01304316 (9) [back to overview]	Cmax of PBBA
NCT01304316 (9) [back to overview]	Cmax of Tetracaine
NCT01304316 (9) [back to overview]	Diastolic BP Maximum Change From Baseline
NCT01304316 (9) [back to overview]	Half Life of Oxymetazoline
NCT01304316 (9) [back to overview]	Pulse Oximetry Maximum Change From Baseline
NCT01304316 (9) [back to overview]	Pulse Rate Maximum Change From Baseline
NCT01304316 (9) [back to overview]	Systolic BP Maximum Change From Baseline
NCT01304316 (9) [back to overview]	Cmax of Oxymetazoline
NCT01304316 (9) [back to overview]	Half Life of PBBA
NCT01330017 (8) [back to overview]	Mean Change From Baseline in the a.m. Symptom Score for the Instantaneous Nasal Symptom Assessment by Study Day of the Treatment Period
NCT01330017 (8) [back to overview]	Mean Change From Baseline for the Instantaneous Nasal Symptom Assessment Score By Study Day of the Treatment Period
NCT01330017 (8) [back to overview]	Mean Change From Baseline for the Daily Reflective Nasal Symptom Assessment Score by Study Day of the Treatment Period
NCT01330017 (8) [back to overview]	Time to Maximal Effect
NCT01330017 (8) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score
NCT01330017 (8) [back to overview]	Change From Baseline for the Instantaneous Nasal Symptom Assessment Score at Day 7
NCT01330017 (8) [back to overview]	Mean Change From Baseline in the Morning (a.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period
NCT01330017 (8) [back to overview]	Mean Change From Baseline in the Evening (p.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period
NCT01332578 (8) [back to overview]	Area Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min)
NCT01332578 (8) [back to overview]	AUC (0-60 Min)
NCT01332578 (8) [back to overview]	Maximum Plasma Concentration (Cmax)
NCT01332578 (8) [back to overview]	Time to Completion of Gastric Emptying
NCT01332578 (8) [back to overview]	Time to Maximum Plasma Concentration (Tmax)
NCT01332578 (8) [back to overview]	Time to Onset of Gastric Emptying
NCT01332578 (8) [back to overview]	Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter)
NCT01332578 (8) [back to overview]	Time to Onset and Completion of Disintegration of Reference Tablets
NCT01365650 (6) [back to overview]	AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose)
NCT01365650 (6) [back to overview]	t1/2z (the Terminal Half-life, Where Possible)
NCT01365650 (6) [back to overview]	AUC 0-∞ (the AUC From Time Zero to Infinity, Where Possible)
NCT01365650 (6) [back to overview]	MRT (the Mean Residence Time)
NCT01365650 (6) [back to overview]	Cmax (the Maximum Observed Plasma Concentration)
NCT01365650 (6) [back to overview]	Tmax (the Time to Maximum Concentration)
NCT01378325 (1) [back to overview]	Number of Physician Interventions Needed to Maintain Maternal Blood Pressure After Spinal Anesthesia Within 20% of Baseline and to Treat Bradycardia During Cesarean Delivery.
NCT01413958 (14) [back to overview]	Mean Change From Baseline in Daily Instantaneous Symptom Assessment Score Per Day
NCT01413958 (14) [back to overview]	Mean Change From Baseline in Daily Instantaneous Symptom Assessment Score
NCT01413958 (14) [back to overview]	Mean Change From Baseline for the Morning Reflective Symptom Assessment Scores for Each Day During the Treatment Period.
NCT01413958 (14) [back to overview]	Mean Change From Baseline for the Morning Instantaneous Symptom Assessment Scores for Each Day During the Treatment Period
NCT01413958 (14) [back to overview]	Mean Change From Baseline for the Evening Reflective Symptom Assessment Scores for Each Day During the Treatment Period
NCT01413958 (14) [back to overview]	Day 7 Mean Change From Baseline in Daily Instantaneous Symptom Assessment Score
NCT01413958 (14) [back to overview]	Time to Maximal Phenylephrine Effect
NCT01413958 (14) [back to overview]	Mean Change From Baseline for the Evening Instantaneous Symptom Assessment Scores for Each Day During the Treatment Period.
NCT01413958 (14) [back to overview]	Mean Change From Baseline in the Evening Reflective Symptom Assessment Score
NCT01413958 (14) [back to overview]	Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities (RQLQ)
NCT01413958 (14) [back to overview]	Mean Change From Baseline in the Morning Reflective Symptom Assessment Score
NCT01413958 (14) [back to overview]	Mean Change From Baseline in Morning Predose Instantaneous Nasal Congestion Symptom Score
NCT01413958 (14) [back to overview]	Mean Change From Baseline in Daily Reflective Nasal Congestion Score Per Day
NCT01413958 (14) [back to overview]	Mean Change From Baseline in Daily Reflective Nasal Congestion Score
NCT01448057 (2) [back to overview]	Physician Global Evaluation of Effectiveness on Nasal Symptoms
NCT01448057 (2) [back to overview]	Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms
NCT01481740 (6) [back to overview]	Neonatal Acidosis
NCT01481740 (6) [back to overview]	Incidence of Nausea and Vomiting
NCT01481740 (6) [back to overview]	Incidence of Nausea and Vomiting
NCT01481740 (6) [back to overview]	Incidence of Nausea and Vomiting
NCT01481740 (6) [back to overview]	Incidence of Hypotension
NCT01481740 (6) [back to overview]	Incidence of Hypotension
NCT01576809 (3) [back to overview]	Safety and Tolerability of the Syrup
NCT01576809 (3) [back to overview]	Subject Acceptability of the Syrup
NCT01576809 (3) [back to overview]	Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup
NCT01660893 (14) [back to overview]	Number of Participants With Heart Rate Higher Than 125 Bpm
NCT01660893 (14) [back to overview]	Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 90 mm Hg
NCT01660893 (14) [back to overview]	Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg
NCT01660893 (14) [back to overview]	Alcohol Sniff Test
NCT01660893 (14) [back to overview]	Completion of the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic (Yes/no).
NCT01660893 (14) [back to overview]	Absolute Maximum Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
NCT01660893 (14) [back to overview]	Number of Participants With Heart Rate Lower Than 50 Bpm
NCT01660893 (14) [back to overview]	Absolute Maximum Change From Baseline in Heart Rate
NCT01660893 (14) [back to overview]	Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg
NCT01660893 (14) [back to overview]	Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg
NCT01660893 (14) [back to overview]	The Profile Over Time of Heart Rate
NCT01660893 (14) [back to overview]	The Profile Over Time of Systolic Blood Pressure
NCT01660893 (14) [back to overview]	The Profile Over Time of Diastolic Blood Pressure
NCT01660893 (14) [back to overview]	Intraoral Soft-tissue Anesthesia (Yes/no)
NCT01701505 (10) [back to overview]	Incidence of Adverse Events by Dose Level Regardless of Age
NCT01701505 (10) [back to overview]	Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic.
NCT01701505 (10) [back to overview]	Number of Participants With Adverse Events by Dose Level and Age
NCT01701505 (10) [back to overview]	Number of Participants With Adverse Events by Dose Level and Age
NCT01701505 (10) [back to overview]	Systolic Blood Pressure
NCT01701505 (10) [back to overview]	Number of Participants With Adverse Events by Dose Level and Age
NCT01701505 (10) [back to overview]	Oxygen Saturation
NCT01701505 (10) [back to overview]	Heart Rate
NCT01701505 (10) [back to overview]	Naris Examination (NE) to Assess Reactions to the Study Drug.
NCT01701505 (10) [back to overview]	Diastolic Blood Pressure
NCT01710787 (16) [back to overview]	The Profile Over Time of Systolic Blood Pressure
NCT01710787 (16) [back to overview]	The Profile Over Time of Heart Rate
NCT01710787 (16) [back to overview]	The Profile Over Time of Diastolic Blood Pressure
NCT01710787 (16) [back to overview]	Intraoral Soft-tissue Anesthesia (Yes/no)
NCT01710787 (16) [back to overview]	Intraoral Soft-tissue Anesthesia (Onset and Duration)
NCT01710787 (16) [back to overview]	Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and to a Value Higher Than 160 mm Hg
NCT01710787 (16) [back to overview]	Number of Participants With a Heart Rate Lower Than 50 Bpm
NCT01710787 (16) [back to overview]	Number of Participants With a Heart Rate Higher Than 125 Bpm
NCT01710787 (16) [back to overview]	Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Lower Than 90 mm Hg
NCT01710787 (16) [back to overview]	Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 10 mm Hg and to a Value Lower Than 50 mm Hg
NCT01710787 (16) [back to overview]	Number of Participants Who Completed the Study Dental Procedure After Without Need for Rescue by Injection of Local Anesthetic.
NCT01710787 (16) [back to overview]	Absolute Maximum Change From Baseline in Systolic Blood Pressure
NCT01710787 (16) [back to overview]	Absolute Maximum Change From Baseline in Heart Rate
NCT01710787 (16) [back to overview]	Absolute Maximum Change From Baseline in Diastolic Blood Pressure
NCT01710787 (16) [back to overview]	Alcohol Sniff Test
NCT01710787 (16) [back to overview]	Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and to a Value Higher Than 105 mm Hg
NCT01745380 (16) [back to overview]	Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic.
NCT01745380 (16) [back to overview]	Maximum Change From Baseline in Diastolic Blood Pressure
NCT01745380 (16) [back to overview]	The Profile Over Time of Heart Rate
NCT01745380 (16) [back to overview]	The Profile Over Time of Diastolic Blood Pressure
NCT01745380 (16) [back to overview]	Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic by Age Group (≤50 and >50 Years)
NCT01745380 (16) [back to overview]	Number of Participants With an Increase From Baseline in Systolic Blood Pressure Greater Than or Equal to 25 mm Hg and/or to a Value Higher Than 160 mm Hg
NCT01745380 (16) [back to overview]	Number of Participants With an Increase From Baseline in Diastolic Blood Pressure Greater Than or Equal to 15 mm Hg and/or to a Value Higher Than 105 mm Hg
NCT01745380 (16) [back to overview]	Number of Participants With a Heart Rate Lower Than 50 Bpm
NCT01745380 (16) [back to overview]	Number of Participants With a Heart Rate Higher Than 125 Bpm
NCT01745380 (16) [back to overview]	Number of Participants With a Decrease From Baseline in Systolic Blood Pressure Greater Than or Equal to 15 mm Hg and/or to a Value Lower Than 90 mm Hg
NCT01745380 (16) [back to overview]	Number of Participants With a Decrease From Baseline in Diastolic Blood Pressure Greater Than or Equal to 10 mm Hg and/or to a Value Lower Than 50 mm Hg
NCT01745380 (16) [back to overview]	Number of Participants Who Received Three Sprays and Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic.
NCT01745380 (16) [back to overview]	Maximum Change From Baseline in Systolic Blood Pressure
NCT01745380 (16) [back to overview]	Maximum Change From Baseline in Heart Rate
NCT01745380 (16) [back to overview]	The Profile Over Time of Systolic Blood Pressure
NCT01745380 (16) [back to overview]	Alcohol Sniff Test
NCT01800877 (1) [back to overview]	MAP While on Vasopressors
NCT01807624 (13) [back to overview]	Tmax of Oxymetazoline and PBBA
NCT01807624 (13) [back to overview]	Increase in SBP > 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	Increase in DBP > 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	SpO2 Decrease of > 5% on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	SpO2 Increase of > 5% on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	Increase in Pulse Rate > 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	AUC0-infinity of Oxymetazoline and PBBA
NCT01807624 (13) [back to overview]	AUC0-t of Oxymetazoline and PBBA
NCT01807624 (13) [back to overview]	Half-life of Oxymetazoline and PBBA
NCT01807624 (13) [back to overview]	Decrease in DBP > 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	Decrease in Pulse Rate > 20 Bpm on 2 Consecutive Measurements After Administration of Study Medication
NCT01807624 (13) [back to overview]	Cmax of Oxymetazoline and PBBA
NCT01807624 (13) [back to overview]	Decrease in SBP > 20 mmHg on 2 Consecutive Measurements After Administration of Study Medication
NCT01813149 (1) [back to overview]	Expression of α1-adrenoceptors (α1-AR) in Dermal Nerve Bundles in the CRPS-affected Limb of Phenylephrine Responders and Non-responders
NCT01844830 (9) [back to overview]	Maximum Change From Baseline in Heart Rate
NCT01844830 (9) [back to overview]	Maximum Change From Baseline in Systolic Blood Pressure
NCT01844830 (9) [back to overview]	Maximum Change From Baseline in Diastolic Blood Pressure
NCT01844830 (9) [back to overview]	Incidence of Adverse Events (AEs) by Dosage Cohort
NCT01844830 (9) [back to overview]	Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic.by Dosage Cohort.
NCT01844830 (9) [back to overview]	Results of Naris Examination (NE) - Patency and Ulcerations
NCT01844830 (9) [back to overview]	Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic. by Age Group (3-5, 6-11, and 12-17 Years Old, Inclusive).
NCT01844830 (9) [back to overview]	Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic.
NCT01844830 (9) [back to overview]	Incidence of Adverse Events (AEs) by Age Group
NCT01847131 (2) [back to overview]	The Numbers of Subjects Who Developed Rhinitis Medicamentosa After Using Oxymetazoline
NCT01847131 (2) [back to overview]	Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction
NCT01848041 (5) [back to overview]	Contrast Sensitivity
NCT01848041 (5) [back to overview]	Corrected Snellen Visual Acuity
NCT01848041 (5) [back to overview]	Palpebral Fissure Distance Measurement
NCT01848041 (5) [back to overview]	Marginal Reflex Distance
NCT01848041 (5) [back to overview]	Humphrey Visual Field
NCT02025426 (8) [back to overview]	Cardiac Output
NCT02025426 (8) [back to overview]	Cerebral Tissue Oxygen Saturation
NCT02025426 (8) [back to overview]	Neonatal Umbilical Cord Gases, BE
NCT02025426 (8) [back to overview]	Neonatal Umbilical Cord Gases, pCO2
NCT02025426 (8) [back to overview]	Neonatal Umbilical Cord Gases, pH
NCT02025426 (8) [back to overview]	Number of Participants With Intraoperative Hypotension
NCT02025426 (8) [back to overview]	Number of Participants With Intraoperative Nausea
NCT02025426 (8) [back to overview]	Number of Participants With Intraoperative Vomiting
NCT02062710 (1) [back to overview]	Change in Cough Reflex Sensitivity to Capsaicin
NCT02095158 (2) [back to overview]	Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales
NCT02095158 (2) [back to overview]	Percentage of Participants With Treatment-Related Adverse Events
NCT02132117 (6) [back to overview]	Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29
NCT02132117 (6) [back to overview]	Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales
NCT02132117 (6) [back to overview]	Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29
NCT02132117 (6) [back to overview]	Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1
NCT02132117 (6) [back to overview]	Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29
NCT02132117 (6) [back to overview]	Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29
NCT02132312 (3) [back to overview]	Acute Postoperative Pain
NCT02132312 (3) [back to overview]	Intraoperative Pupil Diameter
NCT02132312 (3) [back to overview]	Safety as Measured by Treatment-emergent Adverse Events, the Number of Affected Patients/at Risk (%) and the Number of Events.
NCT02203630 (31) [back to overview]	Length of ICU Stay
NCT02203630 (31) [back to overview]	Number of Participants Rehospitalized After Discharge
NCT02203630 (31) [back to overview]	Number of Participants With Arrhythmia Events
NCT02203630 (31) [back to overview]	Number of Participants With Cardiac Arrest Events
NCT02203630 (31) [back to overview]	Number of Patients With ST-segment Abnormalities on ECG
NCT02203630 (31) [back to overview]	Maximum Heart Rate
NCT02203630 (31) [back to overview]	Mean Central Venous Oxygen Saturation
NCT02203630 (31) [back to overview]	Number of Participants Receiving Non-study Vasopressors
NCT02203630 (31) [back to overview]	Cause of Death
NCT02203630 (31) [back to overview]	Location of Death
NCT02203630 (31) [back to overview]	Mean Troponin-I
NCT02203630 (31) [back to overview]	Number of Days Hemodialysis Needed
NCT02203630 (31) [back to overview]	Number of Times an Anti-arrhythmic Agent is Used
NCT02203630 (31) [back to overview]	Number of Uses of Rate-controlling Agent
NCT02203630 (31) [back to overview]	Amount of Time Non-study Vasopressors Used
NCT02203630 (31) [back to overview]	Number of Days Mechanical Ventilation Needed
NCT02203630 (31) [back to overview]	Number of Days Without Mechanical Ventilation
NCT02203630 (31) [back to overview]	Number of Days Without Vasopressor Use
NCT02203630 (31) [back to overview]	Number of Direct Current (DC) Cardioversion Events
NCT02203630 (31) [back to overview]	Use of Corticosteroid
NCT02203630 (31) [back to overview]	Mean Blood Pressure (Maximum and Minimum)
NCT02203630 (31) [back to overview]	Total Time in Arrhythmia
NCT02203630 (31) [back to overview]	Number of Participants Developing Peripheral Limb Ischemia
NCT02203630 (31) [back to overview]	Mean Central Venous Pressure
NCT02203630 (31) [back to overview]	28-day Mortality
NCT02203630 (31) [back to overview]	CK-MB
NCT02203630 (31) [back to overview]	Creatinine Kinase (CK)
NCT02203630 (31) [back to overview]	Days Spent Out of the Hospital
NCT02203630 (31) [back to overview]	Days Without Dialysis
NCT02203630 (31) [back to overview]	Hospital Days Not in ICU
NCT02203630 (31) [back to overview]	Length of Hospital Stay
NCT02285634 (4) [back to overview]	Change in Diastolic Blood Pressure
NCT02285634 (4) [back to overview]	Change in Heart Rate
NCT02285634 (4) [back to overview]	Change in Mean Arterial Blood Pressure
NCT02285634 (4) [back to overview]	Change in Systolic Blood Pressure
NCT02354833 (4) [back to overview]	Percentage of Participants Experiencing Both Nausea and Emesis
NCT02354833 (4) [back to overview]	Number of Rescue Boluses to Maintain SBP
NCT02354833 (4) [back to overview]	Median Total Rescue Bolus Dose of Ephedrine (mg) to Maintain SBP
NCT02354833 (4) [back to overview]	Median Total Rescue Bolus Dose of Phenylephrine (mcg) to Maintain SBP
NCT02373137 (13) [back to overview]	Best Spectacle-Corrected Visual Acuity
NCT02373137 (13) [back to overview]	Best Spectacle-Corrected Visual Acuity
NCT02373137 (13) [back to overview]	Endothelial Cell Count
NCT02373137 (13) [back to overview]	Best Spectacle-Corrected Visual Acuity
NCT02373137 (13) [back to overview]	Corneal Higher-Order Aberrations
NCT02373137 (13) [back to overview]	Adverse Events/Complication Rates
NCT02373137 (13) [back to overview]	Corneal Higher-Order Aberrations
NCT02373137 (13) [back to overview]	Endothelial Cell Count
NCT02373137 (13) [back to overview]	Graft Failure/Graft Rejection
NCT02373137 (13) [back to overview]	Graft Thickness
NCT02373137 (13) [back to overview]	Interface Haze
NCT02373137 (13) [back to overview]	Interface Haze
NCT02373137 (13) [back to overview]	National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)
NCT02436759 (2) [back to overview]	Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group
NCT02436759 (2) [back to overview]	Mean Change From Baseline in Marginal Reflex Distance (MRD) in the Study Eye
NCT02453841 (4) [back to overview]	Blood Pressure Following Oxymetazoline Administration
NCT02453841 (4) [back to overview]	Ease of Hemostasis
NCT02453841 (4) [back to overview]	Heart Rate Following Oxymetazoline Administration.
NCT02453841 (4) [back to overview]	Amount of Bleeding
NCT02701582 (9) [back to overview]	Creatinine Change
NCT02701582 (9) [back to overview]	Area Under Curve of MAP Below 65
NCT02701582 (9) [back to overview]	Organ Oxygenation as Measured by Arterial Blood Gas Values
NCT02701582 (9) [back to overview]	Pulmonary Status as Measured by the Number of Participants Who Require Supplemental Oxygen
NCT02701582 (9) [back to overview]	Patients Requiring Fluid Bolus for Management
NCT02701582 (9) [back to overview]	Organ Oxygenation as Measured by Serum Lactate
NCT02701582 (9) [back to overview]	Number of Patients Treated for Hypotension With Phenylephrine Drip
NCT02701582 (9) [back to overview]	Number of ICU Stays Greater Than 1.5 Days
NCT02701582 (9) [back to overview]	Fluid Balance Measured by Inputs and Outputs (I/Os) of All Measurable Fluid in Peri-operative Period
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 55 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 60 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 65 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 70 mmHg
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 75 mmHg
NCT02726620 (43) [back to overview]	30-day Mortality
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Epinephrine
NCT02726620 (43) [back to overview]	Estimated Intraoperative Blood Loss
NCT02726620 (43) [back to overview]	In-hospital Mortality
NCT02726620 (43) [back to overview]	Incidence of a MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Incidence of a MAP < 50 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 50 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Norepinephrine
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Ephinephrine
NCT02726620 (43) [back to overview]	Usage Frequency of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 65 mmHg
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Timing of Cardiovascular Drugs for MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Time to Discharge Readiness at the Postanesthesia Care Unit (PACU)
NCT02726620 (43) [back to overview]	Postoperative Rise in Creatinine Levels
NCT02726620 (43) [back to overview]	Incidence of a MAP < 55 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 55 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Incidence of a MAP < 60 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]	Incidence of a MAP < 60 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]	Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]	Intraoperative Administration of Intravenous Fluids
NCT02726620 (43) [back to overview]	Depth and Duration of Intraoperative Hypotension - Threshold MAP 50 mmHg
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]	Average Use of Cardiovascular Drugs: Norepinephrine
NCT02778100 (8) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon
NCT02778100 (8) [back to overview]	PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon
NCT02778100 (8) [back to overview]	PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon
NCT02778100 (8) [back to overview]	PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon
NCT02778100 (8) [back to overview]	Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC0-3) of Baseline-Adjusted Glucose From Time Zero up to 3 Hours
NCT02778100 (8) [back to overview]	PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose
NCT02778100 (8) [back to overview]	PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax) of Baseline-Adjusted Glucose
NCT02778100 (8) [back to overview]	Number of Participants With One or More Serious Adverse Event(s) (SAEs)
NCT02895035 (4) [back to overview]	Number of Eyes With Pupil Diameter Less Than 6 mm at Any Time During Surgery
NCT02895035 (4) [back to overview]	Number of Eyes With Pupil Diameter Less Than 6 mm During Cortical Clean-up
NCT02895035 (4) [back to overview]	Mean Area Under the Curve Change From Baseline in Pupil Diameter Over Time to the End of Cataract Surgery
NCT02895035 (4) [back to overview]	Maximum Intraoperative Change in Pupil Diameter
NCT02909140 (9) [back to overview]	Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion
NCT02909140 (9) [back to overview]	Pupil Size Immediately Prior to Capsulorrhexis
NCT02909140 (9) [back to overview]	Pupil Size Upon Completion of Surgery
NCT02909140 (9) [back to overview]	Mean Time Taken to Perform Phacoemulsification
NCT02909140 (9) [back to overview]	Cumulative Energy Dispersed for Each Arm
NCT02909140 (9) [back to overview]	Mean Time Taken to Perform Phacoemulsification in Each Arm
NCT02909140 (9) [back to overview]	Percentage of Patients in Each Arm That Required Another Mydriatic Agent
NCT02909140 (9) [back to overview]	Percentage of Patients in Each Arm That Required Use of an Iris Expansion Device During the Procedure
NCT02909140 (9) [back to overview]	Pupil Size (mm) Immediately After Nuclear Disassembly
NCT02965924 (2) [back to overview]	Change in Intraocular Pressure (IOP)
NCT02965924 (2) [back to overview]	Change in Episcleral Venous Pressure (EVP)
NCT03228914 (1) [back to overview]	Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Average Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Average Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in the Nasal Congestion Severity Score
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Change From Baseline in Sinus Pressure/Tenderness Scores
NCT03339726 (17) [back to overview]	Mean Change From Baseline in the Nasal Congestion Severity Score
NCT03352323 (1) [back to overview]	Responder
NCT03380390 (3) [back to overview]	Percentage of Participants With at Least a 1-Grade Worsening From Baseline in the Clinician's Telangiectasia Assessment (CTA) at Any Time-point
NCT03380390 (3) [back to overview]	Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT03380390 (3) [back to overview]	Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Clinical Erythema Assessment Scale at Any Time-point
NCT03415243 (29) [back to overview]	Small Intestine Transit Time
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 15 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 120 Minutes
NCT03415243 (29) [back to overview]	Mean Time for Gastric Emptying by Measuring 90 Percent Values
NCT03415243 (29) [back to overview]	Mean Time to Complete Gastric Emptying
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 90 Minutes of Administration
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 15 Minutes of Administration
NCT03415243 (29) [back to overview]	Total Area Under the Gastric Emptying Curve
NCT03415243 (29) [back to overview]	Number of Participants With Clinically Significant Change in Laboratory Test Values
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 105 Minutes of Administration
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 120 Minutes of Administration
NCT03415243 (29) [back to overview]	Mean Time to Onset of Gastric Emptying
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 105 Minutes
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 180 Minutes of Administration
NCT03415243 (29) [back to overview]	Mean Time for Gastric Emptying by Measuring 25 Percent Values
NCT03415243 (29) [back to overview]	Gastric Emptying Half-Life
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 240 Minutes of Administration
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 30 Minutes of Administration
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 45 Minutes of Administration
NCT03415243 (29) [back to overview]	Mean Time for Gastric Emptying by Measuring 50 Percent Values
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 60 Minutes of Administration
NCT03415243 (29) [back to overview]	Percentage of Radiolabeled Drug Remaining in the Stomach After 75 Minutes of Administration
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 90 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 75 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 60 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 45 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 30 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 240 Minutes
NCT03415243 (29) [back to overview]	Area Under the Gastric Emptying Curve From Time 0 to 180 Minutes
NCT03592121 (1) [back to overview]	Change in Delayed Orgasm Grade
NCT03751098 (3) [back to overview]	Proportion of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication
NCT03751098 (3) [back to overview]	Proportion of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication
NCT03751098 (3) [back to overview]	Change in Pupil Diameter From Baseline
NCT03751631 (3) [back to overview]	Change in Pupil Diameter From Baseline
NCT03751631 (3) [back to overview]	Percentage of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication
NCT03751631 (3) [back to overview]	Percentage of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication
NCT04153188 (8) [back to overview]	Measurement of Pain Associated With PDL Treatment
NCT04153188 (8) [back to overview]	Measurement of The Percentage of Subjects Reporting Satisfaction At the 6-Month Post-Baseline Visit
NCT04153188 (8) [back to overview]	Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline
NCT04153188 (8) [back to overview]	Subject Self-Assessment (SSA) At the 1- ,2-, 3- and 6-Month Post-Baseline Visits
NCT04153188 (8) [back to overview]	Measurement of Improvement in Vessel Size At the 1-, 2-, 3- and 6-Month Post-Baseline Visits
NCT04153188 (8) [back to overview]	Mean Subject Assessment of Global Aesthetic Improvement (GAI) Grades At the 1-, 2-, 3- and 6-Month Post-Baseline
NCT04153188 (8) [back to overview]	Mean Investigator Assessment of Global Aesthetic Improvement (GAI) Grades At the 1-, 2-, 3- and 6-Month Post-Baseline
NCT04153188 (8) [back to overview]	Clinical Erythema Assessment (CEA) At the 1- ,2- and 3-Month Post-Baseline Visits
NCT04831047 (4) [back to overview]	Change in Palpebral Fissure Height
NCT04831047 (4) [back to overview]	Change in Patient-reported Eye Appearance - FACE-Q Eye Appearance
NCT04831047 (4) [back to overview]	Change in Patient-reported Eye Appearance - FACE-Q Upper Eyelid Appearance
NCT04831047 (4) [back to overview]	Change in Eye Redness as Measured by the Validated Bulbar Redness Grading Scale
NCT05439460 (1) [back to overview]	Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio)

The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Pseudoephedrine and Placebo.

"To estimate the effect of a pseudoephedrine (PSE) 60 mg immediate release tablet on nasal congestion over a 6-hour observation period relative to placebo~The values for the nasal congestion score scale are 0,1,2,3 for measure of symptoms, defined as 0-none, 1-mild, 2-moderate, 3-severe. They are subject-evaluated results." (NCT00276016)
Timeframe: Baseline to endpoint (6 hour period)

Intervention	Units on a scale (Mean)
	Baseline	Endpoint
Placebo	2.20	-0.12
Pseudoephedrine	2.26	-0.47

Intervention	Units on a scale (Mean)
	Baseline score	Change from Baseline to Endpoint Score
Phenylephrine	2.20	-0.18
Placebo	2.20	-0.12

Intervention	ml/min x 1/log[PE] (Mean)
	before L-NMMA infusion	after L-NMMA infusion
Chronic Kidney Disease	-0.48	-0.31
Normotensive Group	-0.22	-0.16

Intervention	units on a scale (Least Squares Mean)
Combination1	-0.80
Combination3	-0.92
Mometasone	-0.63
Oxymetazoline	-1.06
Placebo	-0.57

Intervention	units on a scale (Least Squares Mean)
Combination1	-3.29
Combination3	-3.36
Mometasone	-2.97
Oxymetazoline	-2.44
Placebo	-1.90

Intervention	units on a scale (Mean)
Placebo FF + Placebo OXY	1.85
FF + Placebo OXY	1.83
Placebo FF + OXY	2.03
FF + OXY	1.55

Intervention	units on a scale (Mean)
Placebo FF + Placebo OXY	3.07
FF + Placebo OXY	3.25
Placebo FF + OXY	2.99
FF + OXY	2.60

Intervention	liters per minute (Median)
Placebo FF + Placebo OXY	5240
FF + Placebo OXY	5680
Placebo FF + OXY	4485.5
FF + OXY	5520

Intervention	units on a scale (Mean)
Placebo FF + Placebo OXY	1.75
FF + Placebo OXY	1.37
Placebo FF + OXY	1.85
FF + OXY	1.26

Intervention	percentage of substrate (Mean)
L-Name in Young	NA
Phenylephrine	NA
L-arginine in Young	NA
L-arginine in Old	NA
L-NAME in Old	NA

Intervention	mmHg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood pressure
African Americans	23.0	16.9
Caucasians	18.9	16.4

Intervention	units on a scale (Median)
Colloid, Then Phenylephrine Infusion	9
Crystalloid, Then Phenylephrine Infusion	9

Intervention	mcg of phenylephrine (Mean)
Colloid, Then Phenylephrine Infusion	1077
Crystalloid, Then Phenylephrine Infusion	1477

Intervention	percentage of participants (Number)
Colloid, Then Phenylephrine Infusion	35.1
Crystalloid, Then Phenylephrine Infusion	45.8

Intervention	percentage of participants (Number)
Colloid, Then Phenylephrine Infusion	10.8
Crystalloid, Then Phenylephrine Infusion	27

Intervention	percentage of participants (Number)
Colloid, Then Phenylephrine Infusion	16.2
Crystalloid, Then Phenylephrine Infusion	18.9

Intervention	Percentage of participants (Number)
	Phenylephrine HCL ER, 30 mg	Phenylephrine HCL IR, 10 mg	No Preference
All Participants	88	6	6

Intervention	participants (Number)
	0-2 hrs PONV	2-6 hrs PONV	6-24 hrs PONV
Combination Group	20	28	22
Metoclopramide	33	35	26
Phenylephrine Infusion	39	41	22

Intervention	mmHG (Mean)
	Systolic blood pressure	Diastolic blood pressure
Kovacaine Nasal Spray	4.50	-2.67
Lidocaine Injection	3.43	-5.07

Intervention	Minutes (Mean)
	Site 1 Duration	Site 2 Duration	Site 3 Duration	Site 4 Duration
Kovacaine Nasal Spray	21.1	16.1	31.8	31.4
Lidocaine Injection	34.2	32.1	25.0	29.3

Intervention	mmHg (Mean)
	Standard K305 Dose	High K305 Dose
Kovacaine Nasal Spray	10.8	11.7

phenylephrine

Description

Cross-References

Synonyms (207)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (7)

Drug Classes (3)

Pathways (1)

Protein Targets (31)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (117)

Molecular Functions (32)

Ceullar Components (31)

Bioassays (111)

Research

Studies (13,104)

Study Types

Clinical Trials (280)

Trial Overview

Trial Outcomes

The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Pseudoephedrine and Placebo.

The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo

α1-adrenoceptor Vasoreactivity With L-NMMA

The Umbilical Artery pH

The Umbilical Artery Blood Base Excess

Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score

Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15

RQLQ Score [6 Weeks]

RQLQ Score [Baseline]

Total Nasal Congestion Symptom Score

Total NPIF

RQLQ Score [2 Weeks]

RQLQ Score [4 Weeks]

Effect of NO Inhibition on Myocardial Substrate Metabolism in Humans

Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension

ED50 After Phenylephrine

Change in Blood Pressure

APGAR Scores

Dosage of Phenylephrine Used

Incidence of Maternal Bradycardia

Incidence of Maternal Hypotension

Incidence of Maternal Nausea and Vomiting

Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).

Percentage of Participants That Preferred the Convenience of Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets

Percentage of Participants That Preferred Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets for the Relief of Nasal Congestion

Occurrence of Postreperfusion Syndrome (PRS)

Pruritus

Maternal Hemodynamics

Intraoperative Nausea and Vomiting

Satisfaction

Postoperative Nausea and Vomiting (PONV)

Maximum Change in Pulse Oximetry From Baseline

Pulpal Anesthesia

Maximum Change in Pulse From Baseline

Maximum Change in Blood Pressure From Baseline

Soft Tissue Anesthesia Duration

Cmax of PBBA

Cmax of Tetracaine

Diastolic BP Maximum Change From Baseline

Half Life of Oxymetazoline

Pulse Oximetry Maximum Change From Baseline

Pulse Rate Maximum Change From Baseline

Systolic BP Maximum Change From Baseline

Cmax of Oxymetazoline

Half Life of PBBA

Mean Change From Baseline in the a.m. Symptom Score for the Instantaneous Nasal Symptom Assessment by Study Day of the Treatment Period

Mean Change From Baseline for the Instantaneous Nasal Symptom Assessment Score By Study Day of the Treatment Period

Mean Change From Baseline for the Daily Reflective Nasal Symptom Assessment Score by Study Day of the Treatment Period

Time to Maximal Effect

Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score

Change From Baseline for the Instantaneous Nasal Symptom Assessment Score at Day 7

Mean Change From Baseline in the Morning (a.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period

Intervention	Units on a Scale (Mean)
	Baseline (n = 107, 106, 104, 106, 101)	Day 2 (n = 104, 105, 102, 103, 101)	Day 3 (n = 104, 103, 102, 102, 101)	Day 4 (n = 104, 103,101,101, 101)	Day 5 (n = 104, 103, 101, 99, 101)	Day 6 (n = 104, 104, 100, 99, 100)	Day 7 (n = 104, 102, 100, 98, 100)
PE 10 mg	2.271	-0.147	-0.265	-0.324	-0.304	-0.353	-0.382
PE 20 mg	2.311	0.010	-0.206	-0.255	-0.314	-0.422	-0.376
PE 30 mg	2.298	-0.060	-0.130	-0.253	-0.283	-0.337	-0.408
PE 40 mg	2.311	-0.010	-0.112	-0.351	-0.232	-0.379	-0.404
Placebo	2.406	-0.180	-0.130	-0.280	-0.240	-0.260	-0.380

Intervention	Units on a Scale (Mean)
	Baseline (n = 107, 106, 104, 106, 101)	Day 2 (n = 102, 104, 100, 99, 100)	Day 3 (n = 102, 102, 100, 98, 100)	Day 4 (n = 102, 102, 99, 97, 100)	Day 5 (n = 102, 102, 99, 95, 100)	Day 6 (n =102, 102, 98, 95, 100)	Day 7 (n = 102, 101, 98, 94, 100)
PE 10 mg	2.271	-0.147	-0.265	-0.324	-0.304	-0.353	-0.382
PE 20 mg	2.311	0.010	-0.206	-0.255	-0.314	-0.422	-0.376
PE 30 mg	2.298	-0.060	-0.130	-0.253	-0.283	-0.337	-0.408
PE 40 mg	2.311	-0.010	-0.112	-0.351	-0.232	-0.379	-0.404
Placebo	2.406	-0.180	-0.130	-0.280	-0.240	-0.260	-0.380

Intervention	Units on a Scale (Mean)
	Baseline (n = 109. 108, 106, 111, 102)	Day 1 (n = 102, 106, 101, 102, 101)	Day 2 (n = 104, 106, 102, 104, 101)	Day 3 (n = 104, 104, 102, 103, 101)	Day 4 (n = 104, 104, 101, 102, 101)	Day 5 (n = 104, 104, 101, 100, 101)	Day 6 (n = 104, 104, 100, 100, 100)	Day 7 (n = 104, 103, 100, 99, 100)
PE 10 mg	2.394	-0.353	-0.297	-0.451	-0.519	-0.475	-0.543	-0.576
PE 20 mg	2.452	-0.367	-0.320	-0.449	-0.468	-0.550	-0.689	-0.573
PE 30 mg	2.440	-0.431	-0.367	-0.441	-0.559	-0.529	-0.635	-0.610
PE 40 mg	2.437	-0.389	-0.392	-0.425	-0.520	-0.484	-0.544	-0.556
Placebo	2.457	-0.364	-0.345	-0.444	-0.449	-0.444	-0.460	-0.490

Intervention	Units on a Scale (Mean)
	Baseline (n = 109, 108, 106, 111, 102)	Day 2 (n = 104, 106, 102, 104, 101)	Day 3 (n = 104, 104, 102, 103, 101)	Day 4 (n = 104, 104, 101, 102, 101)	Day 5 (n = 104, 104, 101, 100, 100)	Day 6 (n = 104, 104, 100, 100, 100)	Day 7 (n = 104, 103, 100, 99, 100)
PE 10 mg	2.417	-0.243	-0.359	-0.503	-0.426	-0.474	-0.541
PE 20 mg	2.517	-0.200	-0.362	-0.439	-0.458	-0.612	-0.472
PE 30 mg	2.481	-0.216	-0.324	-0.485	-0.465	-0.584	-0.594
PE 40 mg	2.492	-0.308	-0.369	-0.510	-0.474	-0.474	-0.539
Placebo	2.514	-0.283	-0.362	-0.422	-0.392	-0.428	-0.438

Intervention	Units on a Scale (Mean)
	Baseline (n = 109, 108, 106, 111, 102)	Day 1 (n = 102, 106, 101, 102, 101)	Day 2 (n = 102, 103, 102, 103, 101)	Day 3 (n = 104, 104, 101, 101, 101)	Day 4 (n = 104, 104, 101, 99, 100)	Day 5 (n = 104, 102, 97, 99, 99)	Day 6 (n = 104, 103, 100, 100, 100)	Day 7 (n = 104, 102, 100, 98, 100)
PE 10 mg	2.376	-0.321	-0.360	-0.546	-0.536	-0.526	-0.613	-0.613
PE 20 mg	2.361	-0.285	-0.410	-0.512	-0.474	-0.610	-0.750	-0.650
PE 30 mg	2.363	-0.359	-0.483	-0.527	-0.597	-0.564	-0.648	-0.588
PE 40 mg	2.362	-0.321	-0.466	-0.480	-0.533	-0.475	-0.597	-0.564
Placebo	2.380	-0.287	-0.386	-0.505	-0.450	-0.485	-0.470	-0.520

Intervention	minutes (Mean)
	Onset Time of Disintegration	Completion Time of Disintegration
Standard Paracetamol Tablets	42.50	62.88

Intervention	ng*h/mL (Mean)
Single i.n. Dose of 30 mg Ketorolac Tromethamine	9001.8
Single i.n. Dose of Oxymetazoline Hydrochloride Followed by a	9310.3
Seven Days of Treatment With i.n. Fluticasone Propionate	8794.3

Intervention	hours (Mean)
Single i.n. Dose of 30 mg Ketorolac Tromethamine	5.583
Single i.n. Dose of Oxymetazoline Hydrochloride Followed by a	5.172
Seven Days of Treatment With i.n. Fluticasone Propionate	5.216

Intervention	ng*h/mL (Mean)
Single i.n. Dose of 30 mg Ketorolac Tromethamine	9906.9
Single i.n. Dose of Oxymetazoline Hydrochloride Followed by a	9959.1
Seven Days of Treatment With i.n. Fluticasone Propionate	9445.4

Intervention	hours (Mean)
Single i.n. Dose of 30 mg Ketorolac Tromethamine	7.241
Single i.n. Dose of Oxymetazoline Hydrochloride Followed by a	6.861
Seven Days of Treatment With i.n. Fluticasone Propionate	7.088